US20170224733A1 - Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System - Google Patents
Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System Download PDFInfo
- Publication number
- US20170224733A1 US20170224733A1 US15/425,773 US201715425773A US2017224733A1 US 20170224733 A1 US20170224733 A1 US 20170224733A1 US 201715425773 A US201715425773 A US 201715425773A US 2017224733 A1 US2017224733 A1 US 2017224733A1
- Authority
- US
- United States
- Prior art keywords
- cells
- tumor
- amino acid
- car
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 284
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 227
- 210000003169 central nervous system Anatomy 0.000 title claims description 36
- 238000011282 treatment Methods 0.000 title description 78
- 238000000034 method Methods 0.000 claims abstract description 102
- 210000004027 cell Anatomy 0.000 claims description 215
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 198
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 46
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 43
- 208000005017 glioblastoma Diseases 0.000 claims description 42
- 230000036210 malignancy Effects 0.000 claims description 33
- 238000002271 resection Methods 0.000 claims description 33
- 230000003902 lesion Effects 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 230000002601 intratumoral effect Effects 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 2
- 208000030266 primary brain neoplasm Diseases 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 description 198
- 235000001014 amino acid Nutrition 0.000 description 180
- 229940024606 amino acid Drugs 0.000 description 162
- 108090000176 Interleukin-13 Proteins 0.000 description 117
- 102000003816 Interleukin-13 Human genes 0.000 description 117
- 238000012986 modification Methods 0.000 description 99
- 230000004048 modification Effects 0.000 description 99
- 230000000139 costimulatory effect Effects 0.000 description 78
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 62
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 62
- 238000001802 infusion Methods 0.000 description 61
- 230000014509 gene expression Effects 0.000 description 54
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 52
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 52
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 46
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 46
- 102000004127 Cytokines Human genes 0.000 description 45
- 108090000695 Cytokines Proteins 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 44
- 239000013598 vector Substances 0.000 description 43
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 42
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 42
- 238000000185 intracerebroventricular administration Methods 0.000 description 42
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 35
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 35
- 230000011664 signaling Effects 0.000 description 33
- 125000006850 spacer group Chemical group 0.000 description 31
- 108010076504 Protein Sorting Signals Proteins 0.000 description 29
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 27
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 27
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000007914 intraventricular administration Methods 0.000 description 25
- 206010018338 Glioma Diseases 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 24
- 238000010186 staining Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 22
- 230000000306 recurrent effect Effects 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 238000003364 immunohistochemistry Methods 0.000 description 17
- 230000001086 cytosolic effect Effects 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 15
- 210000003071 memory t lymphocyte Anatomy 0.000 description 15
- 102000019034 Chemokines Human genes 0.000 description 14
- 108010012236 Chemokines Proteins 0.000 description 14
- 208000032612 Glial tumor Diseases 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000008685 targeting Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 11
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 11
- 108091006905 Human Serum Albumin Proteins 0.000 description 11
- 102000008100 Human Serum Albumin Human genes 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 102100033467 L-selectin Human genes 0.000 description 11
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 11
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 11
- 102000019207 human interleukin-13 Human genes 0.000 description 11
- 238000007917 intracranial administration Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 10
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002688 persistence Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000000844 Cell Surface Receptors Human genes 0.000 description 9
- 108010001857 Cell Surface Receptors Proteins 0.000 description 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 9
- 102100022338 Integrin alpha-M Human genes 0.000 description 9
- 102000003812 Interleukin-15 Human genes 0.000 description 9
- 108090000172 Interleukin-15 Proteins 0.000 description 9
- 241000021375 Xenogenes Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 108700004025 env Genes Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 101100058140 Brassica napus BBM1 gene Proteins 0.000 description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 8
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 8
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 7
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 210000004289 cerebral ventricle Anatomy 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 230000004907 flux Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 6
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 6
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 6
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 208000029824 high grade glioma Diseases 0.000 description 6
- 201000011614 malignant glioma Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012797 qualification Methods 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 5
- 108700012434 CCL3 Proteins 0.000 description 5
- 102000000013 Chemokine CCL3 Human genes 0.000 description 5
- 102000001326 Chemokine CCL4 Human genes 0.000 description 5
- 108010055165 Chemokine CCL4 Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 206010061819 Disease recurrence Diseases 0.000 description 5
- 101710139422 Eotaxin Proteins 0.000 description 5
- 102100023688 Eotaxin Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101150104383 ALOX5AP gene Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 101100286681 Homo sapiens IL13 gene Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 101150030213 Lag3 gene Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010051696 Metastases to meninges Diseases 0.000 description 4
- 101100236114 Mus musculus Lrrfip1 gene Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 231100001156 grade 3 toxicity Toxicity 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 231100000171 higher toxicity Toxicity 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 210000003140 lateral ventricle Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 3
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 3
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 3
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 231100000026 common toxicity Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 102000046157 human CSF2 Human genes 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- -1 CD45RO Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 102100026497 Zinc finger protein 654 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 201000008873 bone osteosarcoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 231100001039 immunological change Toxicity 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000037959 spinal tumor Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010301 Confusion and disorientation Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010027468 Metastases to spine Diseases 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndromes Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241001300078 Vitrea Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000018711 interleukin-13 production Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000018411 neoplasm of temporal lobe Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- Tumor-specific T cell based immunotherapies including therapies employing engineered T cells and ex vivo expanded or selected T cells, have been investigated for anti-tumor treatment.
- the T cells used in such therapies do not remain active in vivo for a long enough period.
- the tumor-specificity of the T cells is relatively low.
- the engineered T cells have insufficient access to the tumor. Therefore, there is a need in the art for tumor-specific cancer therapies with more effective anti-tumor function.
- MG malignant glioma
- AA-grade III anaplastic astrocytoma
- GBM-grade IV glioblastoma multiforme
- compositions comprising T cells (e.g., CAR T cells, Tumor Infiltrating lymphocytes (“TIL”), TCR-engineered T cells, or T cell clones) to the cerebrospinal fluid (“CSF”) of a patient.
- T cells include T cells that have be manipulated, for example, by introduction of a nucleic acid molecule expressing a desired receptor, by ex vivo expansion of isolated or genetically-modified T cells or by ex vivo selection of a subset of T cells obtained from a patient or a donor or by a combination of two or more of these techniques.
- Administration to the CNS can be accomplished, for example, by administration to the ventricular system or the central cavity of the spinal column.
- Administration to the CNS is distinct from both intratumoral administration (injection or infusion into the tumor itself) and administration to a cavity created by resection of a tumor.
- intratumoral administration injection or infusion into the tumor itself
- administration to a cavity created by resection of a tumor administration to a cavity created by resection of a tumor.
- the CNS administration methods described herein can be combined with intraturmoral and/or post-resection, intracavity administration.
- the CNS administration described herein permits infusion of relatively large volumes of the composition comprising T cells, for example 1 ml-2 ml or more in a single infusion. Thus, several million T cells can be administered in a single infusion.
- a method of treating a patient diagnosed with a malignancy of the central nervous system comprises infusing a composition comprising an effective amount of T cells into an anatomical compartment of a patient diagnosed with a malignancy of the central nervous system, the anatomical compartment containing cerebrospinal fluid (“CSF”).
- the method includes infusion of a composition into a ventricular system or a portion of a central canal of a spinal cord, for example.
- the malignancy of the central nervous system includes a primary tumor or a metastasized tumor found somewhere in the central nervous system, including a portion of the brain, spinal column, or the like.
- the anatomical compartment contains a contiguous volume of at least about 50, 100, or 150 mL of cerebrospinal fluid.
- TCR-engineered T cells are prepared by introduction of TCR ⁇ genes into T cells (e.g., autologous T cells) followed by ex vivo expansion of T cells; and infusion of T cells into the patient.
- the infusion of the TCR-engineered T cells confers tumor reactivity to patients whose tumor expresses the appropriate antigen and HLA restriction element.
- the TCR can be targeted to any of a variety of tumor antigens, including, for example melanoma-associated antigen recognized by T cells 1 (MART-1), glycoprotein (gp) 100, carcinoembryonic antigen (CEA), p53, melanoma-associated antigen (MAGE-A3, and New York esophageal squamous cell carcinoma antigen (NYESO).
- Described herein is a method of treating a patient diagnosed with a malignancy of the central nervous system comprising introducing into the cerebrospinal fluid (CSF) of the patient a composition comprising an effective amount of T cells.
- CSF cerebrospinal fluid
- the T cells are autologous or allogenic T cells; the T cells have been manipulated ex vivo by one or more of: expansion, fractionation or transfection with a recombinant nucleic acid molecule; the T cells comprise cells that have been transfected with a recombinant nucleic acid molecule encoding a polypeptide that binds to a tumor cell antigen; the polypeptide is a chimeric antigen receptor; the composition is administered intraventricularly; the composition is administered to the central canal of the spinal cord; the administration is to the left ventrical or the right ventrical; the composition comprises at least 1 ⁇ 10 6 cells; the composition comprising T cells is administered at least two times; the administrations differ in the total number of T cells administered; the administrations escalate in dose; the administrations de-escalate in dose; the T cells comprise CAR T cells; the T cells comprise autologous tumor infiltrating lymphocytes; the T cells comprise TCR-engineered T cells; the malignancy is a diffuse, in
- the T cells comprise CART cells that target IL13R ⁇ 2 and the cells comprise a nucleic acid molecule encoding a chimeric antigen receptor comprising: human IL-13 or a variant thereof having 1-10 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3 ⁇ transmembrane domain or a variant thereof having 1-10 amino acid modifications; at least one costimulatory domain; and CD3 signaling domain of a variant thereof having 1-10 amino acid modifications.
- the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 amino acid modifications;
- the variant of a human IL13 has 1-10 amino acid modification that increase binding specificity for IL13R ⁇ 2 versus IL13R ⁇ 1;
- the human IL-13 or variant thereof is an IL-13 variant comprising the amino acid sequence of SEQ ID NO:3 with 1 to 5 amino acid modifications, provided that the amino acid at position 11 of SEQ ID NO:3 is other than E;
- the chimeric antigen receptor comprises two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 amino acid modifications and an OX40 costimulatory domain or
- the T cells express a chimeric antigen receptor that binds HER2 comprise a nucleic acid molecule encoding a chimeric antigen receptor comprising: a HER2 targeting sequence; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-5 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-5 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-5 amino acid modifications, and a CD3s transmembrane domain or a variant thereof having 1-5 amino acid modifications; a costimulatory domain selected from a CD28 costimulatory domain or a variant thereof having 1-5 amino acid modifications and a 4-IBB costimulatory domain or a variant thereof having 1-5 amino acid modifications; and CD3s signaling domain of a variant thereof having 1-5 amino acid modifications.
- a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-5 amino acid modifications, a CD
- the HER2 targeting domain is a HER2 scFv; the HER2 scFv comprising the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS GSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGSTSGGGSGGGSGGGGSSE VQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS (SEQ ID NO:49) or a variant thereof having 1 to 5 amino acid modifications; the chimeric antigen receptor comprises: a HER2 targeting sequence; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8
- Also described herein is a method of treating a patient diagnosed with a malignancy of the central nervous system comprising infusing a composition comprising an effective amount of T cells into an anatomical compartment of a patient diagnosed with a malignancy of the central nervous system, the anatomical compartment containing cerebrospinal fluid (CSF).
- CSF cerebrospinal fluid
- the anatomical compartment comprises a portion of a ventricular system; the anatomical compartment comprises a portion of a central canal of a spinal cord; the malignancy of the central nervous system includes a brain tumor; the malignancy of the central nervous system includes a metastasized tumor; the anatomical compartment contains a contiguous volume of at least about 50 mL of cerebrospinal fluid; the anatomical compartment contains a contiguous volume of at least about 100 mL of cerebrospinal fluid; and the anatomical compartment contains a contiguous volume of at least about 150 mL of cerebrospinal fluid.
- cancers that can be treated by the methods described herein are primary CNS malignancies and secondary malignancies arising from a cancer located elsewhere, for example.
- the malignancy treated according to the disclosed methods comprises a tumor.
- treatment results in at least a 50% reduction in tumor volume, at least a 60% reduction in tumor volume, at least a 70% reduction in tumor volume, at least an 80% reduction in tumor volume, or at least an 90% reduction in tumor volume.
- the treatment results in elimination of the malignancy.
- the patient does not experience any grade 3 or higher toxicity.
- the patient was administered a regimen of steroids prior to treatment with the composition comprising an effective amount of T cells, and in some embodiments the regimen of steroids is reduced to a lower dose following the treatment.
- the patient has an increased life expectancy compared to a patient receiving standard of care treatment, including radiation therapy, small molecule drug therapy, antibody therapeutics, or a combination thereof.
- a patient receiving standard of care treatment including radiation therapy, small molecule drug therapy, antibody therapeutics, or a combination thereof.
- the patient receiving standard of care (“SOC”) treatment can expect to survive about 15 months from initial diagnosis (overall survival or OS)
- the patient receiving the disclosed treatment can expect an OS of 15, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months or more.
- the patient receiving the claimed treatment can expect an OS of 42, 48, 54, 60, 66, 72, 78, 84, 90 months or more.
- the composition comprises at least 2 ⁇ 10 6 T cells or 2 ⁇ 10 6 T cells expressing a cell surface receptor targeting a tumor antigen, while in some embodiments, the composition comprises at least 1 ⁇ 10 6 T cells or 1 ⁇ 10 6 T cells expressing a cell surface receptor targeting a tumor antigen. In some embodiments, the composition comprises at least 5 ⁇ 10 6 T cells or 5 ⁇ 10 6 T cells expressing a cell surface receptor targeting a tumor antigen, while in some embodiments, the composition comprises at least 10 ⁇ 10 6 T cells or 10 ⁇ 10 6 T cells expressing a cell surface receptor targeting a tumor antigen.
- the disclosed methods comprised repeated administrations of the compositions, for instance repeating administration of the composition at least five times, repeating administration of the composition at least ten times, or repeating administration until the patient receives a total dose of at least 90 ⁇ 10 6 T cells or T cells expressing a cell surface receptor targeting a tumor antigen.
- the administration is repeated once a week or once every two weeks. In some embodiments, the repeated administrations are continued over the course of 15 weeks.
- Also disclosed herein are methods of increasing a level of at least one cytokine or chemokine in the cerebrospinal fluid (CSF) of a patient comprising, administering a composition comprising an effective amount of T cells into the CSF of a patient with a malignancy of the central nervous system, wherein the level of at least one cytokine or chemokine in the CSF is increased following administration of the composition comprising an effective amount of T cells compared to a baseline level of the at least one cytokine or chemokine prior to the administration.
- CSF cerebrospinal fluid
- the level of the at least one cytokine or chemokine in the CSF following the administration is increased 10-fold or 5-fold compared to the baseline level.
- the level of at least five or at least ten cytokines or chemokines is increased following administration of the composition comprising an effective amount of T cells compared to a baseline level of the at least five cytokines or chemokines prior to the administration.
- the at least one cytokine or chemokine comprises EGF, Eotaxin, FGF, G-CSF, GM-CSF, HGF, IFN- ⁇ , IFN- ⁇ , IL-10, IL-12, IL-13, IL-15, IL-17, IL-1R ⁇ , IL-1 ⁇ , IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIG, MIP-1 ⁇ , MIP-1 ⁇ , RANTES, TNF- ⁇ , or VEGF.
- the increase in cytokine or chemokine expression is a local increase (i.e., specific to the CSF).
- CSF cerebrospinal fluid
- an effective amount of T cells ranges from about 1 ⁇ 10 6 cells to about 100 ⁇ 10 6 cells, and in some embodiments, an effective amount of T cells ranges from about 2 ⁇ 10 6 cells to about 50 ⁇ 10 6 cells.
- the increased number of T cells observed is sustained for at least about six days, or the number of T cells observed does not return to the baseline number for about seven days.
- the T cells observed include infused T cells (e.g. CAR-expressing T cells), and in some embodiments, the T cells observed include endogenous T cells.
- Also disclosed herein are methods of increasing a number of T cells in the cerebrospinal fluid (CSF) of a patient comprising, administering a composition comprising an effective amount of T cells into the CSF of a patient with a malignancy of the central nervous system, wherein the number of T cells detectable in the CSF is increased compared to pre-administration levels.
- CSF cerebrospinal fluid
- the number of T cells detectable in the CSF is increased compared to pre-administration levels for up to seven days following administration.
- the T cells detectable in the CSF comprise endogenous T cells and CAR-expressing T cells, and/or Type 1 T cells, and/or Type 2 T cells.
- the T cells detectable in the CSF comprise CD3+ T cells, and in some embodiments, the T cells detectable in the CSF comprise CD14+ CD11b+ HLA-DR+ mature myeloid populations. In some embodiments, CD19+ B cells and CD11b+ CD15+ granulocytes are detectable in the CSF following administration of the composition.
- reactive lymphocytes, monocytes, and macrophages are detectable in the CSF following administration of the composition.
- Also disclosed herein are methods of determining the suitability of a patient with a malignancy for treatment with an IL-13R ⁇ 2-specific CAR T cell comprising, determining if a score attributed to a sample from the patient exhibits IL-13R ⁇ 2 expression above a predetermined threshold.
- the score attributed to the sample is calculated by determining the immunoreactivity of a resected tumor sample from a patient diagnosed with a malignancy by immunohistochemically staining the sample with a marker of IL-13R ⁇ 2, analyzing the strength of the staining, and calculating a score based on the strength of the staining, wherein a score that corresponds to moderate to strong staining intensity in the sample indicates that treatment with an IL-13R ⁇ 2-specific CAR T cell is suitable for the patient.
- the score comprises counting the number of cells that have a weak, moderate, or strong staining intensity and assigning each intensity a weight
- the H score a method of quantitating immunohistochemical results, is based on the following formula: (3 ⁇ the percentage of strongly staining cells)+(2 ⁇ the percentage of moderately staining cells)+(1 ⁇ the percentage of weakly staining cells), resulting in a range of 0 to 300).
- the patient has a H score that is: greater that 50, 50-100, greater than 100, 100-200, greater than 200, 100-300, or greater than 250 for the relevant tumor-associated antigen.
- an expression of Ki67 in the sample is also determined by immunohistochemical staining.
- Also disclosed herein are methods of treating a patient with a malignancy comprising, administering to a patient diagnosed with a malignancy a composition comprising an effective dose of IL-13R ⁇ 2-specific CART cells, wherein the patient expresses IL-13R ⁇ 2 above a predetermined threshold.
- the predetermined threshold of IL-13R ⁇ 2 expression was previously identified as being suitable for a treatment comprising IL-13R ⁇ 2-specific CAR T cell therapy.
- TIL are tumor infiltrating lymphocytes that can be isolated from a patient or a donor, expand ex vivo and re-infused into the patient in need thereof.
- CAR T cells express chimeric T cell receptors that comprise an extracellular domain, a transmembrane region and an intracellular signaling domain.
- the extracellular domain includes a portion that binds the targeted cell and, optionally, a spacer, comprising, for example a portion human Fc domain.
- the transmembrane portion includes suitable transmembrane domain, for example, a CD4 transmembrane domain, a CD8 transmembrane domain, a CD28 transmembrane domain, a CD3 transmembrane domain or a 4IBB transmembrane domain.
- the intracellular signaling domain includes the signaling domain from the zeta chain of the human CD3 complex (CD3) and one or more costimulatory domains, e.g., a 4-1BB costimulatory domain.
- the target cell binding portion of extracellular domain (for example a scFv or an ligand) enables the CAR, when expressed on the surface of a T cell, to direct T cell activity to those cells expressing the targeted cell surface molecule, for example HER2 or IL13R ⁇ 2, a receptor expressed on the surface of tumor cells, including malignant glioma cells.
- T cells for example, patient-specific, autologous T cells
- Various T cell subsets can be used.
- CAR can be expressed in other immune cells such as NK cells.
- a patient is treated with an immune cell expressing a CAR or TCR the cell can be an autologous or allogenic T cell.
- the cells used are CD4+ and CD8+ central memory T cells (T CM ), which are CD45RO+CD62L+, and the use of such cells can improve long-term persistence of the cells after adoptive transfer compared to the use of other types of patient-specific T cells.
- the T CM cells can include CD4+ cells and CD8+ cells.
- Such CAR useful in the methods described herein are those that target IL13R ⁇ 2.
- Such CAR can include IL13 having an amino acid modification, such as an E13Y mutation, that increases binding specificity.
- the T cells used in the methods described herein can contain a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, and a CD3 ⁇ transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a costimulatory domain; and CD3 ⁇ signaling domain of a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.
- CAR chimeric antigen receptor
- the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4-IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.
- a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications is present.
- the CAR expressed by the T cells comprises: a variant of a human IL13 having 1-10 amino acid modification that increase binding specificity for IL13R ⁇ 2 versus IL13R ⁇ 1; the human IL-13 or variant thereof is an IL-13 variant comprising the amino acid sequence of SEQ ID NO:3 with 1 to 5 amino acid modifications, provided that the amino acid at position 11 of SEQ ID NO:3 other than E; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a
- the T cells harbor a nucleic acid molecule that expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 10 and 31-48;
- the chimeric antigen receptor comprises a IL-13/IgG4/CD4t/41-BB region comprising the amino acid of SEQ ID NO:11 and a CD3 ⁇ signaling domain comprising the amino acid sequence of SEQ ID NO:7; and
- the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NOs: 10 and 31-48.
- Also disclosed are methods comprising intraventricular administration of a population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3 ⁇ transmembrane domain or a variant thereof having 1-10 amino acid modifications; a costimulatory domain; and CD3 signaling domain of a variant thereof having 1-10 amino acid modifications.
- the population of human T cells comprise a vector expressing a chimeric antigen receptor comprising an amino acid sequence selected from SEQ ID NOs: 10 and 31-48;
- the population of human T cells are comprises of central memory T cells (T CM cells) (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least 10%, 15%, 20%, 25%, 30% or 35% of the T cells or the T CM cells are CD4+ and at least 10%, 15%, 20%, 25%, 30% or 35% of the T cells or the T CM cells are CD8+ cells).
- T CM cells central memory T cells
- a method of treating cancer in a patient comprising CNS administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogeneic T cells comprising T CM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least 15%, 20%, 25%, 30%, 35% of the T CM cells are CD4+ and at least 15%, 20%, 25%, 30%, 35% of the T CM cells are CD8+ cells) transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10 and 31-48.
- a population of autologous or allogeneic human T cells e.g., autologous or allogeneic T cells comprising T CM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least
- the population of human T cells comprise central memory T cells; the cancer is glioblastoma; and the transduced human T cells where prepared by a method comprising obtaining T cells from the patient, treating the T cells to isolate central memory T cells, and transducing at least a portion of the central memory cells to with a viral vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10 and 31-48.
- the T cells administered to the patient harbor a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from and SEQ ID NOs: 10 and 31-48; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO: 10 and 31-48 except for the presence of no more than 5 amino acid substitutions, deletions or insertions; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10 and 31-48 except for the presence of no more than 5 amino acid substitutions; and a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10 and 31-48 except for the presence of no more than 2 amino acid substitutions.
- chimeric antigen receptor comprises an scFv targeted to HER2 (e.g., comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGSTSGGGSGGGSG GGGSSEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT NGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYW GQGTLVTVSS; SEQ ID NO: 49) or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a spacer region
- the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4-IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.
- a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications in present.
- T cells administered to the patient express a CAR that comprises: an scFv targeted to HER2 (e.g., a humanized scFv); two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-2 amino acid modifications; human IL-13 or a variant thereof having 1-2 amino acid modifications; a transmembrane
- the T cells administered the patient harbor a nucleic acid molecule that expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 53-56.
- Also disclosed are methods comprising intraventricular administration of a population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor comprising: an scFv targeted to HER2; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3 ⁇ transmembrane domain or a variant thereof having 1-10 amino acid modifications; a costimulatory domain; and CD3 ⁇ signaling domain of a variant thereof having 1-10 amino acid modifications.
- the population of human T cells comprise a vector expressing a chimeric antigen receptor comprising an amino acid sequence selected from: SEQ ID NOs: 53-56;
- the population of human T cells are comprises of central memory T cells (T CM cells) (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least 10%, 15%, 20%, 25%, 30%, 35% of the T cells or T CM cells are CD4+ and/or at least 10%, 15%, 20%, 25%, 30%, 35% of the T cells or T CM cells are CD8+ cells).
- T CM cells central memory T cells
- a method of treating cancer in a patient comprising intraventricular administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogenic T cells comprising T CM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least 15%, 20%, 25%, 30%, 35% of the T CM cells are CD4+ and/or at least 15%, 20%, 25%, 30%, 35% of the T CM cells are CD8+ cells) transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 53-56.
- a population of autologous or allogeneic human T cells e.g., autologous or allogenic T cells comprising T CM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are T CM cells; at least 15%, 20%,
- the population of human T cells comprise central memory T cells; the cancer is glioblastoma; and the transduced human T cells where prepared by a method comprising obtaining T cells from the patient, treating the T cells to isolate central memory T cells, and transducing at least a portion of the central memory cells to with a viral vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 53-56.
- a method of treating cancer in a patient comprising intraventricular administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogenic T cells comprising T CM cells harboring: a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NOs: 53-56; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs: 53-56 except for the presence of no more than 5 amino acid substitutions, deletions or insertions; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs: 53-56 except for the presence of no more than 5 amino acid substitutions; and a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs:
- Certain CAR described herein for example, the IL13(EQ)BB ⁇ CAR and the IL13(EQ)CD28-BB ⁇ CAR, have certain beneficial characteristics compared to certain other IL13-targeted CAR. For example, they have improved selectivity for IL13R ⁇ , elicit lower Th2 cytokine production, particularly lower IL13 production.
- T cells expressing a CAR targeting IL13R ⁇ 2 can be useful in treatment of cancers such as glioblastoma, as well as other cancers that expresses IL13R ⁇ 2.
- this disclosure includes methods for treating cancer using T cells expressing a CAR described herein.
- T cells expressing a CAR targeting HER2 can be useful in treatment of cancers such as glioblastoma, as well as other cancer that expresses HER2, for example breast cancer that has spread to the central nervous system.
- this disclosure includes methods for treating cancer using T cells expressing a CAR described herein.
- the CAR described herein can include a spacer region located between the targeting domain and the transmembrane domain.
- spacers can be used. Some of them include at least portion of a human Fc region, for example a hinge portion of a human Fc region or a CH3 domain or variants thereof. Table 1 below provides various spacers that can be used in the CARs described herein.
- Some spacer regions include all or part of an immunoglobulin (e.g., IgG1, IgG2, IgG3, IgG4) hinge region, i.e., the sequence that falls between the CH1 and CH2 domains of an immunoglobulin, e.g., an IgG4 Fc hinge or a CD8 hinge.
- Some spacer regions include an immunoglobulin CH3 domain or both a CH3 domain and a CH2 domain.
- the immunoglobulin derived sequences can include one ore more amino acid modifications, for example, 1, 2, 3, 4 or 5 substitutions, e.g., substitutions that reduce off-target binding.
- amino acid modification refers to an amino acid substitution, insertion, and/or deletion in a protein or peptide sequence.
- An “amino acid substitution” or “substitution” refers to replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid.
- a substitution can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping).
- Amino acids with nonpolar R groups Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine
- Amino acids with uncharged polar R groups Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine
- Amino acids with charged polar R groups negatively charged at pH 6.0: Aspartic acid, Glutamic acid
- Basic amino acids positively charged at pH 6.0
- Lysine, Arginine, Histidine at pH 6.0
- Another grouping may be those amino acids with phenyl groups: Phenylalanine, Tryptophan, and Tyrosine.
- transmembrane domains can be used in CAR expressed by the cells used in the methods described herein.
- Table 2 includes examples of suitable transmembrane domains. Where a spacer region is present, the transmembrane domain is located carboxy terminal to the spacer region.
- CAR expressed by the cells used in the methods described herein include one or more (e.g., two) costimulatory domains.
- the costimulatory domain(s) are located between the transmembrane domain and the CD3 ⁇ signaling domain.
- Table 3 includes examples of suitable costimulatory domains together with the sequence of the CD3 ⁇ signaling domain.
- FIG. 1 is a schematic depiction of IL13(E13Y)-zetakine CAR (Left) composed of the IL13R ⁇ 2-specific human IL-13 variant (huIL-13(E13Y)), human IgG4 Fc spacer (hu ⁇ 4 Fc), human CD4 transmembrane (huCD4 tm), and human CD3 ⁇ chain cytoplasmic (huCD3 ⁇ cyt) portions as indicated.
- IL13(EQ)BB ⁇ CAR which is the same as the IL13(E13Y)-zetakine with the exception of the two point mutations, L235E and N297Q indicated in red, that are located in the CH2 domain of the IgG4 spacer, and the addition of a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt).
- FIGS. 2A-C depict certain vectors and open reading frames.
- A is a diagram of the cDNA open reading frame of the 2670 nucleotide IL13(EQ)BBZ-T2ACD19t construct, where the IL13R ⁇ 2-specific ligand IL13(E13Y), IgG4(EQ) Fc hinge, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3 cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are indicated.
- the human GM-CSF receptor alpha and CD19 signal sequences that drive surface expression of the IL13(EQ)BB ⁇ CAR and CD19t are also indicated.
- B is a diagram of the sequences flanked by long terminal repeats (indicated by ‘R’) that will integrate into the host genome.
- C is a map of the IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid.
- FIG. 3 depicts the construction of pHIV7.
- FIG. 4 depicts the elements of pHIV7.
- FIG. 5 depicts a production scheme for IL13(EQ)BB ⁇ /CD19t+T CM .
- FIGS. 6A-C depicts the results of flow cytometric analysis of surface transgene and T cell marker expression.
- IL13(EQ)BB ⁇ /CD19t+T CM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+ (i.e., CD8 negative) CAR+ cells (A), or anti-CD19-PE and anti-CD4-FITC to detect CD4+CD19t+ and CD8+ (i.e., CD4 negative) CAR+ cells (B).
- FIGS. 7A-D depict the results of experiments comparing route of CAR+ T cell delivery (i.c. versus i.v.) for large established tumors.
- EGFP-ffLuc+ PBT030-2 TSs (1 ⁇ 10 5 ) were implanted into the right forebrain of NSG mice.
- mice were injected i.c.
- CD3+ T cells were only detected in the i.c. treated group, with no CD3+ cells detected in the tumor or surrounding brain parenchyma for i.v. treated mice.
- FIGS. 8A-B depict the results of studies showing that CAR+ T cell injected intracranially, either intratumoral (i.c.t.) or intraventricular (i.c.v.), can traffic to tumors on the opposite hemisphere.
- EGFP-ffLuc+ PBT030-2 TSs (1 ⁇ 10 5 ) were stereotactically implanted into the right and left forebrains of NSG mice.
- Schematic of multifocal glioma experimental model A).
- CD3 IHC showing T cells infiltrating both the right and left tumor sites (B).
- FIG. 9 depicts the amino acid sequence of IL13(EQ)BB ⁇ /CD19t+ (SEQ ID NO:10).
- FIG. 10 depicts a sequence comparison of IL13(EQ)41BB ⁇ [IL13 ⁇ EQ ⁇ 41BB ⁇ T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13).
- FIG. 11 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm2-41BB Zeta (SEQ ID NO:31 with GMCSFRa signal peptide; SEQ ID NO:39 without GMCSFRa signal peptide).
- FIG. 12 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:32 with GMCSFRa signal peptide; SEQ ID NO:40 without GMSCFRa signal peptide).
- FIG. 13 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD4tm-41BB-Zeta (SEQ ID NO:33 with GMCSFRa signal peptide; SEQ ID NO:41 without GMCSFRa signal peptide).
- FIG. 14 depicts the amino acid sequence of IL13(EmY)-IgG4(L235E,N297Q)-CD8tm-41BB-Zeta (SEQ ID NO:34 with GMCSFRa signal peptide; SEQ ID NO:42 without GMCSFRa signal peptide).
- FIG. 15 depicts the amino acid sequence of IL13(EmY)-Linker-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:35 with GMCSFRa signal peptide; SEQ ID NO:43 without GMCSFRa signal peptide).
- FIG. 16 depicts the amino acid sequence of IL13(EmY)-HL-CD28m-CD28gg-41BB-Zeta (SEQ ID NO:36 with GMCSFRa signal peptide; SEQ ID NO:44 without GMSCFRa signal peptide).
- FIG. 17 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:37 with GMSCFRa signal peptide; SEQ ID NO:45 without GMCSFRa signal peptide).
- FIG. 18 depicts the amino acid sequence of IL13(EmY) IgG4(L235E,N297Q)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:38 with GMCSFRa signal peptide; SEQ ID NO:46 without GMCSFRa signal peptide).
- FIG. 19 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm-41BB Zeta (SEQ ID NO:47 with GMCSFRa signal peptide; SEQ ID NO:48 without GMCSFRa signal peptide).
- FIG. 20 depicts the amino acid sequence of Her2scFv-IgG4(L235E, N297Q)-CD28tm-CD28gg-Zeta-T2A-CD19t.
- the various domains are listed in order below the sequence and are indicated by alternating underlining and non-underlining.
- the mature CAR sequence (SEQ ID NO:26) does not include the GMCSFRa signal peptide, the T2A skip sequence or truncated CD19.
- FIG. 21 depicts the amino acid sequence of Her2scFv-IgG4(L235E,N297Q)-CD8tm-41BB-Zeta-T2A-CD19t.
- the various domains are listed in order below the sequence and are indicated by alternating underlining and non-underlining.
- the mature CAR sequence (SEQ ID NO:27) does not include the GMCSFRa signal peptide, the T2A skip sequence or truncated CD19.
- FIGS. 22A-D depict HER2-specific CAR constructs and CAR T cell expansion data.
- FIGS. 23A-D depict in vitro characterization of HER2-CAR T cells against breast cancer cell lines.
- FIGS. 24A-F depict the result of studies on the in vitro tumor activity of HER2-CAR T cells.
- FIGS. 25A-I depict the result of studies on the in vivo anti-tumor efficacy of local intratumorally-delivered HER2-CAR T cells.
- FIGS. 26A-D depict the results of studies on local delivery of HER2-CAR T cells in human orthotopic BBM xenograft models.
- FIGS. 27A-D depict the results of studies on intraventricular delivery of HER2-CAR T cells.
- FIG. 28 schematically depicts the locations of tumor cell injection and CAR T cell injection for a study of intratumoral and intraventricular injection of CAR T cells targeting IL13 ⁇ 2R in a murine model of glioblastoma.
- FIGS. 29A-C depict the results of studies demonstrating regression of established glioma tumor xenografts after administration of IL13(EQ)BB ⁇ /CD19t+ T CM .
- ffLuc + PBT030-2 tumor cells (1 ⁇ 10 5 ) were stereotactically implanted into the right and left forebrains of NSG mice.
- mice were injected either ict or icv with 1 ⁇ 10 6 IL13(EQ)BB ⁇ + Tcm (1.6 ⁇ 10 6 total cells; 63% CAR+) as described in FIG. 4.1 above.
- A Representative mice from each group showing relative tumor burden using Xenogen Living Image.
- FIG. 30 depicts the results of studies demonstrating that huCD3+ cells are detected in the right and left brain tumors/hemispheres after ict and icv administration of IL13(EQ)BB ⁇ /CD19t+ T CM .
- ffLuc + PBT030-2 tumor cells (1 ⁇ 10 5 ) were stereotactically implanted into the right and left forebrains of NSG mice. On day 6, mice were injected either ict (left images) or icv (right images) with 1 ⁇ 10 6 IL13(EQ)BB ⁇ + Tcm (1.6 ⁇ 10 6 total cells; 63% CAR+).
- mice were euthanized from each group, brains were harvested, embedded in paraffin, and IHC was performed with anti-human CD3 antibody to detect T cells.
- Representative IHC images of the left and right tumor sites from mice of each group (ict: m406 and m410; icy: m414 and m415) are depicted. Inlays depict the xenogen flux images of the mice at the day of euthanasia and brain harvest.
- FIG. 31 schematically depicts the time course of CAR T cell preparation and treatment for a clinical trial of CAR T cells for treatment of glioblastoma (A) and provides several dosing schemes (B).
- FIG. 32 presents analysis of CAR T cell persistence, as monitored by CD19 (A) and presence of GBM cells as monitored by IL13R ⁇ 2 expression (B).
- FIG. 33 presents imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration.
- FIG. 34 is a series of graphs showing the levels of various cytokines during the course of treatment for one patient.
- FIGS. 35A-C are images depicting egression of recurrent multifocal glioblastoma, including spinal metastasis, following intraventricular delivery of IL13R ⁇ 2-targeted CAR T cells.
- a patient presenting with a recurrent multifocal GBM, including one metastatic site in the spine and extensive leptomeningeal disease was treated with six local infusions of IL13BB ⁇ Tcm into the resection cavity of the largest recurrent tumor focus (1 cycle of 2 M, and 5 cycles of 10M CAR+ T cells). While the CAR T cell injection site remained stable without evidence of disease recurrence for over 7-weeks, other disease foci distant from the CAR T cell injection site continued to progress (data not shown).
- This patient then received five weekly intraventricular (icy) infusions of IL13BB ⁇ Tcm (1 cycles of 2 M, and 4 cycles of 10M CAR+ T cells). Shown are MRI and/or PET images of (A) transverse brain section, (B) saggital brain section, and (C) transverse (top) and frontal (bottom) sections of the spine before (left) and one week after (right) completion of i.c.v. therapy, with tumor lesion sites indicated by red arrows in each image.
- icy intraventricular
- FIGS. 36A-B shows treatment regimens with enrollment on NCT02208362 and a compassionate use protocol. Enrollment on NCT02208362 was set at day 0 (A), with initiation of compassionate use protocol on day 107 (B).
- NovoTTF-100A a portable medical device that delivers low intensity, intermediate frequency, alternating electric fields by means of noninvasive, disposable scalp electrodes; FGFR, fibroblast growth factor receptor; MRI, magnetic resonance imaging, all of which was performed on the brain unless otherwise indicated; ICT, intracavitary; PET, positron emission tomography, performed at the indicated sites; ICV, intracerebroventricular.
- FIGS. 37A-C shows immunohistochemistry of primary and recurrent tumors.
- Tumor resected at initial diagnosis (A) and recurrent tumor (T1) resected at time of Rickham placement under NCT02208362 (B, C).
- Immunochemical staining using either IL13R ⁇ 2-specific or Ki67-specific DAB with hematoxylin counterstain are depicted, with red boxes outlining the successive magnified images going left to right.
- FIGS. 38A-B shows tumor lesion identification.
- A Identifying characteristics of GBM lesions T1-T8.
- B Brain MRI scans depicting the sites of T1-T7.
- FIGS. 39A-C shows resected tumor region remains stable, without evidence of disease progression/recurrence following intracavitary delivery of IL13BB ⁇ T CM .
- A Flow cytometry analysis of the IL13BB ⁇ T CM cell product. Top row, transduction with the indicated construct drove coordinate surface expression of the IL13BB ⁇ CAR (detected with anti-IL13) and the CD19t marker (detected with anti-CD19) via the T2A ribosomal skip sequence.
- T cell markers TCR- ⁇ / ⁇ , CD3, CD4 and CD8, as well as the exhaustion markers LAG-3, TIM-3, KLRG1 and PD-1 are depicted in the middle row; staining profiles for the memory markers CD62L, CD45RO, CCR7, CD27, and CD28, as well as the na ⁇ ve T cell marker CD45RA are depicted in the bottom row.
- B Treatment schema under NCT02208362.
- ICT intracavitary
- 6 cycles of ICT cell doses (1 cycle of 2 ⁇ 10 6 , and 5 cycles of 10 ⁇ 10 6 CAR+ cells) were administered with one week rest between cycles 3 and 4.
- C Yellow circles on brain MM scans show the site of resected tumor where catheter was placed (T1), as well as the resected-only tumor sites in the frontal lobe (T2, T3), and the newly arising tumor sites (T6, T7) over the 51-day ICT treatment time period.
- FIGS. 40A-E shows regression of recurrent multifocal glioblastoma, including spinal metastases, following intracerebroventricular delivery of IL13R ⁇ 2-targeted CART cells.
- A Treatment schema under compassionate use protocol. After the patient underwent placement of an intracerebroventricular (ICV) Rickham catheter, 5 cycles of ICV cell doses (1 cycle of 2 ⁇ 10 6 and 4 cycles of 10 ⁇ 10 6 CAR+ cells, indicated as cycles 7 through 11) were administered with one week rest between cycles 9 and 10. Red arrow, site of IL13BB ⁇ T CM delivery.
- ICV intracerebroventricular
- MM and/or PET images of (B) transverse brain sections, (C) saggital brain sections, and (D) transverse (top) and frontal (bottom) sections of the spine before (left) and one week after (right) completion of ICV therapy, with tumor lesion sites indicated by yellow circles in each image.
- E Maximum lesion areas for non-resected tumors T4-T8 depict their respective decreases over time with ICV therapy.
- FIG. 41 shows regression of recurrent multifocal GBM following ICV delivery of IL13R ⁇ 2-targeted CAR T cells. Maximum lesion areas for non-resected tumors T4-T7 are depicted.
- FIG. 42A-C shows analysis of cell infiltrates and cytokines from cerebrospinal fluid (CSF) samples.
- CSF cerebrospinal fluid
- A CSF cellular infiltrate numbers spiked after ICV cycles 9, 10 and 11, with flow cytometric evidence of CD19+ B cells, both CAR+ (i.e., CD19t+) and non-engineered CD3+ T cells, CD11b+ CD15+ granulocytes, and CD11b+ CD14+ HLA-DR+ monocytes.
- B Evaluation of the CD3+ T cell population in the CSF for the presence of gene-modified (i.e., CD19t+) T cells.
- CD3-gated cells from the CSF collected at the indicated day of cycles 9, 10 and 11 were co-stained for CD19 and CD8 (top histograms). Percentages of immunoreactive cells were then used to calculate numbers of total CD3+ T cells and CD19+CD3+(IL13BB ⁇ T CM ) cells per mL of CSF fluid at each time point.
- C Fold change in cytokine levels with ICV treatment cycles 7-11. Only those cytokines from the 30-plex analysis that exhibited a 10-fold or more change compared to pre-treatment levels are depicted.
- a chimeric antigen is a recombinant biomolecule that contains, at a minimum, an extracellular recognition domain, a transmembrane region, and an intracellular signaling domain.
- the term “antigen,” therefore, is not limited to molecules that bind antibodies, but to any molecule that can bind specifically to a target.
- a CAR can include a ligand that specifically binds a cell surface receptor.
- the extracellular recognition domain (also referred to as the extracellular domain or simply by the recognition element which it contains) comprises a recognition element that specifically binds to a molecule present on the cell surface of a target cell.
- the transmembrane region anchors the CAR in the membrane.
- the intracellular signaling domain comprises the signaling domain from the zeta chain of the human CD3 complex and optionally comprises one or more costimulatory signaling domains.
- CARs can both to bind antigen and transduce T cell activation, independent of MHC restriction. Thus, CARs are “universal” immunoreceptors which can treat a population of patients with antigen-positive tumors irrespective of their HLA genotype. Adoptive immunotherapy using T lymphocytes that express a tumor-specific CAR can be a powerful therapeutic strategy for the treatment of cancer.
- the CAR described herein can be produced using a vector in which the CAR open reading frame is followed by a T2A ribosome skip sequence and a truncated CD19 (CD19t), which lacks the cytoplasmic signaling tail (truncated at amino acid 323).
- CD19t truncated CD19
- co-expression of CD19t provides an inert, non-immunogenic surface marker that allows for accurate measurement of gene modified cells, and enables positive selection of gene-modified cells, as well as efficient cell tracking and/or imaging of the therapeutic T cells in vivo following adoptive transfer.
- Co-expression of CD19t provides a marker for immunological targeting of the transduced cells in vivo using clinically available antibodies and/or immunotoxin reagents to selectively delete the therapeutic cells, and thereby functioning as a suicide switch.
- a patient receiving an infusion, administration, or injection of CAR T cells may receive a single dose comprising between 1 ⁇ 10 6 and 15 ⁇ 10 6 cells.
- a single dose for use in the disclosed methods can comprise 1 ⁇ 10 6 , 2 ⁇ 10 6 , 3 ⁇ 10 6 , 4 ⁇ 10 6 , 5 ⁇ 10 6 , 6 ⁇ 10 6 , 7 ⁇ 10 6 , 8 ⁇ 10 6 , 9 ⁇ 10 6 , 10 ⁇ 10 6 , 11 ⁇ 10 6 , 12 ⁇ 10 6 , 13 ⁇ 10 6 , 14 ⁇ 10 6 , or 15 ⁇ 10 6 cells.
- a patient may receive a cumulative or total dose of cells between 20 ⁇ 10 6 and 150 ⁇ 10 6 T cells.
- the patient may receive about 20 ⁇ 10 6 , about 25 ⁇ 10 6 , about 30 ⁇ 10 6 , about 35 ⁇ 10 6 , about 40 ⁇ 10 6 , about 45 ⁇ 10 6 , about 50 ⁇ 10 6 , about 55 ⁇ 10 6 , about 60 ⁇ 10 6 , about 65 ⁇ 10 6 , about 70 ⁇ 10 6 , about 75 ⁇ 10 6 , about 80 ⁇ 10 6 , about 85 ⁇ 10 6 , about 90 ⁇ 10 6 , about 95 ⁇ 10 6 , about 100 ⁇ 10 6 , about 105 ⁇ 10 6 , about 110 ⁇ 10 6 , about 115 ⁇ 10 6 , about 120 ⁇ 10 6 , about 125 ⁇ 10 6 , about 130 ⁇ 10 6 , about 135 ⁇ 10 6 , about 140 ⁇ 10 6 , about 145 ⁇ 10 6 , or about 150 ⁇ 10 6 or more T cells over the course of treatment.
- a patient can receive a
- the disclosed methods can comprise an infusion, administration, or injection once a day, once every two days, once every three days, once every four days, once every five days, once every six days, a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every other month, once every three months, or once every six months.
- the disclosed methods can comprise continuous infusion, for instance, from a wearable pump.
- the total time course of treatment may be about 5 weeks, about 10 weeks, about 15 weeks, about 20 weeks, about 25 weeks, about 30 weeks, about 35 weeks, about 40 weeks, about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 65 weeks, about 70 weeks, about 75 weeks, or more.
- the patient may receive 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more infusions, administrations, or injections of T cells over the course of treatment according to the disclosed methods.
- a patient can receive 11 infusions of T cells over the course of 15 weeks.
- Treating cancer, and more specifically gliomas like glioblastoma, according to the disclosed methods can result in numerous therapeutic effects.
- treatment with the disclosed CAR T cells can result in an increase in the level of cytokines and chemokines in the CSF of a patient being treated according to the disclosed methods.
- Cytokine and/or chemokine expression may increase by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%, or cytokine and/or chemokine expression may increase by at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold compared to baseline levels, as measured prior to treatment with a composition comprising CAR T cells. This increase in expression may be observed for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more cytokines or chemokines.
- the expression of at least one of EGF, Eotaxin, FGF, G-CSF, GM-CSF, HGF, IFN- ⁇ , IFN- ⁇ , IL-10, IL-12, IL-13, IL-15, IL-17, IL-1R ⁇ , IL-1 ⁇ , IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIG, MIP-1 ⁇ , MIP-1 ⁇ , RANTES, TNF- ⁇ , and VEGF may increase as a result of treatment with CAR T cells as disclosed herein.
- the increase in cytokine and/or chemokine expression may be local (i.e. the increase is only observable in the CNS and CFS, while serum levels of cytokines and chemokines remain unchanged.
- Treatment according to the disclosed methods may also result in an increase in T cells detectable in the CSF. While at least some of the T cells detectable in the CSF following treatment will likely be CAR-expressing T cells, there may also be an increase in endogenous T cells that are recruited to the CSF. Although not wanting to be bound by theory, the increase in endogenous T cells may be a result of the recruitment of Type 1 and Type 2 T helper cells due to the increase in local cytokine levels. Additionally, the detectable T cells can comprise CD3+ T cells, as well as CD14+ CD11b+ HLA-DR+ mature myeloid populations, CD19+ B cells and CD11b+CD15+ granulocytes, and/or reactive lymphocytes, monocytes, and macrophages.
- the increase in the number of T cells in the CSF may be detectable for a specific period of time following treatment according to the disclosed methods.
- a detectable increase in T cells in the CSF may persist or be sustained for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more days following administration of a composition comprising T cells.
- an increase in the number of T cells observed in the CSF may not return to baseline levels (i.e. the number of T cells detectable prior to treatment) for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days.
- the number of T cells detectable in the CSF may increase by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%, or by at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold compared to baseline levels, as measured prior to treatment with a composition comprising CAR T cells.
- FIG. 31 The time course of CAR T cell preparation and treatment is depicted in FIG. 31 .
- research participants underwent resection of their tumor(s) followed by placement of a Rickham catheter and baseline imaging.
- Patient UPN097 underwent tumor resection and was treated in Cycle 1 with 2 ⁇ 10 6 cells and in Cycle 2 with 10 ⁇ 10 6 cells. In both Cycle 1 and Cycle 2 the cells were administered to the cavity left by resection. After the second cycle Patient UPN097 was taken off the study due to rapid tumor progression.
- Patient UPN109 was treated in Cycle 1 with 2 ⁇ 10 6 cells and in Cycles 2 and 3 with 10 ⁇ 10 6 cells. After a rest period, Patient UPN109 was treated in Cycles 4, 5 and 6 with 10 ⁇ 10 6 cells. In Cycles 1-6 the cells were administered intratumorally. In Cycle 7 the patient was treated with 2 ⁇ 10 6 cells. In Cycles 8 and 9 the patient was treated with 10 ⁇ 10 6 cells. In Cycles 7-10 the administration was intraventricular.
- intraventricular refers to the space inside the ventricular system, specifically the cerebral ventricles. Accordingly, the term “intraventricular” and “intracerebroventricular” may be used interchangeably throughout this disclosure. Accordingly, “intraventricular administration” or “intraventricular injection” refer to delivery of a composition into the ventricals of the brain (i.e. the cerebral ventricles).
- the cerebral ventricles are a series of interconnected, fluid-filled spaces that lie in the core of the forebrain and brainstem. This system comprises four ventricles: the right and left lateral ventricles (one of which is found in each hemisphere of the brain), the third ventricle, and the fourth ventricle.
- the disclosed methods comprise various routes of administering the compositions comprising T cells.
- the disclosed compositions may be delivered or administered intraventricularly.
- the disclosed compositions may be delivered or administered into the spinal canal (i.e. intrathecal delivery).
- the disclosed compositions may be delivered or administered into the epidural space of the spinal cord (i.e. epidural delivery).
- the disclosed compositions may be delivered or administered directly into a tumor (i.e. intratumoral delivery).
- the disclosed compositions may be delivered or administered into a cavity formed by the resection of tumor tissue (i.e. intracavity delivery).
- the disclosed methods can comprise a combination of the aforementioned routes of administration. For instance, a patient may receive at least one dose of the composition comprising T cells via intracavity delivery, followed by at least one dose of the composition via intraventricular delivery.
- FIG. 32A presents analysis of CAR T cell persistence, as monitored by CD19. This analysis shows good T cell persistence 8 days after the Cycle 2.
- FIG. 32B shows decreased presence of GBM cells as monitored by IL13R ⁇ 2 expression.
- FIG. 33A and FIG. 33B depict imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration.
- FIG. 33A one can see that few CD3+ or CD8+ T cells are present pretreatment.
- FIG. 33B which is a sample at Day 16 post-treatment taken from the left frontal tumor cavity wall shows a large area of necrotic tumor and significant presence of CD3+ and CD8+ cells.
- Gliomas express IL13 receptors, and in particular, high-affinity IL13 receptors.
- IL13 receptors unlike the IL13 receptor, glioma cells overexpress a unique IL13R ⁇ 2 chain capable of binding IL13 independently of the requirement for IL4R ⁇ or ⁇ c44.
- IL13 has pleotropic immunoregulatory activity outside the CNS. Both IL13 and IL4 stimulate IgE production by B lymphocytes and suppress pro-inflammatory cytokine production by macrophages.
- Detailed studies using autoradiography with radiolabeled IL13 have demonstrated abundant IL13 binding on nearly all malignant glioma tissues studied. This binding is highly homogeneous within tumor sections and in single cell analysis.
- IL13R ⁇ 2 is a very specific cell-surface target for glioma and is a suitable target for a CAR designed for treatment of a glioma.
- Certain patients may be more suitable than others to receive the disclosed methods of treatment. For instance, those patients with malignancies that highly express IL-13R ⁇ 2 may particularly benefit from treatment with the disclosed CAR T-cells.
- Suitability of a patient can be determined by staining a resected tumor sample from a patient to determine the amount of expression of IL-13R ⁇ 2. The sample may be scored based on the number of cells exhibiting weak, moderate, or strong staining intensity. Determining the expression level of Ki67 may also be beneficial for determining the aggressiveness of the disease. Once it has been determined that a patient is well suited to receive the disclosed CAR T cells, the patient may be treated according to the disclosed methods.
- Binding of IL13-based therapeutic molecules to the broadly expressed IL13R ⁇ 1/IL4 ⁇ / ⁇ c receptor complex has the potential of mediating undesired toxicities to normal tissues outside the CNS, and thus limits the systemic administration of these agents.
- An amino acid substitution in the IL13 alpha helix A at amino acid 13 of tyrosine for the native glutamic acid selectively reduces the affinity of IL13 to the IL13R ⁇ 1/IL4 ⁇ / ⁇ c receptor. Binding of this mutant (termed IL13(E13Y)) to IL13R ⁇ 2, however, was increased relative to wild-type IL13.
- this minimally altered IL13 analog simultaneously increases IL13's specificity and affinity for glioma cells.
- CAR described herein include an IL13 containing a mutation (E to Y or E to some other amino acid such as K or R or L or V) at amino acid 13 (according to the numbering of Debinski et al. 1999 Clin Cancer Res 5:3143s).
- IL13 having the natural sequence also may be used, however, and can be useful, particularly in situations where the modified T cells are to be locally administered, such as by injection directly into a tumor mass.
- gliomas are known to have a generally poor patient prognosis.
- GBM glioblastoma multiforme
- the 1-year and 2-year relative survival rates for GBM are 29.6% and 9.0%, respectively. Only 3.4% of patients with a GBM diagnosis survive more than 5 years.
- Current conventional treatments include, but are not limited to, radiation therapy, small molecules (e.g. temozolomide, irinotecan, imatinib mesylate, erlotinib, and hydroxyurea), and biologics such as antibodies (e.g. bevacizumab).
- the disclosed methods of treatment improve clinical prognosis in patients compared to current standards. For instance, the disclosed methods can increase 1-year, 2-year, and 5-year survival rates.
- the 1-year survival rate of a patient being treated according to the disclosed methods can at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%.
- the 2-year survival rate of a patient being treated according to the disclosed methods can at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%.
- the 5-year survival rate of a patient being treated according to the disclosed methods can at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%.
- the disclosed methods also increase the life expectancy of a patient compared to another patient receiving conventional treatments or SOC treatment, including radiation therapy, small molecule drug therapy, therapeutic biologics like therapeutic antibodies, or a combination thereof.
- the patient receiving SOC treatment in which the patient receiving SOC treatment can expect to survive about 15 months from initial diagnosis (overall survival or OS), the patient receiving the disclosed treatment can expect an OS of 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months or more.
- the patient receiving the claimed treatment can expect an OS of 42, 48, 54, 60, 66, 72, 78, 84, 90 months or more.
- the disclosed methods may improve a patient's prognosis through a variety of clinical outcomes. For instance, the disclosed methods can result in a reduction in tumor volume in a patient being treated with a composition comprising T cells. In some embodiments, the disclosed methods of treatment can result in at least a 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100% reduction in tumor volume. In some embodiments, the tumors in a patient may be completely eliminated and the patient can be cured of the malignancy.
- the disclosed methods are safe and well-tolerated. Patients being treated according to the disclosed methods may not experience significant side effects, and furthermore, may be able to discontinue taking auxiliary medications. For instance, in some embodiments, the disclosed methods will not result in any grade 3 or higher toxicities according to NCI Common Toxicity Criteria (CTC).
- CTC NCI Common Toxicity Criteria
- the CTC provides a quantifiable scale of 0-5, with 0 meaning no adverse event, 1 meaning mild, 2 meaning moderate, 3 meaning sever and undesirable, 4 meaning life threatening or disabling, and 5 meaning death.
- side effects and or toxicities may include events like mild or moderate headaches, fatigue, myalgia, and minor nervous system disorders such as olfactory aura, but high grade toxicities will be avoided.
- Steroids like dexamethasone are commonly used in the clinical management of gliomas to prevent neurological side effects like brain edema.
- the disclosed methods of treatment can decrease the need for such auxiliary treatments. For instance, if a patient is receiving a regimen of steroids (e.g. dexamethasone) prior to treatment according to the disclosed methods, the patient may be able to reduce the dose of the steroid regimen or discontinue the steroid regimen altogether without experiencing clinically deleterious effects.
- steroids e.g. dexamethasone
- Brain metastases of breast cancer can express HER2.
- Certain of the CAR described herein that are useful in treatment of malignant glioma are targeted to HER2.
- the CAR described herein can be produced by any means known in the art, though preferably they are produced using recombinant DNA techniques.
- Nucleic acids encoding the several regions of the chimeric receptor can be prepared and assembled into a complete coding sequence by standard techniques of molecular cloning known in the art (genomic library screening, PCR, primer-assisted ligation, site-directed mutagenesis, etc.) as is convenient.
- the resulting coding region is preferably inserted into an expression vector and used to transform a suitable expression host cell line, preferably a T lymphocyte cell line, and most preferably an autologous T lymphocyte cell line.
- Various T cell subsets isolated from the patient can be transduced with a vector for CAR expression.
- Central memory T cells are one useful T cell subset.
- Central memory T cell can be isolated from peripheral blood mononuclear cells (PBMC) by selecting for CD45RO+/CD62L+ cells, using, for example, the CliniMACS® device to immunomagnetically select cells expressing the desired receptors.
- PBMC peripheral blood mononuclear cells
- the cells enriched for central memory T cells can be activated with anti-CD3/CD28, transduced with, for example, a SIN lentiviral vector that directs the expression of the CAR as well as a truncated human CD19 (CD19t), a non-immunogenic surface marker for both in vivo detection and potential ex vivo selection.
- the activated/genetically modified central memory T cells can be expanded in vitro with IL-2/IL-15 and then cryopreserved.
- Example 1 Construction and Structure of an IL13R ⁇ 2-Specific CAR
- the codon optimized CAR sequence contains a membrane-tethered IL-13 ligand mutated at a single site (E13Y) to reduce potential binding to IL13R ⁇ 1, an IgG4 Fc spacer containing two mutations (L235E; N297Q) that greatly reduce Fc receptor-mediated recognition models, a CD4 transmembrane domain, a costimulatory 4-1BB cytoplasmic signaling domain, and a CD3 ⁇ cytoplasmic signaling domain.
- a T2A ribosome skip sequence separates this IL13(EQ)BB ⁇ CAR sequence from CD19t, an inert, non-immunogenic cell surface detection/selection marker.
- FIG. 1A is a schematic drawing of the 2670 nucleotide open reading frame encoding the IL13(EQ)BBZ-T2ACD19t construct.
- the IL13R ⁇ 2-specific ligand IL13(E13Y), IgG4(EQ) Fc, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3 ⁇ cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are all indicated.
- the IL13(EQ)BBZ-T2ACD19t construct includes a IL13R ⁇ 2-specific, hinge-optimized, costimulatory chimeric immunoreceptor sequence (designated IL13(EQ)BBZ), a ribosome-skip T2A sequence, and a CD19t sequence.
- the IL13(EQ)BBZ sequence was generated by fusion of the human GM-CSF receptor alpha leader peptide with IL13(E13Y) ligand 5 L235E/N297Q-modified IgG4 Fc hinge (where the double mutation interferes with FcR recognition), CD4 transmembrane, 4-1BB cytoplasmic signaling domain, and CD3 ⁇ cytoplasmic signaling domain sequences. This sequence was synthesized de novo after codon optimization.
- the T2A sequence was obtained from digestion of a T2A-containing plasmid.
- the CD19t sequence was obtained from that spanning the leader peptide sequence to the transmembrane components (i.e., basepairs 1-972) of a CD19-containing plasmid. All three fragments, 1) IL13(EQ)BBZ, 2) T2A, and 3) CD19t, were cloned into the multiple cloning site of the epHIV7 lentiviral vector. When transfected into appropriate cells, the vector integrates the sequence depicted schematically in FIG. 1B into the host cells genome.
- FIG. 1C provides a schematic drawing of the 9515 basepair IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid itself.
- IL13(EQ)BBZ CAR differs in several important respects from a previously described IL13R ⁇ 2-specific CAR referred to as IL13(E13Y)-zetakine (Brown et al. 2012 Clinical Cancer Research 18:2199).
- the IL13(E13Y)-zetakine is composed of the IL13R ⁇ 2-specific human IL-13 mutein (huIL-13(E13Y)), human IgG4 Fc spacer (hu ⁇ 4 Fc), human CD4 transmembrane (huCD4 tm), and human CD3 ⁇ chain cytoplasmic (huCD3 ⁇ cyt) portions as indicated.
- the IL13(EQ)BB ⁇ ) has two point mutations, L235E and N297Q that are located in the CH2 domain of the IgG4 spacer, and a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt).
- Example 2 Construction and Structure of epHIV7 Used for Expression of an IL13R ⁇ 2-Specific CAR
- the pHIV7 plasmid is the parent plasmid from which the clinical vector IL13(EQ)BBZ-T2A-CD19t_epHIV7 was derived in the T cell Therapeutics Research Laboratory (TCTRL) at City of Hope (COH).
- TTRL T cell Therapeutics Research Laboratory
- COH City of Hope
- the epHIV7 vector used for expression of the CAR was produced from pHIV7 vector.
- this vector uses the human EF1 promoter to drive expression of the CAR.
- Both the 5′ and 3′ sequences of the vector were derived from pv653RSN as previously derived from the HXBc2 provirus.
- the polypurine tract DNA flap sequences (cPPT) were derived from HIV-1 strain pNL4-3 from the NIH AIDS Reagent Repository.
- the woodchuck post-transcriptional regulatory element (WPRE) sequence was previously described.
- pHIV7 is schematically depicted in FIG. 3 .
- pv653RSN containing 653 bp from gag-pol plus 5′ and 3′ long-terminal repeats (LTRs) with an intervening SL3-neomycin phosphotransferase gene (Neo) was subcloned into pBluescript, as follows: In Step 1, the sequences from 5′ LTR to rev-responsive element (RRE) made p5′HIV-1 51, and then the 5′ LTR was modified by removing sequences upstream of the TATA box, and ligated first to a CMV enhancer and then to the SV40 origin of replication (p5′HIV-2).
- RRE rev-responsive element
- Step 2 after cloning the 3′ LTR into pBluescript to make p3′HIV-1, a 400-bp deletion in the 3′ LTR enhancer/promoter was made to remove cis-regulatory elements in HIV U3 and form p3′HIV-2.
- Step 3 fragments isolated from the p5′HIV-3 and p3′HIV-2 were ligated to make pHIV-3.
- Step 4 the p3′HIV-2 was further modified by removing extra upstream HIV sequences to generate p3′HIV-3 and a 600-bp BamHI-SalI fragment containing WPRE was added to p3′HIV-3 to make the p3′HIV-4.
- Step 5 the pHIV-3 RRE was reduced in size by PCR and ligated to a 5′ fragment from pHIV-3 (not shown) and to the p3′HIV-4, to make pHIV-6.
- Step 6 a 190-bp BglII-BamHI fragment containing the cPPT DNA flap sequence from HIV-1 pNL4-3 (55) was amplified from pNL4-3 and placed between the RRE and the WPRE sequences in pHIV6 to make pHIV-7.
- This parent plasmid pHIV7-GFP (GFP, green fluorescent protein) was used to package the parent vector using a four-plasmid system.
- a packaging signal, psi ⁇ , is required for efficient packaging of viral genome into the vector.
- the RRE and WPRE enhance the RNA transcript transport and expression of the transgene.
- the flap sequence, in combination with WPRE, has been demonstrated to enhance the transduction efficiency of lentiviral vector in mammalian cells.
- helper functions required for production of the viral vector
- the helper functions are divided into three separate plasmids to reduce the probability of generation of replication competent lentivirus via recombination: 1) pCgp encodes the gag/pol protein required for viral vector assembly; 2) pCMV-Rev2 encodes the Rev protein, which acts on the RRE sequence to assist in the transportation of the viral genome for efficient packaging; and 3) pCMV-G encodes the glycoprotein of the vesiculo-stomatitis virus (VSV), which is required for infectivity of the viral vector.
- VSV vesiculo-stomatitis virus
- the regions of homology include a packaging signal region of approximately 600 nucleotides, located in the gag/pol sequence of the pCgp helper plasmid; a CMV promoter sequence in all three helper plasmids; and a RRE sequence in the helper plasmid pCgp. It is highly improbable that replication competent recombinant virus could be generated due to the homology in these regions, as it would require multiple recombination events. Additionally, any resulting recombinants would be missing the functional LTR and tat sequences required for lentiviral replication.
- the CMV promoter was replaced by the EF1 ⁇ -HTLV promoter (EF1p), and the new plasmid was named epHIV7 ( FIG. 4 ).
- the EF1p has 563 bp and was introduced into epHIV7 using NruI and NheI, after the CMV promoter was excised.
- the IL13(EQ)BBZ-T2ACD19t_epHIV7 vector construct does not contain an intact 3′LTR promoter, so the resulting expressed and reverse transcribed DNA proviral genome in targeted cells will have inactive LTRs.
- no HIV-I derived sequences will be transcribed from the provirus and only the therapeutic sequences will be expressed from their respective promoters.
- the removal of the LTR promoter activity in the SIN vector is expected to significantly reduce the possibility of unintentional activation of host genes.
- Table 4 summarizes the various regulator elements present in IL13(EQ)BBZ-T2ACD19t_epHIV7.
- a seed bank is generated, which is used to inoculate the fermenter to produce sufficient quantities of plasmid DNA.
- the plasmid DNA is tested for identity, sterility and endotoxin prior to its use in producing lentiviral vector.
- cells were expanded from the 293T working cell (WCB), which has been tested to confirm sterility and the absence of viral contamination.
- a vial of 293T cells from the 293T WCB was thawed.
- Cells were grown and expanded until sufficient numbers of cells existed to plate an appropriate number of 10 layer cell factories (CFs) for vector production and cell train maintenance. A single train of cells can be used for production.
- CFs layer cell factories
- the lentiviral vector was produced in sub-batches of up to 10 CFs. Two sub-batches can be produced in the same week leading to the production of approximately 20 L of lentiviral supernatant/week. The material produced from all sub-batches were pooled during the downstream processing phase, in order to produce one lot of product.
- 293T cells were plated in CFs in 293T medium (DMEM with 10% FBS). Factories were placed in a 37° C. incubator and horizontally leveled in order to get an even distribution of the cells on all the layers of the CF.
- the initial tangential flow ultrafiltration (TFF) concentration of the endonuclease-treated supernatant was used to remove residual low molecular weight components from the crude supernatant, while concentrating the virus ⁇ 20 fold.
- the clarified endonuclease-treated viral supernatant was circulated through a hollow fiber cartridge with a NMWCO of 500 kD at a flow rate designed to maintain the shear rate at ⁇ 4,000 sec-1 or less, while maximizing the flux rate.
- Diafiltration of the nuclease-treated supernatant was initiated during the concentration process to sustain the cartridge performance.
- An 80% permeate replacement rate was established, using 4% lactose in PBS as the diafiltration buffer.
- the viral supernatant was brought to the target volume, representing a 20-fold concentration of the crude supernatant, and the diafiltration was continued for 4 additional exchange volumes, with the permeate replacement rate at 100%.
- T lymphocytes are obtained from a patient by leukopheresis, and the appropriate allogenic or autologous T cell subset, for example, Central Memory T cells (T CM ), are genetically altered to express the CAR, then administered back to the patient by any clinically acceptable means, to achieve anti-cancer therapy.
- T CM Central Memory T cells
- Suitable T CM can be prepared as follows. Apheresis products obtained from consented research participants are ficolled, washed and incubated overnight. Cells are then depleted of monocyte, regulatory T cell and na ⁇ ve T cell populations using GMP grade anti-CD14, anti-CD25 and anti-CD45RA reagents (Miltenyi Biotec) and the CliniMACSTM separation device. Following depletion, negative fraction cells are enriched for CD62L+ T CM cells using DREG56-biotin (COH clinical grade) and anti-biotin microbeads (Miltenyi Biotec) on the CliniMACSTM separation device.
- DREG56-biotin COH clinical grade
- anti-biotin microbeads Miltenyi Biotec
- T CM cells are formulated in complete X-Vivo15 plus 50 IU/mL IL-2 and 0.5 ng/mL IL-15 and transferred to a Teflon cell culture bag, where they are stimulated with Dynal ClinExTM Vivo CD3/CD28 beads. Up to five days after stimulation, cells are transduced with IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentiviral vector at a multiplicity of infection (MOI) of 1.0 to 0.3.
- MOI multiplicity of infection
- Cultures are maintained for up to 42 days with addition of complete X-Vivo15 and IL-2 and IL-15 cytokine as required for cell expansion (keeping cell density between 3 ⁇ 10 5 and 2 ⁇ 10 6 viable cells/mL, and cytokine supplementation every Monday, Wednesday and Friday of culture). Cells typically expand to approximately 10 9 cells under these conditions within 21 days. At the end of the culture period cells are harvested, washed twice and formulated in clinical grade cryopreservation medium (Cryostore CS5, BioLife Solutions).
- cryopreserved and released product On the day(s) of T cell infusion, the cryopreserved and released product is thawed, washed and formulated for re-infusion.
- the cryopreserved vials containing the released cell product are removed from liquid nitrogen storage, thawed, cooled and washed with a PBS/2% human serum albumin (HSA) Wash Buffer. After centrifugation, the supernatant is removed and the cells resuspended in a Preservative-Free Normal Saline (PFNS)/2% HSA infusion diluent. Samples are removed for quality control testing.
- PFNS Preservative-Free Normal Saline
- HSA Preservative-Free Normal Saline
- FIGS. 6A-C depict the results of flow cytometric analysis of surface transgene and T cell marker expression.
- IL13(EQ)BB ⁇ /CD19t+ T CM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+ (i.e., CD8 negative) CAR+ cells ( FIG. 6A ), or anti-CD19-PE and anti-CD4-FITC to detect CD4+ CD19t+ and CD8+ (i.e., CD4 negative) CAR+ cells ( FIG. 6B ).
- IL13(EQ)BB ⁇ /CD19t+ T CM HD006.5 and HD187.1 were stained with fluorochrome-conjugated anti-CD3, TCR, CD4, CD8, CD62L and CD28 (grey histograms) or isotype controls (black histograms).
- FIG. 6C In each of FIGS. 6A-C , the percentages indicated are based on viable lymphocytes (DAPI negative) stained above isotype.
- PBT030-2 engrafted mice were treated with either two i.v. infusions (5 ⁇ 10 6 CAR+ T CM ; days 19 and 26) or four i.c. infusions (1 ⁇ 10 6 CAR+ T CM ; days 19, 22, 26 and 29) of IL13(EQ)BBZ+ T CM , or mock T CM (no CAR).
- two i.v. infusions 5 ⁇ 10 6 CAR+ T CM ; days 19 and 26
- four i.c. infusions (1 ⁇ 10 6 CAR+ T CM ; days 19, 22, 26 and 29) of IL13(EQ)BBZ+ T CM , or mock T CM (no CAR).
- IL13(EQ)BBZ+ T CM IL13(EQ)BBZ+ T CM
- mock T CM mock T CM
- FIGS. 7A-B brains from a cohort of mice 7 days post T cell injection were harvested and evaluated for CD3+ human T cells by IHC.
- mice treated i.v. with either mock T CM or IL13(EQ)BB ⁇ T CM there were no detectable CD3+ human T cells in the tumor or in others mouse brain regions where human T cells typically reside (i.e. the leptomeninges) ( FIG. 7C ), suggesting a deficit in tumor tropism. This is in contrast to the significant number of T cells detected in the i.c. treated mice ( FIG. 7D ).
- Tumor derived cytokines are important in recruiting T cells to the tumor.
- PBT030-2 tumor cells were evaluated and it was found that this line produces high levels of MCP-1/CCL2 comparable to U251T cells (data not shown), a glioma line previously shown to attract i.v. administered effector CD8+ T cells to i.c. engrafted tumors.
- Malignant gliomas are highly invasive tumors and are often multi-focal in presentation.
- the studies described above establish that IL13BBZ T CM can eliminate infiltrated tumors such as PBT030-2, and mediate long-term durable antitumor activity.
- the complete amino acid sequence of IL13(EQ)BB ⁇ /CD19t is depicted in FIG. 9 .
- the entire sequence (SEQ ID NO:1) includes: a 22 amino acid GMCSF signal peptide (SEQ ID NO:2), a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); a 22 amino acid CD4 transmembrane sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; a 112 amino acid CD3 ⁇ sequence (SEQ ID NO:7); a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9).
- the mature chimeric antigen receptor sequence includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; and a 112 amino acid CD3 ⁇ sequence (SEQ ID NO:7).
- IL-13/IgG4/CD4t/41-BB sequence SEQ ID NO:11
- SEQ ID NO:11 which includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); and a 42 amino acid 4-1BB sequence (SEQ ID NO:6).
- the IL13/IgG4/CD4t/4-1BB sequence (SEQ ID NO:11) can be joined to the 112 amino acid CD3 ⁇ sequence (SEQ ID NO:7) by a linker such as a Gly Gly Gly linker.
- the CAR sequence (SEQ ID NO:10) can be preceded by a 22 amino acid GMCSF signal peptide (SEQ ID NO:2).
- FIG. 10 depicts a comparison of the sequences of IL13(EQ)41BB ⁇ [IL13 ⁇ EQ ⁇ 41BB ⁇ T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13).
- FIGS. 11-18 depict the amino acid sequences of additional CAR directed against IL13R ⁇ 2.
- the various domains are labelled except for the GlyGlyGly spacer located between certain intracellular domains.
- Each includes human IL13 with and Glu to Tyr (SEQ ID NO:3; amino acid substitution E13Y shown in highlighted).
- the amino acid sequence expressed can include a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9) to permit coordinated expression of a truncated CD19 sequence on the surface of CAR-expressing cells.
- a panel of CAR comprising human IL13(E13Y) domain, a CD28 tm domain, a CD28gg costimulatory domain, a 4-1BB costimulatory domain, and a CD3 ⁇ domain CAR backbone and including either a HL (22 amino acids) spacer, a CD8 hinge (48 amino acids) spacer, IgG4-HL-CH3 (129 amino acids) spacer or a IgG4(EQ) (229 amino acids) spacer were tested for their ability to mediate IL13R ⁇ 2-specific killing as evaluated in a 72-hour co-culture assay. With the exception of HL (22 amino acids) which appeared to have poor CAR expression in this system, all were active.
- Her2scFv-IgG4(L235E, N297Q)-CD28tm-CD28gg-Zeta-T2A-CD19t is referred to as Her2scFv-IgG4(L235E, N297Q)-CD28tm-CD28gg-Zeta-T2A-CD19t.
- This CAR includes a variety of important features including: a scFv targeted to HER2; an IgG4 Fc region that is mutated at two sites within the CH2 region (L235E; N297Q) in a manner that reduces binding by Fc receptors (FcRs); a CD28 transmembrane domain, a CD28 co-stimulatory domain, and CD3 ⁇ activation domain.
- the immature CAR includes: GMCSFR signal peptide, HER2 scFv, IgG4 that acts as a spacer, a CD8 transmembrane domain, a 4-IBB co-stimulatory domain that includes a LL to GG sequence alteration, a three Gly sequence, CD3 Zeta stimulatory domain.
- the transcript also encodes a T2A ribosomal sequence and a truncated CD19 sequence that are not part of the CAR protein sequence.
- the mature CAR is identical to the immature CAR, but lacks the GMCSF signal peptide.
- FIG. 22A is a schematic diagram of two the HER2-specific CAR constructs depicted in FIG. 20 and FIG. 21 .
- HER2(EQ)28 ⁇ the scFv is tethered to the membrane by a modified IgG4 Fc linker (double mutant, L235E; N297Q), containing a CD28 transmembrane domain, an intracellular CD28 co-stimulatory domain and a cytolytic CD3 ⁇ domain.
- the T2A skip sequence separates the CAR from a truncated CD19 (CD19t) protein employed for cell tracking.
- HER2(EQ)BB ⁇ is similar except that the costimulatory domain is 4-1BB rather than CD28 and the transmembrane domain is a CD8 transmembrane domain rather than a CD28 transmembrane domain.
- Human central memory (TCM) cells were transfected with a lentiviral vector expressing either HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ .
- FIG. 22B depicts representative FACS data of human TCM surface phenotype.
- FIG. 22C depicts the results of assays for CD19 and Protein L expression in TCM transfected with a lentiviral vector expressing either HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ .
- FIG. 23A depicts the HER2 expression level of each of these lines.
- FIG. 23B Flow cytometry (gated on CAR+ T cells) was used to characterize CD107a degranulation and IFN ⁇ production in Mock (untransduced), HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ CAR T cells following a 5 hr co-culture with either MDA-MB-361 tumor cells (low HER2 expressing) or BBM1 tumor cells (high HER2 expressing).
- FIG. 23C Similar studies were conducted with the other breast cancer cells lines, and the results are summarized in FIG. 23C . Production of IFN ⁇ production by HER2-CAR T cells following a 24 hr culture with recombinant HER2 protein or tumor targets was measured by ELISA and the results of this analysis are shown in FIG. 23D .
- FIG. 24A Flow cytometry was used to assess tumor cell killing following a 72 h co-culture of Mock (untransduced), HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ CAR T cells with tumor targets.
- the results of this analysis are presented in FIG. 24A .
- PD-1 and LAG-3 induction in total CAR T cells after a 72 h co-culture with HER2-negative MDA-MB-468 or HER2-positive BBM1 cells was measured, and the results of this analysis are presented in FIG. 24B .
- PD-1 induction in CD8+ CAR T cells following a 72 h co-culture with tumor targets that are HER2-negative (LCL lymphoma, MDA-MB-468, U87 glioma), low-HER2 expressing (MDA-MB-361, 231BR) or high-HER2 expressing (SKBR3, BT474, BBM1) was measured, and the results of this analysis are presented in FIG. 24C .
- HER2(EQ)BB ⁇ causes lower PD-1 induction that does HER2(EQ)28 ⁇ .
- Tumor cell killing with Effector:Tumor (E:T) ratio ranging from 0.25:1 to 2:1 was measured for both HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ CAR T cells.
- FIG. 24D shows that both HER2(EQ)28 ⁇ and HER2(EQ)BB ⁇ are effective in tumor cell killing in vitro.
- CFSE proliferation of HER2-CAR T cells following a 72 h co-culture with MDA-MB-468 or BBM1 cells was measured by flow cytometry.
- FIG. 24E shows that HER2(EQ)BB ⁇ CAR T cells proliferate more than HER2(EQ)28 ⁇ CAR T cells.
- FIGS. 25A-25C are H&E staining of tumors. Mice were treating by injection directly into the tumor with Mock (untransduced) or HER2(EQ)BB ⁇ CAR T cells.
- BBM1 cells 0.2M or BT474 (0.15M) were intracranially injected in NSG mice.
- HER2(EQ)28 ⁇ or HER2(EQ)BB ⁇ , or Mock (untransduced) T cells (1M) were injected intratumorally.
- BBM1 ( FIG. 26A ) and BT474 ( FIG. 26B ) tumors were monitored by luciferase-based optical imaging. Kaplan Meier curves are presented in FIG. 26C and FIG. 26D .
- FIG. 27A illustrates the region of tumor implantation by stereotactic injection of BBM1 cells (0.2M), and intraventricular T cell delivery. Staining of tumors is depicted in FIG. 27B .
- HER2(EQ)28 ⁇ , HER2(EQ)BB ⁇ , or Mock (unstransduced) T cells (0.5M) were injected intratumorally. Tumor growth was monitored by luciferase-based optical imaging.
- FIG. 27C presents the flux averages for each treatment group, and FIG. 27D presents the Kaplan Meier survival curve for each treatment group.
- Example 14 Comparison of Intracranial and Intratumoral Administration of T CM Expressing a CAR Targeted to IL13R ⁇ 2
- ic intracranial
- ict intratumoral
- icy intraventricular
- mice that had been enriched from PBMC by CliniMACSTM/AutoMACS selection were lenti-transduced with IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentivirus, expanded and then cryopreserved using methods similar to that described above.
- mice were observed daily for overall health, including body weight and alertness. Tumor burden, as measured by Xenogen imaging, was examined; and immunohistochemistry (IHC) to detect T cell recruitment/infiltration of the tumors was also performed on a subset of mice.
- IHC immunohistochemistry
- mice from each group were euthanized, their brains harvested, embedded in paraffin and immunohistochemistry (IHC) was performed to evaluate the presence of human CD3-expressing cells (i.e., human T cells).
- IHC immunohistochemistry
- mice While this was not a survival study, and thus mice were all euthanized at specific time points to evaluate T cell trafficking in the brains (described below), the mice were monitored daily for any obvious signs of distress or general toxicity. Mice treated with either the ict or icv regimen did not exhibit any weight loss, and were bright, alert and reactive throughout the experiment. Thus, regardless of the route of T cell administration, there were no signs of any therapy-associated adverse effects.
- ict delivery of IL13(EQ)BB ⁇ /CD19t+T CM exhibited robust anti-tumor activity against the PBT030-2 tumors as expected.
- icv delivery of IL13(EQ)BB ⁇ /CD19t+ T CM appeared to provide greater therapeutic benefit against is engrafted PBT030-2 tumors than that observed with ict administration, especially against the tumor lesion in the contralateral (left) hemisphere.
- CD3+ T cells were found at both the left and right tumor sites in mice that had received either ict or icv administered T cells. These data are representative of 3 mice in each group at one week, and 2 mice in each group at two weeks post T cell administration.
- Example 15 Phase 1 Clinical Trial Evaluating IL-13R ⁇ 2 CAR T Cells for Treatment of Glioblastoma
- This example describes the initial findings of a clinical trial evaluating the safety, feasibility and bioactivity of weekly intracranial infusions of autologous IL13BB ⁇ Tcm in patients with recurrent IL13R ⁇ 2+ GBM.
- Enrolled patients undergo leukapheresis to collect autologous PBMC and, concurrent with IL13BB ⁇ + Tcm manufacturing, tumor biopsy or resection is performed, with placement of a reservoir/catheter device.
- patients are treated on a 4-week therapeutic regimen, consisting of 3-weekly intracranial infusions of IL13BB ⁇ + Tcm followed by one rest week for toxicity and disease assessment.
- This patient was initially treated per protocol with six local infusions of IL13BB ⁇ Tcm into the resection cavity of the largest recurrent tumor focus in the posterior temporal-occipital region. Encouragingly, this CAR T cell injection site remained stable without evidence of disease recurrence for over 7-weeks, while other disease foci distant from the CAR T cell injection site continued to progress.
- This patient was then treated on a compassionate use protocol with five weekly intraventricular infusions of IL13BB ⁇ Tcm without any other therapeutic interventions.
- One week following the final intraventricular CAR T cell infusion all intracranial and spinal tumors had regressed with most decreasing more than 75% by volume, and this patient remained clinically stable four months following the start of CAR T cell treatment.
- the CAR, IL13(EQ)BB ⁇ , used in this study is described above.
- the sequence of the immature CAR, including the CD19t marker is depicted in FIG. 9 .
- the entire immature sequence includes: a 22 amino acid GMCSF signal peptide (SEQ ID NO:2), a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); a 22 amino acid CD4 transmembrane sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; a 112 amino acid CD3 ⁇ sequence (SEQ ID NO:7); a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9).
- T CM were enriched from peripheral blood mononuclear cells (PBMC) using the CliniMACS® device to immunomagnetically select for CD45RO+/CD62L+ T CM .
- PBMC peripheral blood mononuclear cells
- CliniMACS® device to immunomagnetically select for CD45RO+/CD62L+ T CM .
- These cells were activated with anti-CD3/CD28 Dynal beads, transduced with a SIN lentiviral vector that directs the expression of the IL13(EQ)BB ⁇ CAR.
- the activated/genetically modified IL13(EQ)BB ⁇ /CD19t+ T CM cells were expanded in vitro with IL-2/IL-15 and then cryopreserved.
- CAR T cells were performed manually over about 5-10 minutes through a Rickham catheter followed by up to 1.0 mL preservative-free normal-saline (PFNS) flush delivered by convection enhanced delivery (CED) at 0.5 ml/hour.
- PFNS preservative-free normal-saline
- CED convection enhanced delivery
- Intraventricular administration of CAR T cells was performed manually over approximately 5-10 minutes through a Rickham catheter placed into the lateral ventricle. This was followed by up to 0.5 mL preservative-free normal-saline (PFNS) flush delivered via a manual push technique over 5-10 minutes.
- PFNS flush is meant to clear the administration line and push remaining CAR T cells through the catheter.
- FIG. 31 The time course of CAR T cell preparation and treatment is depicted in FIG. 31 .
- research participants underwent resection of their tumor(s) followed by placement of a Rickham catheter and baseline imaging.
- Patient UPN097 underwent tumor resection and was treated in Cycle 1 with 2 ⁇ 10 6 cells and in Cycle 2 with 10 ⁇ 10 6 cells. In both Cycle 1 and Cycle 2 the cells were administered to the cavity left by resection. After the second cycle Patient UPN097 was taken off the study due to rapid tumor progression.
- Patient UPN109 was treated in Cycle 1 with 2 ⁇ 10 6 cells and in Cycles 2 and 3 with 10 ⁇ 10 6 cells. After a rest period, Patient UPN109 was treated in Cycles 4, 5 and 6 with 10 ⁇ 10 6 cells. In Cycles 1-6 the cells were administered into. In Cycle 7 the patient was treated with 2 ⁇ 10 6 cells. In Cycles 8 and 9 the patient was treated with 10 ⁇ 10 6 cells. In Cycles 7-10 the administration was intraventricular.
- FIG. 32A presents analysis of CAR T cell persistence, as monitored by CD19. This analysis shows good T cell persistence 8 days after the Cycle 2.
- FIG. 32B shows decreased presence of GBM cells as monitored by IL13R ⁇ 2 expression on cells.
- FIG. 33A and FIG. 33B depict imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration.
- FIG. 33A one can see that few CD3+ or CD8+ T cells are present pretreatment.
- FIG. 33B which is a sample at Day 16 post-treatment taken from the left frontal tumor cavity wall shows a large area of necrotic tumor and significant presence of CD3+ and CD8+ cells.
- FIGS. 34A-D there was an increase in IFN-gamma (a Th1 cytokine) over the two Cycles of treatment while levels of IL-13 (a Th2 cytokine did not change significantly ( FIG. 34A and FIG. 34B ).
- IL-6 a tumor related cytokine, decreased during Cycle 1 and remained at the lower level during Cycle 2 ( FIG. 34C ).
- IL-8 another tumor related cytokine, decreased during Cycle 1, but increased towards its pre-Cycle 1 level during Cycle 2 ( FIG. 34D ).
- FIGS. 35A-B presents MM and/or PET images of transverse brain section ( FIG. 35A ) and saggital brain section ( FIG. 35B ).
- FIG. 35C presents transverse (top) and frontal (bottom) sections of the spine before (left) and one week after (right) completion of intraventricular therapy, with tumor lesion sites indicated by red arrows in each image.
- a 50 year old male was initially diagnosed with a low-grade brain tumor in the right temporal lobe after presenting with grand mal seizures. After four months of monitoring, this right temporal tumor displayed increased enhancement by MRI, and the patient underwent tumor resection which confirmed a diagnosis of WHO grade IV glioma (GBM). The patient then received standard-of-care adjuvant proton radiation to a total dose of 59.4 cobalt Gy equivalent with concurrent temozolomide (140 mg daily), followed by 4-cycles of temozolomide with concomitant use of the Novocure device (NovoTTF-100A) for three months. Six months after the primary tumor resection, PET and MRI images showed evidence of disease progression.
- IL13R ⁇ 2-targeted CAR T cells FIG. 36
- IHC intracranial pressure
- FIG. 37 Peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- NCT01975701 fibroblastic growth factor inhibitor
- the patient was treated on a separate clinical protocol evaluating a fibroblastic growth factor inhibitor (NCT01975701), and progressed through therapy with symptoms of headaches, confusion and disorientation increasing. Additionally, the patient was tapered off steroids prior to T cell injections.
- This patient was treated starting with a low dose of 2 ⁇ 10 6 CAR+ T cells followed by five infusions of 10 ⁇ 10 6 CAR+ T cells ( FIG. 39 ).
- a second catheter was placed in the right lateral ventricle, allowing the patient to receive an additional five intracerebroventricular (ICV) treatment cycles of IL13BB ⁇ TCM, again starting at a low dose of 2 ⁇ 10 6 CAR T cells followed by four infusions of 10 ⁇ 10 6 CAR T cells ( FIG. 40 ).
- ICV intracerebroventricular
- the patient received 11 cell infusions for a total dose of 94 ⁇ 10 6 CAR+ T cells.
- the treatment course encompassed 15-weeks, with evaluation weeks for toxicity and disease assessment (i.e., MM and PET imaging) taking place after every third cycle, and after the final two ICV infusions.
- the patient received no other therapeutic interventions during this CAR T cell treatment course, and findings up to the 190 day evaluation period, encompassing the 11 infusions cycles, is reported here.
- a second IL13BB ⁇ TCM product was manufactured and beginning on day 192 this patient has continued to receive ICV infusions of this second manufactured product approximately every 3 weeks.
- Example 18 Cell Product Manufacture and Infusion
- the lentiviral vector encoding the 4-1BB costimulatory, IL13R ⁇ 2-targeted CAR, IL13BB ⁇ is detailed herein.
- the codon optimized CAR sequence contains a membrane-tethered human IL-13 ligand mutated at a single site (E13Y) to reduce potential binding to IL13R ⁇ 1, a human IgG4 Fc spacer containing two mutations (L235E; N297Q) that prevent Fc receptor-mediated recognition, a human CD4 transmembrane domain, a human costimulatory 4-1BB cytoplasmic signaling domain, and a human CD3 ⁇ cytoplasmic signaling domain.
- a T2A ribosome skip sequence then separates this IL13BB ⁇ CAR sequence from a truncated human CD19 sequence (CD19t), an inert, nonimmunogenic cell surface marker.
- PBMC peripheral blood mononuclear cells
- X Vivo15 media Bio Whittaker
- FCS fetal calf serum
- CliniMACSTM PBS/EDTA buffer Miltenyi Biotec
- HSA human serum albumin
- CSL Behring clinical grade biotinylated-DREG56 mAb
- CD62L+ fraction (TCM) was purified with positive selection on CliniMACSTM according to the manufacturer's instructions, and resuspended in X Vivo15 containing 10% FCS.
- TCM TCM were stimulated with GMP Dynabeads® Human T expander CD3/CD28 (Invitrogen) at a 1:3 ratio (T cell:bead), and transduced with clinical grade IL13BB ⁇ -T2A-CD19t_epHIV7 at an MOI of 0.3 in 5.5 mL X Vivo15 containing 10% FCS with 5 ⁇ g/mL protamine sulfate (APP Pharmaceutical), 50 U/mL rhIL-2 and 0.5 ng/mL rhIL-15 in a 32 Vuelife tissue culture bag (AFC) that was placed at a horizontal position on a culture rack at 37° C., 5% CO2.
- GMP Dynabeads® Human T expander CD3/CD28 Invitrogen
- IL13BB ⁇ -T2A-CD19t_epHIV7 MOI of 0.3 in 5.5 mL X Vivo15 containing 10% FCS with 5 ⁇ g/mL protamine sulf
- T cells were transferred to 730 Vuelife bags (AFC). Seven days after the lentiviral transduction, the CD3/CD28 Dynabeads were removed using the Dynal ClinEx Vivo Magnetic Particle Concentrator bag magnet, and bead-free T cells were drained into a new 730 Vuelife bag.
- the T2A ribosome skip sequence 12 then separates this IL13BB ⁇ sequence from CD19t, an inert, nonimmunogenic cell surface marker marking cell transduction ( FIG. 39A ).
- This T2A linkage results in the coordinate expression of both IL13BB ⁇ and CD19t from a single transcript.
- TCM central memory T cells
- EOP end-of-process
- IL13BB ⁇ TCM product underwent quality control release testing as per the clinical protocol.
- T cells were thawed, washed and reformulated into a final volume of 0.5 mL in pharmaceutical preservative-free normal saline (PFNS) with 2% human serum albumin (HSA).
- PFNS pharmaceutical preservative-free normal saline
- HSA human serum albumin
- Cells were manually injected into the Rickham reservoir using a 21 gauge butterfly needle to deliver a 0.5 mL volume over 5-10 minutes, followed by up to 1 mL PFNS flush delivered by convection enhanced delivery (CED) at 0.5 mL per hour.
- CED convection enhanced delivery
- the post-gadolinium T1 weighted MRI sequences of the brain and spine were acquired on a Siemens Viro 3 Tesla scanner. Lesions were measured on axial T1 MPR weighted images obtained after the administration of Multihance. Imaging with 18-F-fluorodeoxyglucose (18-F-FDG) was performed using a GE Discovery DST HP60 PET-CT scanner (70 cm axial field of view, slice thickness 3.75 mm). Maximal standardized uptake values (SUVs) were obtained utilizing Vital Images Vitrea version 6.7.2 software. Regions of contrast-enhancing tumor foci were outlined by a radiologist for measurements of largest tumor area (mm2) and tumor volumes (cm3) were computed.
- Cryopreserved cell banks of quality control released autologous IL13BB ⁇ TCM were thawed and reformulated for infusion by washing twice with phosphate buffered saline (PBS) with 2% HSA and resuspending in pharmaceutical preservative-free normal saline with 2% HSA.
- Delivery of the therapeutic CAR T cells into either the glioma resection cavity (ICT) or the lateral ventricle (ICV) was achieved using a HolterTM Rickham Ventriculostomy Reservoir (Codman), with a ventricular catheter (Integra Pudenz), and a stylet.
- the reservoir/catheter system was inserted at the time of tumor resection, and the tip of the catheter was partially embedded into the resection wall in order to allow for cell delivery both into the cavity and into the peritumoral brain tissue.
- Post-operative imaging CT and MRI were obtained to confirm catheter position and extent of tumor resection.
- Example 20 IL13BB ⁇ TCM Display a Central Memory-Like T Cell Phenotype
- Enriched TCM (36 ⁇ 10 6 ) were ex vivo stimulated, lentivirally transduced and expanded to yield 638 ⁇ 10 6 total cells in 17 days.
- the final T cell product (CD3+ and TCR+) consisted of CD4 (74%) and CD8 (16%) T cell subsets and expressed IL13BB ⁇ and CD19t with gene modified co-staining for both cell surface proteins ( FIG. 39A ).
- the CAR T cell product exhibited a central memory T cell phenotype, expressing CD45RO (97%), CD62L (57%), CCR7 (28%), CD28 (97%) and CD27 (59%) ( FIG. 39A ).
- the product also expressed of some markers of exhaustion, including TIM-3 (65%) and LAG-3 (49%), but not significant levels of PD-1 and KLRG1 ( FIG. 39A ).
- the patient was treated with weekly infusions of IL13BB ⁇ TCM administered via a reservoir/catheter device through two different intracranial delivery routes, that being intracavitary (ICT) delivery following tumor resection (cycles 1-6) and intracerebroventricular (ICV) delivery into the cerebral spinal fluid (CSF) (cycles 7-11).
- ICT intracavitary
- ICV intracerebroventricular
- CSF cerebral spinal fluid
- the 11 intracranial infusions at a maximum cell dose of 10 ⁇ 10 6 CAR+ T cells, were well-tolerated with no grade 3 or higher toxicity (NCI Common Toxicity Criteria) with possible or higher attribution to the therapy observed. Mild events noted following CAR T cell infusions include.
- the patient's tumor displayed characteristics of a highly aggressive recurrent GBM with poor prognostic features. This included evidence of recurrence from primary diagnosis within six months following standard-of-care therapy, the presentation of multifocal tumor lesions, including spinal lesions and extensive leptomeningeal disease ( FIG. 38 ), histological features of a dedifferentiated GBM, and a high tumor proliferation rate with over 60% of the cells staining positive for Ki67 ( FIG. 37B ). Tumor expression of IL13R ⁇ 2, as evaluated by IHC on FFPE of resected tumor tissue, was similar between the primary and recurrent tumors with an H score of 100 and 80, respectively ( FIG. 37 ).
- Intratumoral IL13R ⁇ 2 expression for the recurrent tumor was heterogeneous, with 10% of the cells showing high staining intensity (2-3+), 60% showing low expression (1+), and 30% of the cells not staining above background (0+).
- the highest levels of IL13R ⁇ 2 expression were often observed in tumor regions of pseudopalisading necrosis ( FIG. 37A ), an expression pattern noted for other GBM tumors.
- this patient Following enrollment on the clinical protocol, this patient underwent surgical resection for three of the five recurrent lesions ( FIG. 38 ), and the reservoir/catheter device was place in the resected cavity of the largest recurrent foci (T1) in the right posterior temporal-occipital area.
- This patient was initially treated per protocol with six weekly intracavitary (ICT) infusions of CAR+ T cells (2 ⁇ 10 6 cycle 1; 10 ⁇ 10 6 cycles 2-6) ( FIG. 1B ), and during this time period the temporal-occipital tumor lesion (T1) remained stable for over 45-days post-surgery without evidence of progressive disease ( FIG. 39C ).
- ICT intracavitary
- CSF was evaluated for cell infiltrates, CAR+ T cell persistence, and cytokine levels.
- ICV infusion i.e., day 1-2 of cycles 6-11
- cell numbers per mL of CSF increased 7.0 ⁇ 3.6 fold as compared to pre-infusion levels (day 0 of each cycle), and increased 153 ⁇ 128 fold as compared to pre-ICV (C7D0) levels ( FIG. 42 ).
- Total cell numbers in the CSF typically decreased over the 7-day treatment cycle.
- the cell infiltrates included a large proportion of CD3+ T cells, both endogenous and CAR-expressing, as well as CD14+CD11b+ HLA-DR+ mature myeloid populations ( FIG. 42A ). Only rare CD19+ B cells and CD11b+CD15+ granulocytes were detected ( FIG. 42A ). Consistent with flow cytometry data, CSF cytopathology on C11D1 reported the presence of reactive lymphocytes, monocytes, and macrophages.
- CAR-T persistence was also monitored over the ICV treatment course. Due to low cell recovery in the CSF for cycles 7 and 8, analysis focused on evaluating cycle 9 and time points immediately following cycles 10 and 11. Importantly, CAR+ T cells were detected at all-time points evaluated ( FIG. 42B ), including C9D0 which corresponded to 7-days post cycle 8, thus demonstrating persistence of the therapeutic cells for at least 7 to 8 days post-infusion. However, CAR T numbers in the CSF post infusion decreased at the later cycles (C10D1 and C11D1) when tumor burden had also significantly decreased ( FIG. 40B ).
- C9D2 CAR+ cell numbers increasing 1.6-fold 2 days later (C9D2) from pre-infusion (C9D0) and then decreasing 2.3-fold by day 8 (C9D8).
- cytokine levels in the CSF corresponded to significant elevations of cytokine levels in the CSF.
- the measured levels and calculated fold-change over baseline for the 30-cytokines measured is presented in Tables 9 and 10 below.
- 11 cytokines increased more than 10-fold from pre-ICV baseline (C7D0) immediately following IL3BB ⁇ T CM infusions, including cytokines IFN ⁇ , TNF, IL-2, IL-10, IL-5, IL-6, and IL-8 and chemokines CXCL9/MIG, CXCL10/IP-10, and CCR2/MCP-1 and soluble cytokine receptor IL-1R ⁇ ( FIG. 3C ).
- cytokines showed greater than a 5-fold increase from baseline (C7D0), including G-CSF, IL-12, IL2-R, IL-4, IL-7, and MIP-lb.
- the inflammatory cytokines that exhibited the highest fold increase immediately following IL3BB ⁇ T CM infusion as compared to pre-ICV (C7D0) was IL-2 (>90-fold for C9D2) and the IFN- ⁇ inducible chemokines CXCL9 and CXCL10 (>40-fold for C8D1, C9D2, C10D1 and C11D2). These cytokines returned to near baseline levels within 7-days between treatment cycles. Cytokines that did not show significant increase following CAR T cell infusions include IL-13, RANTES and VEGF (Tables 9 and 10).
- Example 24 Patient Sample Processing and Analysis
- Tumor resection material was collected through the COH department of Pathology according to the clinical protocol.
- IL13R ⁇ 2 immunohistochemistry was performed on 5 ⁇ m-sections of formalin-fixed paraffin-embedded specimens as previously described, and Ki67 IHC was similarly performed with the exception of antigen retrieval by heating @ pH 8.0, and incubation with a 1:75 dilution of anti-K167 (Dako Corp).
- IL-13R ⁇ 2 immunoreactivity was scored by a clinical neuropathologist and quantified based on the percentage of tumor cells exhibiting weak (1+), moderate (2+), or strong (3+) intensity of cytoplasmic and golgi-like staining.
- the H score is obtained by the formula: (3 ⁇ percentage of strongly staining cells)+(2 ⁇ percentage of moderately staining cells)+percentage of weakly staining cells, giving a range of 0 to 300.
- the H score can be translated into the intensity scoring system described in the enrollment criteria as follows: 0 representing negative (H score 0), 1+ low (H score 1-100), 2+ moderate (H score 101-200) and 3+ high (H score 201-300).
- the criteria for inclusion was at least 20% of the cells scoring 1+ staining intensity (>20%, 1+), representing an H score of 20. Appropriate positive (testicular) and negative (prostate) controls were employed for IL-13R ⁇ 2 IHC staining.
- a “+” sign reflects the presence of membranous staining. This test has been performed at the Department of Pathology, City of Hope National Medical Center and is regarded as investigational for research. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
- Peripheral blood samples were collected in vacutainer tubes ⁇ EDTA. Samples with EDTA were ficolled immediately upon receipt and peripheral blood mononuclear cells (PBMC) were frozen in Crystor CS5 at ⁇ 80° C. and then transferred to liquid nitrogen for long term storage. Samples without EDTA were allowed to coagulate for 2-3 hours at room temperature; serum was collected by centrifugation, aliquoted in single use 100-200 ⁇ l aliquots and stored at ⁇ 80° C. Cerebral spinal fluid (CSF) was collected from the ICV reservoir in a 3 cc syringe, spun down, and supernatants were aliquoted and stored at ⁇ 80° C.
- CSF Cerebral spinal fluid
- the CSF cells were resuspended in HBSS ⁇ / ⁇ (Corning CellGro) with 2% FCS and sodium azide for immediate flow cytometric analysis, with the remaining cells resuspended and frozen in Cryostor CS4 at ⁇ 80° C. and then transferred to liquid nitrogen for long term storage
- Cell surface phenotyping of immune cells was performed by flow cytometry using fluorochrome conjugated antibodies specific for CD3, CD4, CD11b, CD14, CD19, CD27, CD28, CD62L, CD45RA, CD45RO, IL-13, TCR- ⁇ / ⁇ (BD Biosciences), KLRG1, CD15 (BioLegend), HLA-DR, PD1 (eBiosciences), CD8 (Fisher Scientific), LAG-3 (Lifespan Biosciences), CCR7, or TIM-3 (R&D Systems), and their respective isotype controls.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Description
- This application claims the benefit of prior co-pending U.S. Provisional Application Ser. No. 62/292,152, filed Feb. 5, 2016, and of prior co-pending U.S. Provisional Application Ser. No. 62/309,348, filed Mar. 16, 2016. The disclosures of the above applications are hereby incorporated by reference in their entirety.
- Tumor-specific T cell based immunotherapies, including therapies employing engineered T cells and ex vivo expanded or selected T cells, have been investigated for anti-tumor treatment. In some cases, the T cells used in such therapies do not remain active in vivo for a long enough period. In some cases, the tumor-specificity of the T cells is relatively low. In some cases, the engineered T cells have insufficient access to the tumor. Therefore, there is a need in the art for tumor-specific cancer therapies with more effective anti-tumor function.
- Treatment of cancers of the central nervous system can be particularly challenging. For example, treatment of high-grade malignant glioma (MG), including anaplastic astrocytoma (AA-grade III) and glioblastoma multiforme (GBM-grade IV), remains a significant therapeutic challenge. Currently available therapeutic options have limited curative potential and only less than 5% of patients survive more than five years after initial diagnosis.
- Described herein are methods for treating malignancies in the central nervous system by administering compositions comprising T cells (e.g., CAR T cells, Tumor Infiltrating lymphocytes (“TIL”), TCR-engineered T cells, or T cell clones) to the cerebrospinal fluid (“CSF”) of a patient. The T cells include T cells that have be manipulated, for example, by introduction of a nucleic acid molecule expressing a desired receptor, by ex vivo expansion of isolated or genetically-modified T cells or by ex vivo selection of a subset of T cells obtained from a patient or a donor or by a combination of two or more of these techniques. Administration to the CNS can be accomplished, for example, by administration to the ventricular system or the central cavity of the spinal column. Administration to the CNS, as the term is used herein, is distinct from both intratumoral administration (injection or infusion into the tumor itself) and administration to a cavity created by resection of a tumor. However, the CNS administration methods described herein can be combined with intraturmoral and/or post-resection, intracavity administration.
- The CNS administration described herein permits infusion of relatively large volumes of the composition comprising T cells, for example 1 ml-2 ml or more in a single infusion. Thus, several million T cells can be administered in a single infusion.
- A method of treating a patient diagnosed with a malignancy of the central nervous system is thus disclosed, which comprises infusing a composition comprising an effective amount of T cells into an anatomical compartment of a patient diagnosed with a malignancy of the central nervous system, the anatomical compartment containing cerebrospinal fluid (“CSF”). The method includes infusion of a composition into a ventricular system or a portion of a central canal of a spinal cord, for example. In one embodiment of the disclosed method, the malignancy of the central nervous system includes a primary tumor or a metastasized tumor found somewhere in the central nervous system, including a portion of the brain, spinal column, or the like. Preferably the anatomical compartment contains a contiguous volume of at least about 50, 100, or 150 mL of cerebrospinal fluid.
- The manipulated T cells infused in the methods described herein target tumor antigens, for example surface protein and intracellular proteins. The malignancies treated can be primary tumors or secondary tumors arising from cancers originating elsewhere in the body. Because administration to the cerebrospinal fluid allows the T cells access to regions beyond the local site of injection, the methods described herein can be used to attack and reduce the size of tumors remote from the site of injection but within the CNS. TCR-engineered T cells are prepared by introduction of TCRαβ genes into T cells (e.g., autologous T cells) followed by ex vivo expansion of T cells; and infusion of T cells into the patient. The infusion of the TCR-engineered T cells confers tumor reactivity to patients whose tumor expresses the appropriate antigen and HLA restriction element. The TCR can be targeted to any of a variety of tumor antigens, including, for example melanoma-associated antigen recognized by T cells 1 (MART-1), glycoprotein (gp) 100, carcinoembryonic antigen (CEA), p53, melanoma-associated antigen (MAGE-A3, and New York esophageal squamous cell carcinoma antigen (NYESO).
- Described herein is a method of treating a patient diagnosed with a malignancy of the central nervous system comprising introducing into the cerebrospinal fluid (CSF) of the patient a composition comprising an effective amount of T cells.
- In various embodiments: the T cells are autologous or allogenic T cells; the T cells have been manipulated ex vivo by one or more of: expansion, fractionation or transfection with a recombinant nucleic acid molecule; the T cells comprise cells that have been transfected with a recombinant nucleic acid molecule encoding a polypeptide that binds to a tumor cell antigen; the polypeptide is a chimeric antigen receptor; the composition is administered intraventricularly; the composition is administered to the central canal of the spinal cord; the administration is to the left ventrical or the right ventrical; the composition comprises at least 1×106 cells; the composition comprising T cells is administered at least two times; the administrations differ in the total number of T cells administered; the administrations escalate in dose; the administrations de-escalate in dose; the T cells comprise CAR T cells; the T cells comprise autologous tumor infiltrating lymphocytes; the T cells comprise TCR-engineered T cells; the malignancy is a diffuse, infiltrating tumor; the malignancy is a primary brain tumor; one or more tumor foci decrease in size by at least 25%; the malignancy arose from a primary cancer selected from: breast cancer, lung cancer, head and neck cancer, and melanoma; the method is performed after tumor resection; the method further comprises intratumoral administration of a composition comprising T cells; the malignancy is secondary brain tumor; the method further comprises intratumoral administration of a composition comprising therapeutic T cells expressing a chimeric antigen receptor that binds a protein expressed on the surface of glioblastoma cells; the patient has previously undergone resection of a tumor lesion; the tumor antigen is selected from the group consisting of: IL13Rα2, HER2, PSCA, EGFR, EGFRvIII, EphA2, NY-ESO-1, and CD19; T cells comprise both CD4+ cells and CD8+ cells; the T cells have undergone ex vivo expansion; the T cells comprise at least 10% TCM cells; at least 40%, 50%, 60%, 70% or more of the cells infused are CD4+; at least at least 40%, 50%, 60%, 70% or more of the cells infused express a cell surface receptor that targets the tumor antigen (e.g., IL13Rα2); and the dose of cells is based on the number of infused cells that express a cell surface receptor that targets the tumor antigen (e.g., IL13Rα2).
- In some embodiments the T cells comprise CART cells that target IL13Rα2 and the cells comprise a nucleic acid molecule encoding a chimeric antigen receptor comprising: human IL-13 or a variant thereof having 1-10 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-10 amino acid modifications; at least one costimulatory domain; and CD3 signaling domain of a variant thereof having 1-10 amino acid modifications. In some embodiments: the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 amino acid modifications; the variant of a human IL13 has 1-10 amino acid modification that increase binding specificity for IL13Rα2 versus IL13Rα1; the human IL-13 or variant thereof is an IL-13 variant comprising the amino acid sequence of SEQ ID NO:3 with 1 to 5 amino acid modifications, provided that the amino acid at
position 11 of SEQ ID NO:3 is other than E; the chimeric antigen receptor comprises two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 amino acid modifications; the chimeric antigen receptor comprises two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-2 amino acid modifications; the chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-2 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-2 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-2 amino acid modifications; a costimulatory domain; and CD3 ζ signaling domain of a variant thereof having 1-2 amino acid modifications; the CAR comprises a spacer region located between the IL-13 or variant thereof and the transmembrane domain; the spacer region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 14-20, 50 and 52; the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 31-48. - In some embodiments the T cells express a chimeric antigen receptor that binds HER2 comprise a nucleic acid molecule encoding a chimeric antigen receptor comprising: a HER2 targeting sequence; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-5 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-5 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-5 amino acid modifications, and a CD3s transmembrane domain or a variant thereof having 1-5 amino acid modifications; a costimulatory domain selected from a CD28 costimulatory domain or a variant thereof having 1-5 amino acid modifications and a 4-IBB costimulatory domain or a variant thereof having 1-5 amino acid modifications; and CD3s signaling domain of a variant thereof having 1-5 amino acid modifications. In certain embodiments: the HER2 targeting domain is a HER2 scFv; the HER2 scFv comprising the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS GSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGSTSGGGSGGGSGGGGSSE VQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS (SEQ ID NO:49) or a variant thereof having 1 to 5 amino acid modifications; the chimeric antigen receptor comprises: a HER2 targeting sequence; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-2 amino acid modifications, and a CD3s transmembrane domain or a variant thereof having 1-2 amino acid modifications; a costimulatory domain selected from a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications and a 4-IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications; and CD3 signaling domain of a variant thereof having 1-2 amino acid modifications; the nucleic acid molecule expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NO: 26 and 27 or a variant thereof having 1-5 amino acid modifications.
- Also described herein is a method of treating a patient diagnosed with a malignancy of the central nervous system comprising infusing a composition comprising an effective amount of T cells into an anatomical compartment of a patient diagnosed with a malignancy of the central nervous system, the anatomical compartment containing cerebrospinal fluid (CSF). In various embodiments: the anatomical compartment comprises a portion of a ventricular system; the anatomical compartment comprises a portion of a central canal of a spinal cord; the malignancy of the central nervous system includes a brain tumor; the malignancy of the central nervous system includes a metastasized tumor; the anatomical compartment contains a contiguous volume of at least about 50 mL of cerebrospinal fluid; the anatomical compartment contains a contiguous volume of at least about 100 mL of cerebrospinal fluid; and the anatomical compartment contains a contiguous volume of at least about 150 mL of cerebrospinal fluid.
- Among the cancers that can be treated by the methods described herein are primary CNS malignancies and secondary malignancies arising from a cancer located elsewhere, for example. Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical, Carcinoma, AIDS-Related Cancers, Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma, Brain Stem Glioma, Brain Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumors, Central Nervous System Cancers, Cervical Cancer, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CIVIL), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma, Embryonal Tumors, Central Nervous System, Endometrial Cancer, Ependymoblastoma, Ependymoma, Esophageal Cancer, Esthesioneuroblastoma, Ewing Sarcoma Family of Tumors Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor Extrahepatic Bile Duct Cancer, Eye Cancer Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma, Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST)—see Soft Tissue Sarcoma, Germ Cell Tumor, Gestational Trophoblastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer, Hepatocellular (Liver) Cancer, Histiocytosis, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors (Endocrine Pancreas), Kaposi Sarcoma, Kidney cancer, Langerhans Cell Histiocytosis, Laryngeal Cancer, Leukemia, Lip and Oral Cavity Cancer, Liver Cancer (Primary), Lobular Carcinoma In Situ (LCIS), Lung Cancer, Lymphoma, Macroglobulinemia, Male Breast Cancer, Malignant Fibrous Histiocytoma of Bone and Osteosarcoma, Medulloblastoma, Medulloepithelioma, Melanoma, Merkel Cell Carcinoma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Myeloid Leukemia, Acute (AML), Myeloma, Multiple, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer, Oropharyngeal Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma of Bone, Ovarian Cancer, Pancreatic Cancer, Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumors of Intermediate Differentiation, Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Pregnancy and Breast Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal Cancer, Renal Cell (Kidney) Cancer, Renal Pelvis and Ureter, Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoma, Sézary Syndrome, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer, Stomach (Gastric) Cancer, Supratentorial Primitive Neuroectodermal Tumors, T-Cell Lymphoma, Cutaneous, Testicular Cancer, Throat Cancer, Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Trophoblastic Tumor, Ureter and Renal Pelvis Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Vulvar Cancer, Waldenström Macroglobulinemia, and Wilms Tumor.
- In some embodiments, the malignancy treated according to the disclosed methods comprises a tumor. In some embodiments, treatment results in at least a 50% reduction in tumor volume, at least a 60% reduction in tumor volume, at least a 70% reduction in tumor volume, at least an 80% reduction in tumor volume, or at least an 90% reduction in tumor volume. And in some embodiments, the treatment results in elimination of the malignancy.
- In some embodiments, the patient does not experience any
grade 3 or higher toxicity. - In some embodiments, the patient was administered a regimen of steroids prior to treatment with the composition comprising an effective amount of T cells, and in some embodiments the regimen of steroids is reduced to a lower dose following the treatment.
- In some embodiments, the patient has an increased life expectancy compared to a patient receiving standard of care treatment, including radiation therapy, small molecule drug therapy, antibody therapeutics, or a combination thereof. And in some embodiments, in which the patient receiving standard of care (“SOC”) treatment can expect to survive about 15 months from initial diagnosis (overall survival or OS), the patient receiving the disclosed treatment can expect an OS of 15, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months or more. In some embodiments, the patient receiving the claimed treatment can expect an OS of 42, 48, 54, 60, 66, 72, 78, 84, 90 months or more.
- In some embodiments, the composition comprises at least 2×106 T cells or 2×106 T cells expressing a cell surface receptor targeting a tumor antigen, while in some embodiments, the composition comprises at least 1×106 T cells or 1×106 T cells expressing a cell surface receptor targeting a tumor antigen. In some embodiments, the composition comprises at least 5×106 T cells or 5×106 T cells expressing a cell surface receptor targeting a tumor antigen, while in some embodiments, the composition comprises at least 10×106 T cells or 10×106 T cells expressing a cell surface receptor targeting a tumor antigen. In some embodiments, the disclosed methods comprised repeated administrations of the compositions, for instance repeating administration of the composition at least five times, repeating administration of the composition at least ten times, or repeating administration until the patient receives a total dose of at least 90×106 T cells or T cells expressing a cell surface receptor targeting a tumor antigen. In some embodiments, the administration is repeated once a week or once every two weeks. In some embodiments, the repeated administrations are continued over the course of 15 weeks.
- Also disclosed herein are methods of increasing a level of at least one cytokine or chemokine in the cerebrospinal fluid (CSF) of a patient comprising, administering a composition comprising an effective amount of T cells into the CSF of a patient with a malignancy of the central nervous system, wherein the level of at least one cytokine or chemokine in the CSF is increased following administration of the composition comprising an effective amount of T cells compared to a baseline level of the at least one cytokine or chemokine prior to the administration.
- In some embodiments of the disclosed methods, the level of the at least one cytokine or chemokine in the CSF following the administration is increased 10-fold or 5-fold compared to the baseline level.
- In some embodiments, the level of at least five or at least ten cytokines or chemokines is increased following administration of the composition comprising an effective amount of T cells compared to a baseline level of the at least five cytokines or chemokines prior to the administration. In some embodiments, the at least one cytokine or chemokine comprises EGF, Eotaxin, FGF, G-CSF, GM-CSF, HGF, IFN-α, IFN-γ, IL-10, IL-12, IL-13, IL-15, IL-17, IL-1Rα, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, or VEGF. In some embodiments, the increase in cytokine or chemokine expression is a local increase (i.e., specific to the CSF).
- Also disclosed herein are methods of sustaining for at least about five days an increased number of T cells, compared to a baseline number, observed in a cerebrospinal fluid (CSF) of a patient diagnosed with a malignancy of a central nervous system, comprising infusing an effective amount of T cells into a CSF of a patient diagnosed with a malignancy of a central nervous system, in which an increased number of T cells observed, compared to a baseline number observed prior to the infusion step, is sustained for at least about five days.
- In some embodiments, an effective amount of T cells (or T cells expressing a cell surface receptor that targets the tumor antigen) ranges from about 1×106 cells to about 100×106 cells, and in some embodiments, an effective amount of T cells ranges from about 2×106 cells to about 50×106 cells.
- In some embodiments, the increased number of T cells observed is sustained for at least about six days, or the number of T cells observed does not return to the baseline number for about seven days.
- In some embodiments, the T cells observed include infused T cells (e.g. CAR-expressing T cells), and in some embodiments, the T cells observed include endogenous T cells.
- Also disclosed herein are methods of increasing a number of T cells in the cerebrospinal fluid (CSF) of a patient comprising, administering a composition comprising an effective amount of T cells into the CSF of a patient with a malignancy of the central nervous system, wherein the number of T cells detectable in the CSF is increased compared to pre-administration levels.
- In some embodiments, the number of T cells detectable in the CSF is increased compared to pre-administration levels for up to seven days following administration. In some embodiments, the T cells detectable in the CSF comprise endogenous T cells and CAR-expressing T cells, and/or Type 1 T cells, and/or Type 2 T cells.
- In some embodiments, the T cells detectable in the CSF comprise CD3+ T cells, and in some embodiments, the T cells detectable in the CSF comprise CD14+ CD11b+ HLA-DR+ mature myeloid populations. In some embodiments, CD19+ B cells and CD11b+ CD15+ granulocytes are detectable in the CSF following administration of the composition.
- In some embodiments, reactive lymphocytes, monocytes, and macrophages are detectable in the CSF following administration of the composition.
- Also disclosed herein are methods of determining the suitability of a patient with a malignancy for treatment with an IL-13Rα2-specific CAR T cell comprising, determining if a score attributed to a sample from the patient exhibits IL-13Rα2 expression above a predetermined threshold.
- In some embodiments, the score attributed to the sample is calculated by determining the immunoreactivity of a resected tumor sample from a patient diagnosed with a malignancy by immunohistochemically staining the sample with a marker of IL-13Rα2, analyzing the strength of the staining, and calculating a score based on the strength of the staining, wherein a score that corresponds to moderate to strong staining intensity in the sample indicates that treatment with an IL-13Rα2-specific CAR T cell is suitable for the patient. In some embodiments, the score comprises counting the number of cells that have a weak, moderate, or strong staining intensity and assigning each intensity a weight (The H score, a method of quantitating immunohistochemical results, is based on the following formula: (3×the percentage of strongly staining cells)+(2×the percentage of moderately staining cells)+(1×the percentage of weakly staining cells), resulting in a range of 0 to 300). In some cases, the patient has a H score that is: greater that 50, 50-100, greater than 100, 100-200, greater than 200, 100-300, or greater than 250 for the relevant tumor-associated antigen. In some embodiments, an expression of Ki67 in the sample is also determined by immunohistochemical staining.
- Also disclosed herein are methods of treating a patient with a malignancy comprising, administering to a patient diagnosed with a malignancy a composition comprising an effective dose of IL-13Rα2-specific CART cells, wherein the patient expresses IL-13Rα2 above a predetermined threshold.
- In some embodiments, the predetermined threshold of IL-13Rα2 expression was previously identified as being suitable for a treatment comprising IL-13Rα2-specific CAR T cell therapy.
- TIL are tumor infiltrating lymphocytes that can be isolated from a patient or a donor, expand ex vivo and re-infused into the patient in need thereof.
- CAR T cells express chimeric T cell receptors that comprise an extracellular domain, a transmembrane region and an intracellular signaling domain. The extracellular domain includes a portion that binds the targeted cell and, optionally, a spacer, comprising, for example a portion human Fc domain. The transmembrane portion includes suitable transmembrane domain, for example, a CD4 transmembrane domain, a CD8 transmembrane domain, a CD28 transmembrane domain, a CD3 transmembrane domain or a 4IBB transmembrane domain. The intracellular signaling domain includes the signaling domain from the zeta chain of the human CD3 complex (CD3) and one or more costimulatory domains, e.g., a 4-1BB costimulatory domain. The target cell binding portion of extracellular domain (for example a scFv or an ligand) enables the CAR, when expressed on the surface of a T cell, to direct T cell activity to those cells expressing the targeted cell surface molecule, for example HER2 or IL13Rα2, a receptor expressed on the surface of tumor cells, including malignant glioma cells.
- A variety of different T cells, for example, patient-specific, autologous T cells, can be engineered to express a TCR or a CAR. Various T cell subsets can be used. In addition, CAR can be expressed in other immune cells such as NK cells. Where a patient is treated with an immune cell expressing a CAR or TCR the cell can be an autologous or allogenic T cell. In some cases, the cells used are CD4+ and CD8+ central memory T cells (TCM), which are CD45RO+CD62L+, and the use of such cells can improve long-term persistence of the cells after adoptive transfer compared to the use of other types of patient-specific T cells. The TCM cells can include CD4+ cells and CD8+ cells.
- Among the CAR useful in the methods described herein are those that target IL13Rα2. Such CAR can include IL13 having an amino acid modification, such as an E13Y mutation, that increases binding specificity.
- The T cells used in the methods described herein can contain a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a costimulatory domain; and CD3 ζ signaling domain of a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.
- The inclusion of a costimulatory domain, such as the 4-1BB (CD137) or CD28 costimulatory domain in series with CD3ζ in the intracellular region enables the T cell to receive co-stimulatory signals. Thus, in various embodiments, the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4-IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications. In certain embodiments, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications is present.
- In additional embodiments of the methods, the CAR expressed by the T cells comprises: a variant of a human IL13 having 1-10 amino acid modification that increase binding specificity for IL13Rα2 versus IL13Rα1; the human IL-13 or variant thereof is an IL-13 variant comprising the amino acid sequence of SEQ ID NO:3 with 1 to 5 amino acid modifications, provided that the amino acid at
position 11 of SEQ ID NO:3 other than E; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-2 amino acid modifications; human IL-13 or a variant thereof having 1-2 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-2 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-2 amino acid modifications; a costimulatory domain; and CD3ζ signaling domain of a variant thereof having 1-2 amino acid modifications; a spacer region located between the IL-13 or variant thereof and the transmembrane domain (e.g., the spacer region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 14-20, 50 and 52); the spacer comprises an IgG hinge region; the spacer region comprises 10-150 amino acids; the 4-1BB signaling domain comprises the amino acid sequence of SEQ ID NO:6; the CD3ζ signaling domain comprises the amino acid sequence of SEQ ID NO:7; and a linker of 3 to 15 amino acids that is located between the costimulatory domain and the CD3 ζ signaling domain or variant thereof. In certain embodiments where there are two costimulatory domains, one is an 4-IBB costimulatory domain and the other a costimulatory domain selected from: CD28 and CD28gg - In some embodiments of the methods described herein the T cells harbor a nucleic acid molecule that expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 10 and 31-48; the chimeric antigen receptor comprises a IL-13/IgG4/CD4t/41-BB region comprising the amino acid of SEQ ID NO:11 and a CD3 ζ signaling domain comprising the amino acid sequence of SEQ ID NO:7; and the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NOs: 10 and 31-48.
- Also disclosed are methods comprising intraventricular administration of a population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises: human IL-13 or a variant thereof having 1-10 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-10 amino acid modifications; a costimulatory domain; and CD3 signaling domain of a variant thereof having 1-10 amino acid modifications. In various embodiments: the population of human T cells comprise a vector expressing a chimeric antigen receptor comprising an amino acid sequence selected from SEQ ID NOs: 10 and 31-48; the population of human T cells are comprises of central memory T cells (TCM cells) (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are TCM cells; at least 10%, 15%, 20%, 25%, 30% or 35% of the T cells or the TCM cells are CD4+ and at least 10%, 15%, 20%, 25%, 30% or 35% of the T cells or the TCM cells are CD8+ cells).
- Also described is a method of treating cancer in a patient comprising CNS administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogeneic T cells comprising TCM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are TCM cells; at least 15%, 20%, 25%, 30%, 35% of the TCM cells are CD4+ and at least 15%, 20%, 25%, 30%, 35% of the TCM cells are CD8+ cells) transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10 and 31-48. In various embodiments: the population of human T cells comprise central memory T cells; the cancer is glioblastoma; and the transduced human T cells where prepared by a method comprising obtaining T cells from the patient, treating the T cells to isolate central memory T cells, and transducing at least a portion of the central memory cells to with a viral vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 10 and 31-48.
- Also described are method is which the T cells administered to the patient harbor a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from and SEQ ID NOs: 10 and 31-48; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO: 10 and 31-48 except for the presence of no more than 5 amino acid substitutions, deletions or insertions; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10 and 31-48 except for the presence of no more than 5 amino acid substitutions; and a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NO:10 and SEQ ID NOs: 10 and 31-48 except for the presence of no more than 2 amino acid substitutions.
- Described herein are method for treating a patient by CSF administration of T cells harboring a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an scFv targeted to HER2 (e.g., comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGSTSGGGSGGGSG GGGSSEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT NGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYW GQGTLVTVSS; SEQ ID NO: 49) or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a spacer region; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; a costimulatory domain; and CD3 ζ signaling domain of a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications.
- In various embodiments the costimulatory domain is selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4-IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications. In certain embodiments, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications in present.
- In additional embodiments T cells administered to the patient express a CAR that comprises: an scFv targeted to HER2 (e.g., a humanized scFv); two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-10 (e.g., 1 or 2) amino acid modifications; two different costimulatory domains selected from the group consisting of: a CD28 costimulatory domain or a variant thereof having 1-2 amino acid modifications, a 4IBB costimulatory domain or a variant thereof having 1-2 amino acid modifications and an OX40 costimulatory domain or a variant thereof having 1-2 amino acid modifications; human IL-13 or a variant thereof having 1-2 amino acid modifications; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-2 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-2 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-2 amino acid modifications; a costimulatory domain; and CD3ζ signaling domain of a variant thereof having 1-2 amino acid modifications; a spacer region located between the IL-13 or variant thereof and the transmembrane domain (e.g., the spacer region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 14-20, 50 and 52); the spacer comprises an IgG hinge region; the spacer region comprises 10-150 amino acids; the 4-1BB signaling domain comprises the amino acid sequence of SEQ ID NO:6; the CD3ζ signaling domain comprises the amino acid sequence of SEQ ID NO:7; and a linker of 3 to 15 amino acids that is located between the costimulatory domain and the CD3 ζ signaling domain or variant thereof. In certain embodiments where there are two costimulatory domains, one is an 4-IBB costimulatory domain and the other a costimulatory domain selected from: CD28 and CD28gg
- In some embodiments the T cells administered the patient harbor a nucleic acid molecule that expresses a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 53-56.
- Also disclosed are methods comprising intraventricular administration of a population of human T cells transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor comprising: an scFv targeted to HER2; a transmembrane domain selected from: a CD4 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD8 transmembrane domain or variant thereof having 1-10 amino acid modifications, a CD28 transmembrane domain or a variant thereof having 1-10 amino acid modifications, and a CD3ζ transmembrane domain or a variant thereof having 1-10 amino acid modifications; a costimulatory domain; and CD3 ζ signaling domain of a variant thereof having 1-10 amino acid modifications. In various embodiments: the population of human T cells comprise a vector expressing a chimeric antigen receptor comprising an amino acid sequence selected from: SEQ ID NOs: 53-56; the population of human T cells are comprises of central memory T cells (TCM cells) (e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are TCM cells; at least 10%, 15%, 20%, 25%, 30%, 35% of the T cells or TCM cells are CD4+ and/or at least 10%, 15%, 20%, 25%, 30%, 35% of the T cells or TCM cells are CD8+ cells).
- Also described is a method of treating cancer in a patient comprising intraventricular administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogenic T cells comprising TCM cells, e.g., at least 20%, 30%, 40%, 50% 60%, 70%, 80% of the cells are TCM cells; at least 15%, 20%, 25%, 30%, 35% of the TCM cells are CD4+ and/or at least 15%, 20%, 25%, 30%, 35% of the TCM cells are CD8+ cells) transduced by a vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 53-56. In various embodiments: the population of human T cells comprise central memory T cells; the cancer is glioblastoma; and the transduced human T cells where prepared by a method comprising obtaining T cells from the patient, treating the T cells to isolate central memory T cells, and transducing at least a portion of the central memory cells to with a viral vector comprising an expression cassette encoding a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 53-56.
- Also described is a method of treating cancer in a patient comprising intraventricular administration of a population of autologous or allogeneic human T cells (e.g., autologous or allogenic T cells comprising TCM cells harboring: a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NOs: 53-56; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs: 53-56 except for the presence of no more than 5 amino acid substitutions, deletions or insertions; a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs: 53-56 except for the presence of no more than 5 amino acid substitutions; and a nucleic acid molecule encoding an polypeptide comprising an amino acid sequence that is identical to an amino acid sequence selected from SEQ ID NOs: 53-56, except for the presence of no more than 2 amino acid substitutions.
- Certain CAR described herein, for example, the IL13(EQ)BBζ CAR and the IL13(EQ)CD28-BBζ CAR, have certain beneficial characteristics compared to certain other IL13-targeted CAR. For example, they have improved selectivity for IL13Rα, elicit lower Th2 cytokine production, particularly lower IL13 production.
- T cells expressing a CAR targeting IL13Rα2 can be useful in treatment of cancers such as glioblastoma, as well as other cancers that expresses IL13Rα2. Thus, this disclosure includes methods for treating cancer using T cells expressing a CAR described herein.
- T cells expressing a CAR targeting HER2 can be useful in treatment of cancers such as glioblastoma, as well as other cancer that expresses HER2, for example breast cancer that has spread to the central nervous system. Thus, this disclosure includes methods for treating cancer using T cells expressing a CAR described herein.
- The CAR described herein can include a spacer region located between the targeting domain and the transmembrane domain. A variety of different spacers can be used. Some of them include at least portion of a human Fc region, for example a hinge portion of a human Fc region or a CH3 domain or variants thereof. Table 1 below provides various spacers that can be used in the CARs described herein.
-
TABLE 1 Examples of Spacers Name Length Sequence a3 3 aa AAA linker 10 aa GGGSSGGGSG (SEQ ID NO: 14) IgG4 hinge (S→P) 12 aa ESKYGPPCPPCP (SEQ ID NO: 15) (S228P) IgG4 hinge 12 aa ESKYGPPCPSCP (SEQ ID NO: 52) IgG4 hinge + linker 22 aa ESKYGPPCPPCPGGGSSGGGSG (SEQ ID NO: 16) CD28 hinge 39 aa IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPS KP (SEQ ID NO: 17) CD8 hinge-48 aa 48 aa AKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACD (SEQ ID NO: 18) CD8 hinge-45 aa 45 aa TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT RGLDFACD (SEQ ID NO: 19) IgG4(HL-CH3) 129 aa ESKYGPPCPPCPGGGSSGGGSGGQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFS CSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20) IgG4(L235E, N297Q) 229 aa ESKYGPPCPSCPAPEFEGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHQAKT KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH EALHNHYTQKSLSLSLGK (SEQ ID NO: 4) IgG4(S228P, L235E, N297Q) 229 aa ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHQAKT KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH EALHNHYTQKSLSLSLGK (SEQ ID NO: 51) IgG4(CH3) 107 aa GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLT VDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GK (SEQ ID NO: 50) - Some spacer regions include all or part of an immunoglobulin (e.g., IgG1, IgG2, IgG3, IgG4) hinge region, i.e., the sequence that falls between the CH1 and CH2 domains of an immunoglobulin, e.g., an IgG4 Fc hinge or a CD8 hinge. Some spacer regions include an immunoglobulin CH3 domain or both a CH3 domain and a CH2 domain. The immunoglobulin derived sequences can include one ore more amino acid modifications, for example, 1, 2, 3, 4 or 5 substitutions, e.g., substitutions that reduce off-target binding.
- An “amino acid modification” refers to an amino acid substitution, insertion, and/or deletion in a protein or peptide sequence. An “amino acid substitution” or “substitution” refers to replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid. A substitution can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. The following are examples of various groupings of amino acids: 1) Amino acids with nonpolar R groups: Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine; 2) Amino acids with uncharged polar R groups: Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine; 3) Amino acids with charged polar R groups (negatively charged at pH 6.0): Aspartic acid, Glutamic acid; 4) Basic amino acids (positively charged at pH 6.0): Lysine, Arginine, Histidine (at pH 6.0). Another grouping may be those amino acids with phenyl groups: Phenylalanine, Tryptophan, and Tyrosine.
- A variety of transmembrane domains can be used in CAR expressed by the cells used in the methods described herein. Table 2 includes examples of suitable transmembrane domains. Where a spacer region is present, the transmembrane domain is located carboxy terminal to the spacer region.
-
TABLE 2 Examples of Transmembrane Domains Name Accession Length Sequence CD3z J04132.1 21 aa LCYLLDGILFIYGVILTALFL (SEQ ID NO: 21) CD28 NM_006139 27 aa FWVLVVVGGVLACYSLLVTVAFII FWV (SEQ ID NO: 22) CD28(M) NM_006139 28 aa MFWVLVVVGGVLACYSLLVTVAFI IFWV (SEQ ID NO: 22) CD4 M35160 22 aa MALIVLGGVAGLLLFIGLGIFF (SEQ ID NO: 5) CD8tm NM_001768 21 aa IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 23) CD8tm2 NM_001768 23 aa IYIWAPLAGTCGVLLLSLVITLY (SEQ ID NO: 24) CD8tm3 NM_001768 24 aa IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 25) 41BB NM_001561 27 aa IISFFLALTSTALLFLLFF LTLRFSVV (SEQ ID NO: 26) - Many of the CAR expressed by the cells used in the methods described herein include one or more (e.g., two) costimulatory domains. The costimulatory domain(s) are located between the transmembrane domain and the CD3ζ signaling domain. Table 3 includes examples of suitable costimulatory domains together with the sequence of the CD3ζ signaling domain.
-
TABLE 3 Examples of Costimulatory Domains Name Accession Length Sequence CD3ζ J04132.1 113 aa RVKFSRSADAPAYQQGQNQLYNELNLGRREEYD VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR CD28 NM_006139 42 aa RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPR DFAAYRS (SEQ ID NO: 27) CD28gg* NM_006139 42 aa RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPP RDFAAYRS (SEQ ID NO: 28) 41BB NM_001561 42 aa KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCEL (SEQ ID NO: 29) OX40 42 aa ALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADA HSTLAKI (SEQ ID NO: 30) -
FIG. 1 is a schematic depiction of IL13(E13Y)-zetakine CAR (Left) composed of the IL13Rα2-specific human IL-13 variant (huIL-13(E13Y)), human IgG4 Fc spacer (huγ4Fc), human CD4 transmembrane (huCD4 tm), and human CD3ζ chain cytoplasmic (huCD3ζ cyt) portions as indicated. Also depicted is a IL13(EQ)BBζ CAR which is the same as the IL13(E13Y)-zetakine with the exception of the two point mutations, L235E and N297Q indicated in red, that are located in the CH2 domain of the IgG4 spacer, and the addition of a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt). -
FIGS. 2A-C depict certain vectors and open reading frames. A is a diagram of the cDNA open reading frame of the 2670 nucleotide IL13(EQ)BBZ-T2ACD19t construct, where the IL13Rα2-specific ligand IL13(E13Y), IgG4(EQ) Fc hinge, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3 cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are indicated. The human GM-CSF receptor alpha and CD19 signal sequences that drive surface expression of the IL13(EQ)BBζ CAR and CD19t are also indicated. B is a diagram of the sequences flanked by long terminal repeats (indicated by ‘R’) that will integrate into the host genome. C is a map of the IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid. -
FIG. 3 depicts the construction of pHIV7. -
FIG. 4 depicts the elements of pHIV7. -
FIG. 5 depicts a production scheme for IL13(EQ)BBζ/CD19t+TCM. -
FIGS. 6A-C depicts the results of flow cytometric analysis of surface transgene and T cell marker expression. IL13(EQ)BBζ/CD19t+TCM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+ (i.e., CD8 negative) CAR+ cells (A), or anti-CD19-PE and anti-CD4-FITC to detect CD4+CD19t+ and CD8+ (i.e., CD4 negative) CAR+ cells (B). IL13(EQ)BBζ/CD19t+ TCM HD006.5 and HD187.1 stained with fluorochrome conjugated anti-CD3, TCR, CD4, CD8, CD62L and CD28 (grey histograms) or isotype controls (black histograms) (C). In all cases the percentages based on viable lymphocytes (DAPI negative) stained above isotype. -
FIGS. 7A-D depict the results of experiments comparing route of CAR+ T cell delivery (i.c. versus i.v.) for large established tumors. EGFP-ffLuc+ PBT030-2 TSs (1×105) were implanted into the right forebrain of NSG mice. Ondays 19 and 26, mice were injected i.v. through the tail vein with either 5×106 CAR+IL13(EQ)BBζ+TCM (11.8×106 total cells; n=4), or mock TCM (11.8×106 cells; n=4). Alternatively, ondays day 19 tumors. By comparison, i.v. delivered T cells do not shown reduction in tumor burden as compared to untreated or mock TCM controls (A). Kaplan Meier survival curve demonstrates improved survival for mice treated i.c. IL13(EQ)BBZ TCM as compared to mice treated with i.v. administered CAR+TCM (p=0.0003 log rank test) (B). Representative H&E and CD3 IHC of mice treated i.v. (C) versus i.c. (D) with IL13(EQ)BBZ+ TCM. CD3+ T cells were only detected in the i.c. treated group, with no CD3+ cells detected in the tumor or surrounding brain parenchyma for i.v. treated mice. -
FIGS. 8A-B depict the results of studies showing that CAR+ T cell injected intracranially, either intratumoral (i.c.t.) or intraventricular (i.c.v.), can traffic to tumors on the opposite hemisphere. EGFP-ffLuc+ PBT030-2 TSs (1×105) were stereotactically implanted into the right and left forebrains of NSG mice. Onday 6, mice were injected i.c. at the right tumor site with 1.0×106 IL13(EQ)BBζ+TCM (1.6×106 total cells; 63% CAR; n=4). Schematic of multifocal glioma experimental model (A). CD3 IHC showing T cells infiltrating both the right and left tumor sites (B). -
FIG. 9 depicts the amino acid sequence of IL13(EQ)BBζ/CD19t+ (SEQ ID NO:10). -
FIG. 10 depicts a sequence comparison of IL13(EQ)41BBζ[IL13{EQ}41BBζ T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13). -
FIG. 11 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm2-41BB Zeta (SEQ ID NO:31 with GMCSFRa signal peptide; SEQ ID NO:39 without GMCSFRa signal peptide). -
FIG. 12 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:32 with GMCSFRa signal peptide; SEQ ID NO:40 without GMSCFRa signal peptide). -
FIG. 13 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD4tm-41BB-Zeta (SEQ ID NO:33 with GMCSFRa signal peptide; SEQ ID NO:41 without GMCSFRa signal peptide). -
FIG. 14 depicts the amino acid sequence of IL13(EmY)-IgG4(L235E,N297Q)-CD8tm-41BB-Zeta (SEQ ID NO:34 with GMCSFRa signal peptide; SEQ ID NO:42 without GMCSFRa signal peptide). -
FIG. 15 depicts the amino acid sequence of IL13(EmY)-Linker-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:35 with GMCSFRa signal peptide; SEQ ID NO:43 without GMCSFRa signal peptide). -
FIG. 16 depicts the amino acid sequence of IL13(EmY)-HL-CD28m-CD28gg-41BB-Zeta (SEQ ID NO:36 with GMCSFRa signal peptide; SEQ ID NO:44 without GMSCFRa signal peptide). -
FIG. 17 depicts the amino acid sequence of IL13(EmY)-IgG4(HL-CH3)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:37 with GMSCFRa signal peptide; SEQ ID NO:45 without GMCSFRa signal peptide). -
FIG. 18 depicts the amino acid sequence of IL13(EmY) IgG4(L235E,N297Q)-CD28tm-CD28gg-41BB-Zeta (SEQ ID NO:38 with GMCSFRa signal peptide; SEQ ID NO:46 without GMCSFRa signal peptide). -
FIG. 19 depicts the amino acid sequence of IL13(EmY)-CD8h3-CD8tm-41BB Zeta (SEQ ID NO:47 with GMCSFRa signal peptide; SEQ ID NO:48 without GMCSFRa signal peptide). -
FIG. 20 depicts the amino acid sequence of Her2scFv-IgG4(L235E, N297Q)-CD28tm-CD28gg-Zeta-T2A-CD19t. The various domains are listed in order below the sequence and are indicated by alternating underlining and non-underlining. The mature CAR sequence (SEQ ID NO:26) does not include the GMCSFRa signal peptide, the T2A skip sequence or truncated CD19. -
FIG. 21 depicts the amino acid sequence of Her2scFv-IgG4(L235E,N297Q)-CD8tm-41BB-Zeta-T2A-CD19t. The various domains are listed in order below the sequence and are indicated by alternating underlining and non-underlining. The mature CAR sequence (SEQ ID NO:27) does not include the GMCSFRa signal peptide, the T2A skip sequence or truncated CD19. -
FIGS. 22A-D depict HER2-specific CAR constructs and CAR T cell expansion data. -
FIGS. 23A-D depict in vitro characterization of HER2-CAR T cells against breast cancer cell lines. -
FIGS. 24A-F depict the result of studies on the in vitro tumor activity of HER2-CAR T cells. -
FIGS. 25A-I depict the result of studies on the in vivo anti-tumor efficacy of local intratumorally-delivered HER2-CAR T cells. -
FIGS. 26A-D depict the results of studies on local delivery of HER2-CAR T cells in human orthotopic BBM xenograft models. -
FIGS. 27A-D depict the results of studies on intraventricular delivery of HER2-CAR T cells. -
FIG. 28 schematically depicts the locations of tumor cell injection and CAR T cell injection for a study of intratumoral and intraventricular injection of CAR T cells targeting IL13α2R in a murine model of glioblastoma. -
FIGS. 29A-C depict the results of studies demonstrating regression of established glioma tumor xenografts after administration of IL13(EQ)BBζ/CD19t+ TCM. ffLuc+ PBT030-2 tumor cells (1×105) were stereotactically implanted into the right and left forebrains of NSG mice. Onday 6, mice were injected either ict or icv with 1×106 IL13(EQ)BBζ+ Tcm (1.6×106 total cells; 63% CAR+) as described inFIG. 4.1 above. A, Representative mice from each group showing relative tumor burden using Xenogen Living Image. B, Average Xenogen flux of left and right brain hemispheres (region of interest, ROI) from the mice (n=4-5) of each group, where each successive bar representsday whole brain 13 days after T cell injection. *, p=0.0407 when comparing icv group to untreated PBT030-2 group using the unpaired Student's t-test. These data are representative of three separate multifocal GBM experiments. -
FIG. 30 depicts the results of studies demonstrating that huCD3+ cells are detected in the right and left brain tumors/hemispheres after ict and icv administration of IL13(EQ)BBζ/CD19t+ TCM. ffLuc+ PBT030-2 tumor cells (1×105) were stereotactically implanted into the right and left forebrains of NSG mice. Onday 6, mice were injected either ict (left images) or icv (right images) with 1×106 IL13(EQ)BBζ+ Tcm (1.6×106 total cells; 63% CAR+). One week (top images) and two weeks (bottom images) after T cell administration, 2-3 mice were euthanized from each group, brains were harvested, embedded in paraffin, and IHC was performed with anti-human CD3 antibody to detect T cells. Representative IHC images of the left and right tumor sites from mice of each group (ict: m406 and m410; icy: m414 and m415) are depicted. Inlays depict the xenogen flux images of the mice at the day of euthanasia and brain harvest. -
FIG. 31 schematically depicts the time course of CAR T cell preparation and treatment for a clinical trial of CAR T cells for treatment of glioblastoma (A) and provides several dosing schemes (B). -
FIG. 32 presents analysis of CAR T cell persistence, as monitored by CD19 (A) and presence of GBM cells as monitored by IL13Rα2 expression (B). -
FIG. 33 presents imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration. -
FIG. 34 is a series of graphs showing the levels of various cytokines during the course of treatment for one patient. -
FIGS. 35A-C are images depicting egression of recurrent multifocal glioblastoma, including spinal metastasis, following intraventricular delivery of IL13Rα2-targeted CAR T cells. A patient presenting with a recurrent multifocal GBM, including one metastatic site in the spine and extensive leptomeningeal disease was treated with six local infusions of IL13BBζ Tcm into the resection cavity of the largest recurrent tumor focus (1 cycle of 2 M, and 5 cycles of 10M CAR+ T cells). While the CAR T cell injection site remained stable without evidence of disease recurrence for over 7-weeks, other disease foci distant from the CAR T cell injection site continued to progress (data not shown). This patient then received five weekly intraventricular (icy) infusions of IL13BBζ Tcm (1 cycles of 2 M, and 4 cycles of 10M CAR+ T cells). Shown are MRI and/or PET images of (A) transverse brain section, (B) saggital brain section, and (C) transverse (top) and frontal (bottom) sections of the spine before (left) and one week after (right) completion of i.c.v. therapy, with tumor lesion sites indicated by red arrows in each image. -
FIGS. 36A-B shows treatment regimens with enrollment on NCT02208362 and a compassionate use protocol. Enrollment on NCT02208362 was set at day 0 (A), with initiation of compassionate use protocol on day 107 (B). NovoTTF-100A, a portable medical device that delivers low intensity, intermediate frequency, alternating electric fields by means of noninvasive, disposable scalp electrodes; FGFR, fibroblast growth factor receptor; MRI, magnetic resonance imaging, all of which was performed on the brain unless otherwise indicated; ICT, intracavitary; PET, positron emission tomography, performed at the indicated sites; ICV, intracerebroventricular. -
FIGS. 37A-C shows immunohistochemistry of primary and recurrent tumors. Tumor resected at initial diagnosis (A), and recurrent tumor (T1) resected at time of Rickham placement under NCT02208362 (B, C). Immunochemical staining using either IL13Rα2-specific or Ki67-specific DAB with hematoxylin counterstain are depicted, with red boxes outlining the successive magnified images going left to right. -
FIGS. 38A-B shows tumor lesion identification. (A) Identifying characteristics of GBM lesions T1-T8. (B) Brain MRI scans depicting the sites of T1-T7. -
FIGS. 39A-C shows resected tumor region remains stable, without evidence of disease progression/recurrence following intracavitary delivery of IL13BBζ TCM. (A) Flow cytometry analysis of the IL13BBζ TCM cell product. Top row, transduction with the indicated construct drove coordinate surface expression of the IL13BBζ CAR (detected with anti-IL13) and the CD19t marker (detected with anti-CD19) via the T2A ribosomal skip sequence. Staining profiles for the T cell markers TCR-α/β, CD3, CD4 and CD8, as well as the exhaustion markers LAG-3, TIM-3, KLRG1 and PD-1 are depicted in the middle row; staining profiles for the memory markers CD62L, CD45RO, CCR7, CD27, and CD28, as well as the naïve T cell marker CD45RA are depicted in the bottom row. (B) Treatment schema under NCT02208362. After the patient experienced recurrence and underwent tumor excision with placement of an intracavitary (ICT) Rickham catheter, 6 cycles of ICT cell doses (1 cycle of 2×106, and 5 cycles of 10×106 CAR+ cells) were administered with one week rest betweencycles -
FIGS. 40A-E shows regression of recurrent multifocal glioblastoma, including spinal metastases, following intracerebroventricular delivery of IL13Rα2-targeted CART cells. (A) Treatment schema under compassionate use protocol. After the patient underwent placement of an intracerebroventricular (ICV) Rickham catheter, 5 cycles of ICV cell doses (1 cycle of 2×106 and 4 cycles of 10×106 CAR+ cells, indicated ascycles 7 through 11) were administered with one week rest betweencycles -
FIG. 41 shows regression of recurrent multifocal GBM following ICV delivery of IL13Rα2-targeted CAR T cells. Maximum lesion areas for non-resected tumors T4-T7 are depicted. -
FIG. 42A-C shows analysis of cell infiltrates and cytokines from cerebrospinal fluid (CSF) samples. (A) CSF cellular infiltrate numbers spiked after ICV cycles 9, 10 and 11, with flow cytometric evidence of CD19+ B cells, both CAR+ (i.e., CD19t+) and non-engineered CD3+ T cells, CD11b+ CD15+ granulocytes, and CD11b+ CD14+ HLA-DR+ monocytes. (B) Evaluation of the CD3+ T cell population in the CSF for the presence of gene-modified (i.e., CD19t+) T cells. CD3-gated cells from the CSF collected at the indicated day ofcycles - Described below is the structure, construction and characterization of various CAR T cells and their use in treating cancers of the central nervous system. A chimeric antigen (CAR) is a recombinant biomolecule that contains, at a minimum, an extracellular recognition domain, a transmembrane region, and an intracellular signaling domain. The term “antigen,” therefore, is not limited to molecules that bind antibodies, but to any molecule that can bind specifically to a target. For example, a CAR can include a ligand that specifically binds a cell surface receptor. The extracellular recognition domain (also referred to as the extracellular domain or simply by the recognition element which it contains) comprises a recognition element that specifically binds to a molecule present on the cell surface of a target cell. The transmembrane region anchors the CAR in the membrane. The intracellular signaling domain comprises the signaling domain from the zeta chain of the human CD3 complex and optionally comprises one or more costimulatory signaling domains. CARs can both to bind antigen and transduce T cell activation, independent of MHC restriction. Thus, CARs are “universal” immunoreceptors which can treat a population of patients with antigen-positive tumors irrespective of their HLA genotype. Adoptive immunotherapy using T lymphocytes that express a tumor-specific CAR can be a powerful therapeutic strategy for the treatment of cancer.
- In some cases the CAR described herein can be produced using a vector in which the CAR open reading frame is followed by a T2A ribosome skip sequence and a truncated CD19 (CD19t), which lacks the cytoplasmic signaling tail (truncated at amino acid 323). In this arrangement, co-expression of CD19t provides an inert, non-immunogenic surface marker that allows for accurate measurement of gene modified cells, and enables positive selection of gene-modified cells, as well as efficient cell tracking and/or imaging of the therapeutic T cells in vivo following adoptive transfer. Co-expression of CD19t provides a marker for immunological targeting of the transduced cells in vivo using clinically available antibodies and/or immunotoxin reagents to selectively delete the therapeutic cells, and thereby functioning as a suicide switch.
- The disclosed methods of treatment using CAR T cells can be performed at various doses and across various timeframes. For example, a patient receiving an infusion, administration, or injection of CAR T cells (e.g. IL-13Rα2-specific CAR T cells) may receive a single dose comprising between 1×106 and 15×106 cells. In other words, a single dose for use in the disclosed methods can comprise 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 10×106, 11×106, 12×106, 13×106, 14×106, or 15×106 cells. Over the entire course of treatment, a patient may receive a cumulative or total dose of cells between 20×106 and 150×106 T cells. For instance, the patient may receive about 20×106, about 25×106, about 30×106, about 35×106, about 40×106, about 45×106, about 50×106, about 55×106, about 60×106, about 65×106, about 70×106, about 75×106, about 80×106, about 85×106, about 90×106, about 95×106, about 100×106, about 105×106, about 110×106, about 115×106, about 120×106, about 125×106, about 130×106, about 135×106, about 140×106, about 145×106, or about 150×106 or more T cells over the course of treatment. In some embodiments, a patient can receive a total dose of at least 90×106 T cells. In one embodiment, a patient can receive a total dose of 94×106 T cells.
- Furthermore, the doses may be administered according to different regimens and timetables. For example, the disclosed methods can comprise an infusion, administration, or injection once a day, once every two days, once every three days, once every four days, once every five days, once every six days, a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every other month, once every three months, or once every six months. In some embodiments, the disclosed methods can comprise continuous infusion, for instance, from a wearable pump. Similarly, the total time course of treatment may be about 5 weeks, about 10 weeks, about 15 weeks, about 20 weeks, about 25 weeks, about 30 weeks, about 35 weeks, about 40 weeks, about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 65 weeks, about 70 weeks, about 75 weeks, or more. The patient may receive 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more infusions, administrations, or injections of T cells over the course of treatment according to the disclosed methods. For example, in one embodiment, a patient can receive 11 infusions of T cells over the course of 15 weeks.
- Treating cancer, and more specifically gliomas like glioblastoma, according to the disclosed methods can result in numerous therapeutic effects. For instance, treatment with the disclosed CAR T cells can result in an increase in the level of cytokines and chemokines in the CSF of a patient being treated according to the disclosed methods. Cytokine and/or chemokine expression may increase by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%, or cytokine and/or chemokine expression may increase by at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold compared to baseline levels, as measured prior to treatment with a composition comprising CAR T cells. This increase in expression may be observed for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more cytokines or chemokines.
- In particular, the expression of at least one of EGF, Eotaxin, FGF, G-CSF, GM-CSF, HGF, IFN-α, IFN-γ, IL-10, IL-12, IL-13, IL-15, IL-17, IL-1Rα, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF may increase as a result of treatment with CAR T cells as disclosed herein. Furthermore, the increase in cytokine and/or chemokine expression may be local (i.e. the increase is only observable in the CNS and CFS, while serum levels of cytokines and chemokines remain unchanged.
- Treatment according to the disclosed methods may also result in an increase in T cells detectable in the CSF. While at least some of the T cells detectable in the CSF following treatment will likely be CAR-expressing T cells, there may also be an increase in endogenous T cells that are recruited to the CSF. Although not wanting to be bound by theory, the increase in endogenous T cells may be a result of the recruitment of
Type 1 and Type 2 T helper cells due to the increase in local cytokine levels. Additionally, the detectable T cells can comprise CD3+ T cells, as well as CD14+ CD11b+ HLA-DR+ mature myeloid populations, CD19+ B cells and CD11b+CD15+ granulocytes, and/or reactive lymphocytes, monocytes, and macrophages. - The increase in the number of T cells in the CSF may be detectable for a specific period of time following treatment according to the disclosed methods. A detectable increase in T cells in the CSF may persist or be sustained for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more days following administration of a composition comprising T cells. For example, an increase in the number of T cells observed in the CSF may not return to baseline levels (i.e. the number of T cells detectable prior to treatment) for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days. The number of T cells detectable in the CSF may increase by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%, or by at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold compared to baseline levels, as measured prior to treatment with a composition comprising CAR T cells.
- The time course of CAR T cell preparation and treatment is depicted in
FIG. 31 . Concurrent with the manufacturing process, research participants underwent resection of their tumor(s) followed by placement of a Rickham catheter and baseline imaging. - Patient UPN097 underwent tumor resection and was treated in
Cycle 1 with 2×106 cells and inCycle 2 with 10×106 cells. In bothCycle 1 andCycle 2 the cells were administered to the cavity left by resection. After the second cycle Patient UPN097 was taken off the study due to rapid tumor progression. - Patient UPN109 was treated in
Cycle 1 with 2×106 cells and inCycles Cycles Cycle 7 the patient was treated with 2×106 cells. InCycles - As used herein, the term “intraventricular” refers to the space inside the ventricular system, specifically the cerebral ventricles. Accordingly, the term “intraventricular” and “intracerebroventricular” may be used interchangeably throughout this disclosure. Accordingly, “intraventricular administration” or “intraventricular injection” refer to delivery of a composition into the ventricals of the brain (i.e. the cerebral ventricles). The cerebral ventricles are a series of interconnected, fluid-filled spaces that lie in the core of the forebrain and brainstem. This system comprises four ventricles: the right and left lateral ventricles (one of which is found in each hemisphere of the brain), the third ventricle, and the fourth ventricle.
- The disclosed methods comprise various routes of administering the compositions comprising T cells. For instance, in some embodiments, the disclosed compositions may be delivered or administered intraventricularly. In some embodiments, the disclosed compositions may be delivered or administered into the spinal canal (i.e. intrathecal delivery). In some embodiments, the disclosed compositions may be delivered or administered into the epidural space of the spinal cord (i.e. epidural delivery). In some embodiments, the disclosed compositions may be delivered or administered directly into a tumor (i.e. intratumoral delivery). In some embodiments, the disclosed compositions may be delivered or administered into a cavity formed by the resection of tumor tissue (i.e. intracavity delivery). Furthermore, in some embodiments, the disclosed methods can comprise a combination of the aforementioned routes of administration. For instance, a patient may receive at least one dose of the composition comprising T cells via intracavity delivery, followed by at least one dose of the composition via intraventricular delivery.
-
FIG. 32A presents analysis of CAR T cell persistence, as monitored by CD19. This analysis shows goodT cell persistence 8 days after theCycle 2.FIG. 32B shows decreased presence of GBM cells as monitored by IL13Rα2 expression. -
FIG. 33A andFIG. 33B depict imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration. InFIG. 33A one can see that few CD3+ or CD8+ T cells are present pretreatment.FIG. 33B , which is a sample atDay 16 post-treatment taken from the left frontal tumor cavity wall shows a large area of necrotic tumor and significant presence of CD3+ and CD8+ cells. - Gliomas, express IL13 receptors, and in particular, high-affinity IL13 receptors. However, unlike the IL13 receptor, glioma cells overexpress a unique IL13Rα2 chain capable of binding IL13 independently of the requirement for IL4Rβ or γc44. Like its homolog IL4, IL13 has pleotropic immunoregulatory activity outside the CNS. Both IL13 and IL4 stimulate IgE production by B lymphocytes and suppress pro-inflammatory cytokine production by macrophages. Detailed studies using autoradiography with radiolabeled IL13 have demonstrated abundant IL13 binding on nearly all malignant glioma tissues studied. This binding is highly homogeneous within tumor sections and in single cell analysis. However, molecular probe analysis specific for IL13Rα2 mRNA did not detect expression of the glioma-specific receptor by normal brain elements and autoradiography with radiolabeled IL13 also could not detect specific IL13 binding in the normal CNS. These studies suggest that the shared IL13Rα1/IL4β/γc receptor is not expressed detectably in the normal CNS. Therefore, IL13Rα2 is a very specific cell-surface target for glioma and is a suitable target for a CAR designed for treatment of a glioma.
- Certain patients may be more suitable than others to receive the disclosed methods of treatment. For instance, those patients with malignancies that highly express IL-13Rα2 may particularly benefit from treatment with the disclosed CAR T-cells. Suitability of a patient can be determined by staining a resected tumor sample from a patient to determine the amount of expression of IL-13Rα2. The sample may be scored based on the number of cells exhibiting weak, moderate, or strong staining intensity. Determining the expression level of Ki67 may also be beneficial for determining the aggressiveness of the disease. Once it has been determined that a patient is well suited to receive the disclosed CAR T cells, the patient may be treated according to the disclosed methods.
- Binding of IL13-based therapeutic molecules to the broadly expressed IL13Rα1/IL4β/γc receptor complex, however, has the potential of mediating undesired toxicities to normal tissues outside the CNS, and thus limits the systemic administration of these agents. An amino acid substitution in the IL13 alpha helix A at
amino acid 13 of tyrosine for the native glutamic acid selectively reduces the affinity of IL13 to the IL13Rα1/IL4β/γc receptor. Binding of this mutant (termed IL13(E13Y)) to IL13Rα2, however, was increased relative to wild-type IL13. Thus, this minimally altered IL13 analog simultaneously increases IL13's specificity and affinity for glioma cells. Therefore, CAR described herein include an IL13 containing a mutation (E to Y or E to some other amino acid such as K or R or L or V) at amino acid 13 (according to the numbering of Debinski et al. 1999 Clin Cancer Res 5:3143s). IL13 having the natural sequence also may be used, however, and can be useful, particularly in situations where the modified T cells are to be locally administered, such as by injection directly into a tumor mass. - Additionally, gliomas are known to have a generally poor patient prognosis. For example, glioblastoma multiforme (GBM) is a common malignant cancer of the CNS. The 1-year and 2-year relative survival rates for GBM are 29.6% and 9.0%, respectively. Only 3.4% of patients with a GBM diagnosis survive more than 5 years. Furthermore, recurrence following surgical resection and/or treatment with other conventional therapeutics is common. Current conventional treatments include, but are not limited to, radiation therapy, small molecules (e.g. temozolomide, irinotecan, imatinib mesylate, erlotinib, and hydroxyurea), and biologics such as antibodies (e.g. bevacizumab).
- The disclosed methods of treatment improve clinical prognosis in patients compared to current standards. For instance, the disclosed methods can increase 1-year, 2-year, and 5-year survival rates. In some embodiments, the 1-year survival rate of a patient being treated according to the disclosed methods can at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%. In some embodiments, the 2-year survival rate of a patient being treated according to the disclosed methods can at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%. In some embodiments, the 5-year survival rate of a patient being treated according to the disclosed methods can at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%.
- In some embodiments, the disclosed methods also increase the life expectancy of a patient compared to another patient receiving conventional treatments or SOC treatment, including radiation therapy, small molecule drug therapy, therapeutic biologics like therapeutic antibodies, or a combination thereof. In some embodiments, in which the patient receiving SOC treatment can expect to survive about 15 months from initial diagnosis (overall survival or OS), the patient receiving the disclosed treatment can expect an OS of 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months or more. In some embodiments, the patient receiving the claimed treatment can expect an OS of 42, 48, 54, 60, 66, 72, 78, 84, 90 months or more.
- The disclosed methods may improve a patient's prognosis through a variety of clinical outcomes. For instance, the disclosed methods can result in a reduction in tumor volume in a patient being treated with a composition comprising T cells. In some embodiments, the disclosed methods of treatment can result in at least a 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100% reduction in tumor volume. In some embodiments, the tumors in a patient may be completely eliminated and the patient can be cured of the malignancy.
- Additionally, the disclosed methods are safe and well-tolerated. Patients being treated according to the disclosed methods may not experience significant side effects, and furthermore, may be able to discontinue taking auxiliary medications. For instance, in some embodiments, the disclosed methods will not result in any
grade 3 or higher toxicities according to NCI Common Toxicity Criteria (CTC). The CTC provides a quantifiable scale of 0-5, with 0 meaning no adverse event, 1 meaning mild, 2 meaning moderate, 3 meaning sever and undesirable, 4 meaning life threatening or disabling, and 5 meaning death. Thus, side effects and or toxicities may include events like mild or moderate headaches, fatigue, myalgia, and minor nervous system disorders such as olfactory aura, but high grade toxicities will be avoided. - Steroids like dexamethasone are commonly used in the clinical management of gliomas to prevent neurological side effects like brain edema. The disclosed methods of treatment can decrease the need for such auxiliary treatments. For instance, if a patient is receiving a regimen of steroids (e.g. dexamethasone) prior to treatment according to the disclosed methods, the patient may be able to reduce the dose of the steroid regimen or discontinue the steroid regimen altogether without experiencing clinically deleterious effects.
- Brain metastases of breast cancer can express HER2. Certain of the CAR described herein that are useful in treatment of malignant glioma are targeted to HER2.
- The CAR described herein can be produced by any means known in the art, though preferably they are produced using recombinant DNA techniques. Nucleic acids encoding the several regions of the chimeric receptor can be prepared and assembled into a complete coding sequence by standard techniques of molecular cloning known in the art (genomic library screening, PCR, primer-assisted ligation, site-directed mutagenesis, etc.) as is convenient. The resulting coding region is preferably inserted into an expression vector and used to transform a suitable expression host cell line, preferably a T lymphocyte cell line, and most preferably an autologous T lymphocyte cell line.
- Various T cell subsets isolated from the patient, including unselected PBMC or enriched CD3 T cells or enriched CD3 or memory T cell subsets, can be transduced with a vector for CAR expression. Central memory T cells are one useful T cell subset. Central memory T cell can be isolated from peripheral blood mononuclear cells (PBMC) by selecting for CD45RO+/CD62L+ cells, using, for example, the CliniMACS® device to immunomagnetically select cells expressing the desired receptors. The cells enriched for central memory T cells can be activated with anti-CD3/CD28, transduced with, for example, a SIN lentiviral vector that directs the expression of the CAR as well as a truncated human CD19 (CD19t), a non-immunogenic surface marker for both in vivo detection and potential ex vivo selection. The activated/genetically modified central memory T cells can be expanded in vitro with IL-2/IL-15 and then cryopreserved.
- The structure of a useful IL13Rα2-specific CAR is described below. The codon optimized CAR sequence contains a membrane-tethered IL-13 ligand mutated at a single site (E13Y) to reduce potential binding to IL13Rα1, an IgG4 Fc spacer containing two mutations (L235E; N297Q) that greatly reduce Fc receptor-mediated recognition models, a CD4 transmembrane domain, a costimulatory 4-1BB cytoplasmic signaling domain, and a CD3ζ cytoplasmic signaling domain. A T2A ribosome skip sequence separates this IL13(EQ)BBζ CAR sequence from CD19t, an inert, non-immunogenic cell surface detection/selection marker. This T2A linkage results in the coordinate expression of both IL13(EQ)BBζ and CD19t from a single transcript.
FIG. 1A is a schematic drawing of the 2670 nucleotide open reading frame encoding the IL13(EQ)BBZ-T2ACD19t construct. In this drawing, the IL13Rα2-specific ligand IL13(E13Y), IgG4(EQ) Fc, CD4 transmembrane, 4-1BB cytoplasmic signaling, three-glycine linker, and CD3ζ cytoplasmic signaling domains of the IL13(EQ)BBZ CAR, as well as the T2A ribosome skip and truncated CD19 sequences are all indicated. The human GM-CSF receptor alpha and CD19 signal sequences that drive surface expression of the IL13(EQ)BBZ CAR and CD19t are also indicated. Thus, the IL13(EQ)BBZ-T2ACD19t construct includes a IL13Rα2-specific, hinge-optimized, costimulatory chimeric immunoreceptor sequence (designated IL13(EQ)BBZ), a ribosome-skip T2A sequence, and a CD19t sequence. - The IL13(EQ)BBZ sequence was generated by fusion of the human GM-CSF receptor alpha leader peptide with IL13(E13Y)
ligand 5 L235E/N297Q-modified IgG4 Fc hinge (where the double mutation interferes with FcR recognition), CD4 transmembrane, 4-1BB cytoplasmic signaling domain, and CD3ζ cytoplasmic signaling domain sequences. This sequence was synthesized de novo after codon optimization. The T2A sequence was obtained from digestion of a T2A-containing plasmid. The CD19t sequence was obtained from that spanning the leader peptide sequence to the transmembrane components (i.e., basepairs 1-972) of a CD19-containing plasmid. All three fragments, 1) IL13(EQ)BBZ, 2) T2A, and 3) CD19t, were cloned into the multiple cloning site of the epHIV7 lentiviral vector. When transfected into appropriate cells, the vector integrates the sequence depicted schematically inFIG. 1B into the host cells genome.FIG. 1C provides a schematic drawing of the 9515 basepair IL13(EQ)BBZ-T2A-CD19t_epHIV7 plasmid itself. - As shown schematically in
FIG. 2 , IL13(EQ)BBZ CAR differs in several important respects from a previously described IL13Rα2-specific CAR referred to as IL13(E13Y)-zetakine (Brown et al. 2012 Clinical Cancer Research 18:2199). The IL13(E13Y)-zetakine is composed of the IL13Rα2-specific human IL-13 mutein (huIL-13(E13Y)), human IgG4 Fc spacer (huγ4Fc), human CD4 transmembrane (huCD4 tm), and human CD3ζ chain cytoplasmic (huCD3ζ cyt) portions as indicated. In contrast, the IL13(EQ)BBζ) has two point mutations, L235E and N297Q that are located in the CH2 domain of the IgG4 spacer, and a costimulatory 4-1BB cytoplasmic domain (4-1BB cyt). - The pHIV7 plasmid is the parent plasmid from which the clinical vector IL13(EQ)BBZ-T2A-CD19t_epHIV7 was derived in the T cell Therapeutics Research Laboratory (TCTRL) at City of Hope (COH). The epHIV7 vector used for expression of the CAR was produced from pHIV7 vector. Importantly, this vector uses the human EF1 promoter to drive expression of the CAR. Both the 5′ and 3′ sequences of the vector were derived from pv653RSN as previously derived from the HXBc2 provirus. The polypurine tract DNA flap sequences (cPPT) were derived from HIV-1 strain pNL4-3 from the NIH AIDS Reagent Repository. The woodchuck post-transcriptional regulatory element (WPRE) sequence was previously described.
- Construction of pHIV7 is schematically depicted in
FIG. 3 . Briefly, pv653RSN, containing 653 bp from gag-pol plus 5′ and 3′ long-terminal repeats (LTRs) with an intervening SL3-neomycin phosphotransferase gene (Neo), was subcloned into pBluescript, as follows: InStep 1, the sequences from 5′ LTR to rev-responsive element (RRE) made p5′HIV-1 51, and then the 5′ LTR was modified by removing sequences upstream of the TATA box, and ligated first to a CMV enhancer and then to the SV40 origin of replication (p5′HIV-2). InStep 2, after cloning the 3′ LTR into pBluescript to make p3′HIV-1, a 400-bp deletion in the 3′ LTR enhancer/promoter was made to remove cis-regulatory elements in HIV U3 and form p3′HIV-2. InStep 3, fragments isolated from the p5′HIV-3 and p3′HIV-2 were ligated to make pHIV-3. InStep 4, the p3′HIV-2 was further modified by removing extra upstream HIV sequences to generate p3′HIV-3 and a 600-bp BamHI-SalI fragment containing WPRE was added to p3′HIV-3 to make the p3′HIV-4. InStep 5, the pHIV-3 RRE was reduced in size by PCR and ligated to a 5′ fragment from pHIV-3 (not shown) and to the p3′HIV-4, to make pHIV-6. InStep 6, a 190-bp BglII-BamHI fragment containing the cPPT DNA flap sequence from HIV-1 pNL4-3 (55) was amplified from pNL4-3 and placed between the RRE and the WPRE sequences in pHIV6 to make pHIV-7. This parent plasmid pHIV7-GFP (GFP, green fluorescent protein) was used to package the parent vector using a four-plasmid system. - A packaging signal, psi ψ, is required for efficient packaging of viral genome into the vector. The RRE and WPRE enhance the RNA transcript transport and expression of the transgene. The flap sequence, in combination with WPRE, has been demonstrated to enhance the transduction efficiency of lentiviral vector in mammalian cells.
- The helper functions, required for production of the viral vector), are divided into three separate plasmids to reduce the probability of generation of replication competent lentivirus via recombination: 1) pCgp encodes the gag/pol protein required for viral vector assembly; 2) pCMV-Rev2 encodes the Rev protein, which acts on the RRE sequence to assist in the transportation of the viral genome for efficient packaging; and 3) pCMV-G encodes the glycoprotein of the vesiculo-stomatitis virus (VSV), which is required for infectivity of the viral vector.
- There is minimal DNA sequence homology between the pHIV7 encoded vector genome and the helper plasmids. The regions of homology include a packaging signal region of approximately 600 nucleotides, located in the gag/pol sequence of the pCgp helper plasmid; a CMV promoter sequence in all three helper plasmids; and a RRE sequence in the helper plasmid pCgp. It is highly improbable that replication competent recombinant virus could be generated due to the homology in these regions, as it would require multiple recombination events. Additionally, any resulting recombinants would be missing the functional LTR and tat sequences required for lentiviral replication.
- The CMV promoter was replaced by the EF1α-HTLV promoter (EF1p), and the new plasmid was named epHIV7 (
FIG. 4 ). The EF1p has 563 bp and was introduced into epHIV7 using NruI and NheI, after the CMV promoter was excised. - The lentiviral genome, excluding gag/pol and rev that are necessary for the pathogenicity of the wild-type virus and are required for productive infection of target cells, has been removed from this system. In addition, the IL13(EQ)BBZ-T2ACD19t_epHIV7 vector construct does not contain an intact 3′LTR promoter, so the resulting expressed and reverse transcribed DNA proviral genome in targeted cells will have inactive LTRs. As a result of this design, no HIV-I derived sequences will be transcribed from the provirus and only the therapeutic sequences will be expressed from their respective promoters. The removal of the LTR promoter activity in the SIN vector is expected to significantly reduce the possibility of unintentional activation of host genes. Table 4 summarizes the various regulator elements present in IL13(EQ)BBZ-T2ACD19t_epHIV7.
-
TABLE 4 Functional elements of IL13(EQ)41BBZ-T2A-CD19t_epHIV7 Regulatory Location Elements (Nucleotide and Genes Numbers) Comments U5 87-171 5′ Unique sequence psi 233-345 Packaging signal RRE 957-1289 Rev-responsive element flap 1290-1466 Contains polypurine track sequence and central termination sequence to facilitate nuclear import of pre-integration complex EF1p Promoter 1524-2067 EF1-alpha Eukaryotic Promoter sequence driving expression of CD19Rop IL13-IgG4 (EQ)- 2084-4753 Therapeutic insert 41BB-Zeta-T2A- CD19t WPRE 4790-5390 Woodchuck hepatitis virus derived regulatory element to enhance viral RNA transportation delU3 5405-5509 3′ U3 with deletion to generate SIN vector R 5510-5590 Repeat sequence within LTR U5 5591-5704 3′ U5 sequence in LTR AmpR 6540-7398 Ampicillin-resistance gene CoE1 ori 7461-8342 Replication origin of plasmid SV40 ori 8639-8838 Replication origin of SV40 CMV promoter 8852-9451 CMV promoter to generate viral genome RNA R 9507-86 Repeat sequence within LTR - For each plasmid (IL13(EQ)BBZ-T2A-CD19t_epHIV7; pCgp; pCMV-G; and pCMV-Rev2), a seed bank is generated, which is used to inoculate the fermenter to produce sufficient quantities of plasmid DNA. The plasmid DNA is tested for identity, sterility and endotoxin prior to its use in producing lentiviral vector.
- Briefly, cells were expanded from the 293T working cell (WCB), which has been tested to confirm sterility and the absence of viral contamination. A vial of 293T cells from the 293T WCB was thawed. Cells were grown and expanded until sufficient numbers of cells existed to plate an appropriate number of 10 layer cell factories (CFs) for vector production and cell train maintenance. A single train of cells can be used for production.
- The lentiviral vector was produced in sub-batches of up to 10 CFs. Two sub-batches can be produced in the same week leading to the production of approximately 20 L of lentiviral supernatant/week. The material produced from all sub-batches were pooled during the downstream processing phase, in order to produce one lot of product. 293T cells were plated in CFs in 293T medium (DMEM with 10% FBS). Factories were placed in a 37° C. incubator and horizontally leveled in order to get an even distribution of the cells on all the layers of the CF. Two days later, cells were transfected with the four lentiviral plasmids described above using the CaPO4 method, which involves a mixture of Tris:EDTA, 2M CaCl2, 2×HBS, and the four DNA plasmids.
Day 3 after transfection, the supernatant containing secreted lentiviral vectors was collected, purified and concentrated. After the supernatant was removed from the CFs, End-of-Production Cells were collected from each CF. Cells were trypsinized from each factory and collected by centrifugation. Cells were resuspended in freezing medium and cryopreserved. These cells were later used for replication-competent lentivirus (RCL) testing. - To purify and formulate vectors crude supernatant was clarified by membrane filtration to remove the cell debris. The host cell DNA and residual plasmid DNA were degraded by endonuclease digestion (Benzonase®). The viral supernatant was clarified of cellular debris using a 0.45 μm filter. The clarified supernatant was collected into a pre-weighed container into which the Benzonase® is added (final concentration 50 U/mL). The endonuclease digestion for residual plasmid DNA and host genomic DNA as performed at 37° C. for 6 h. The initial tangential flow ultrafiltration (TFF) concentration of the endonuclease-treated supernatant was used to remove residual low molecular weight components from the crude supernatant, while concentrating the virus ˜20 fold. The clarified endonuclease-treated viral supernatant was circulated through a hollow fiber cartridge with a NMWCO of 500 kD at a flow rate designed to maintain the shear rate at ˜4,000 sec-1 or less, while maximizing the flux rate. Diafiltration of the nuclease-treated supernatant was initiated during the concentration process to sustain the cartridge performance. An 80% permeate replacement rate was established, using 4% lactose in PBS as the diafiltration buffer. The viral supernatant was brought to the target volume, representing a 20-fold concentration of the crude supernatant, and the diafiltration was continued for 4 additional exchange volumes, with the permeate replacement rate at 100%.
- Further concentration of the viral product was accomplished by using a high speed centrifugation technique. Each sub-batch of the lentivirus was pelleted using a Sorvall RC-26 plus centrifuge at 6000 RPM (6,088 RCF) at 6° C. for 16-20 h. The viral pellet from each sub-batch was then reconstituted in a 50 mL volume with 4% lactose in PBS. The reconstituted pellet in this buffer represents the final formulation for the virus preparation. The entire vector concentration process resulted in a 200-fold volume reduction, approximately. Following the completion of all of the sub-batches, the material was then placed at −80° C., while samples from each sub-batch were tested for sterility. Following confirmation of sample sterility, the sub-batches were rapidly thawed at 37° C. with frequent agitation. The material was then pooled and manually aliquoted in the Class II Type A/B3 biosafety cabinet in the viral vector suite. A fill configuration of 1 mL of the concentrated lentivirus in
sterile USP class 6, externally threaded O-ring cryovials was used. Center for Applied Technology Development (CATD)'s Quality Systems (QS) at COH released all materials according to the Policies and Standard Operating Procedures for the CBG and in compliance with current Good Manufacturing Practices (cGMPs). - To ensure the purity of the lentiviral vector preparation, it was tested for residual host DNA contaminants, and the transfer of residual host and plasmid DNA. Among other tests, vector identity was evaluated by RT-PCR to ensure that the correct vector is present. All release criteria were met for the vector intended for use in this study.
- T lymphocytes are obtained from a patient by leukopheresis, and the appropriate allogenic or autologous T cell subset, for example, Central Memory T cells (TCM), are genetically altered to express the CAR, then administered back to the patient by any clinically acceptable means, to achieve anti-cancer therapy.
- Suitable TCM can be prepared as follows. Apheresis products obtained from consented research participants are ficolled, washed and incubated overnight. Cells are then depleted of monocyte, regulatory T cell and naïve T cell populations using GMP grade anti-CD14, anti-CD25 and anti-CD45RA reagents (Miltenyi Biotec) and the CliniMACS™ separation device. Following depletion, negative fraction cells are enriched for CD62L+ TCM cells using DREG56-biotin (COH clinical grade) and anti-biotin microbeads (Miltenyi Biotec) on the CliniMACS™ separation device.
- Following enrichment, TCM cells are formulated in complete X-Vivo15 plus 50 IU/mL IL-2 and 0.5 ng/mL IL-15 and transferred to a Teflon cell culture bag, where they are stimulated with Dynal ClinEx™ Vivo CD3/CD28 beads. Up to five days after stimulation, cells are transduced with IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentiviral vector at a multiplicity of infection (MOI) of 1.0 to 0.3. Cultures are maintained for up to 42 days with addition of complete X-Vivo15 and IL-2 and IL-15 cytokine as required for cell expansion (keeping cell density between 3×105 and 2×106 viable cells/mL, and cytokine supplementation every Monday, Wednesday and Friday of culture). Cells typically expand to approximately 109 cells under these conditions within 21 days. At the end of the culture period cells are harvested, washed twice and formulated in clinical grade cryopreservation medium (Cryostore CS5, BioLife Solutions).
- On the day(s) of T cell infusion, the cryopreserved and released product is thawed, washed and formulated for re-infusion. The cryopreserved vials containing the released cell product are removed from liquid nitrogen storage, thawed, cooled and washed with a PBS/2% human serum albumin (HSA) Wash Buffer. After centrifugation, the supernatant is removed and the cells resuspended in a Preservative-Free Normal Saline (PFNS)/2% HSA infusion diluent. Samples are removed for quality control testing.
- Two qualification runs on cells procured from healthy donors were performed using the manufacturing platform described above. Each preclinical qualification run product was assigned a human donor (HD) number—HD006.5 and HD187.1. Importantly, as shown in Table 5, these qualification runs expanded >80 fold within 28 days and the expanded cells expressed the IL13(EQ)BBγ/CD19t transgenes.
-
TABLE 5 Summary of Expression Data from Pre- clinical Qualification Run Product Cell Product CAR CD19 CD4+ CD8+ Fold Expansion HD006.5 20% 22% 24% 76% 84-fold (28 days) Hd187.1 18% 25% 37% 63% 259-fold (28 days) - The two preclinical qualification run products described in Example 4 were used in pre-clinical studies to as described below.
FIGS. 6A-C depict the results of flow cytometric analysis of surface transgene and T cell marker expression. IL13(EQ)BBγ/CD19t+ TCM HD006.5 and HD187.1 were co-stained with anti-IL13-PE and anti-CD8-FITC to detect CD8+ CAR+ and CD4+ (i.e., CD8 negative) CAR+ cells (FIG. 6A ), or anti-CD19-PE and anti-CD4-FITC to detect CD4+ CD19t+ and CD8+ (i.e., CD4 negative) CAR+ cells (FIG. 6B ). IL13(EQ)BBγ/CD19t+ TCM HD006.5 and HD187.1 were stained with fluorochrome-conjugated anti-CD3, TCR, CD4, CD8, CD62L and CD28 (grey histograms) or isotype controls (black histograms). (FIG. 6C ). In each ofFIGS. 6A-C , the percentages indicated are based on viable lymphocytes (DAPI negative) stained above isotype. - Described below are studies that compare the route of delivery, intravenous (i.v.) or intracranial (i.c.), on antitumor activity against invasive primary PBT lines. In pilot studies (data not shown), it was unexpectedly observed that i.v. administered IL13(EQ)BBζ+ TCM provided no therapeutic benefit as compared to PBS for the treatment of small (day 5) PBT030-2 EGFP:ffLuc tumors. This is in contrast to the robust therapeutic efficacy observed with i.c. administered CAR+ T cells. Reasoning that
day 5 PBT030-2 tumors may have been too small to recruit therapeutic T cells from the periphery, a comparison was made of i.v. versus i.c. delivery againstlarger day 19 PBT030-2 EGFP:ffLuc tumors. For these studies, PBT030-2 engrafted mice were treated with either two i.v. infusions (5×106 CAR+ TCM;days 19 and 26) or four i.c. infusions (1×106 CAR+ TCM;days FIGS. 7A and 7B ). In contrast, potent antitumor activity was observed for i.c. administered IL13(EQ)BBζ+ TCM (FIGS. 7A-B ). Next, brains from a cohort ofmice 7 days post T cell injection were harvested and evaluated for CD3+ human T cells by IHC. Surprisingly, for mice treated i.v. with either mock TCM or IL13(EQ)BBζ TCM there were no detectable CD3+ human T cells in the tumor or in others mouse brain regions where human T cells typically reside (i.e. the leptomeninges) (FIG. 7C ), suggesting a deficit in tumor tropism. This is in contrast to the significant number of T cells detected in the i.c. treated mice (FIG. 7D ). - Tumor derived cytokines, particularly MCP-1/CCL2, are important in recruiting T cells to the tumor. Thus, PBT030-2 tumor cells were evaluated and it was found that this line produces high levels of MCP-1/CCL2 comparable to U251T cells (data not shown), a glioma line previously shown to attract i.v. administered effector CD8+ T cells to i.c. engrafted tumors. Malignant gliomas are highly invasive tumors and are often multi-focal in presentation. The studies described above establish that IL13BBZ TCM can eliminate infiltrated tumors such as PBT030-2, and mediate long-term durable antitumor activity. The capacity of intracranially delivered CAR T cells to traffic to multifocal disease was also examined. For this study PBT030-2 EGFP:ffLuc TSs were implanted in both the left and right hemispheres (
FIG. 8A ) and CAR+ T cells were injected only at the right tumor site. Encouragingly, for all mice evaluated (n=3) we detected T cells by CD3 IHC 7-days post T cell infusion both at the site of injection (i.e. right tumor), as well within the tumor on the left hemisphere (FIG. 8B ). These findings provide evidence that CAR+ T cells are able to traffic to and infiltrate tumor foci at distant sites. Similar findings were also observed in a second tumor model using the U251T glioma cell line (data not shown). - The complete amino acid sequence of IL13(EQ)BBζ/CD19t is depicted in
FIG. 9 . The entire sequence (SEQ ID NO:1) includes: a 22 amino acid GMCSF signal peptide (SEQ ID NO:2), a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); a 22 amino acid CD4 transmembrane sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; a 112 amino acid CD3ζ sequence (SEQ ID NO:7); a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9). - The mature chimeric antigen receptor sequence (SEQ ID NO:10) includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; and a 112 amino acid CD3ζ sequence (SEQ ID NO:7). Within this CAR sequence (SEQ ID NO:10) is the IL-13/IgG4/CD4t/41-BB sequence (SEQ ID NO:11), which includes: a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); at 22 amino acid CD4 sequence (SEQ ID NO:5); and a 42 amino acid 4-1BB sequence (SEQ ID NO:6). The IL13/IgG4/CD4t/4-1BB sequence (SEQ ID NO:11) can be joined to the 112 amino acid CD3ζ sequence (SEQ ID NO:7) by a linker such as a Gly Gly Gly linker. The CAR sequence (SEQ ID NO:10) can be preceded by a 22 amino acid GMCSF signal peptide (SEQ ID NO:2).
-
FIG. 10 depicts a comparison of the sequences of IL13(EQ)41BBζ[IL13{EQ}41BBζ T2A-CD19t_epHIV7; pF02630] (SEQ ID NO:12) and CD19Rop_epHIV7 (pJ01683) (SEQ ID NO:13). -
FIGS. 11-18 depict the amino acid sequences of additional CAR directed against IL13Rα2. In each case the various domains are labelled except for the GlyGlyGly spacer located between certain intracellular domains. Each includes human IL13 with and Glu to Tyr (SEQ ID NO:3; amino acid substitution E13Y shown in highlighted). In the expression vector used to express these CAR, the amino acid sequence expressed can include a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9) to permit coordinated expression of a truncated CD19 sequence on the surface of CAR-expressing cells. - A panel of CAR comprising human IL13(E13Y) domain, a CD28 tm domain, a CD28gg costimulatory domain, a 4-1BB costimulatory domain, and a CD3ζ domain CAR backbone and including either a HL (22 amino acids) spacer, a CD8 hinge (48 amino acids) spacer, IgG4-HL-CH3 (129 amino acids) spacer or a IgG4(EQ) (229 amino acids) spacer were tested for their ability to mediate IL13Rα2-specific killing as evaluated in a 72-hour co-culture assay. With the exception of HL (22 amino acids) which appeared to have poor CAR expression in this system, all were active.
- One CAR comprising a HER2 scFv described herein is referred to as Her2scFv-IgG4(L235E, N297Q)-CD28tm-CD28gg-Zeta-T2A-CD19t. This CAR includes a variety of important features including: a scFv targeted to HER2; an IgG4 Fc region that is mutated at two sites within the CH2 region (L235E; N297Q) in a manner that reduces binding by Fc receptors (FcRs); a CD28 transmembrane domain, a CD28 co-stimulatory domain, and CD3ζ activation domain.
FIG. 20 presents the amino acid sequence of this CAR, including the sequence of the truncated CD19 sequence used for monitoring CAR expression and the T2A ribosomal skip sequence that allows the CAR to be produced without fusion of the truncated CD19 sequence. As shown inFIG. 21 , the immature CAR includes: GMCSFR signal peptide, HER2 scFv, IgG4 that acts as a spacer, a CD8 transmembrane domain, a 4-IBB co-stimulatory domain that includes a LL to GG sequence alteration, a three Gly sequence, CD3 Zeta stimulatory domain. The transcript also encodes a T2A ribosomal sequence and a truncated CD19 sequence that are not part of the CAR protein sequence. The mature CAR is identical to the immature CAR, but lacks the GMCSF signal peptide. -
FIG. 22A is a schematic diagram of two the HER2-specific CAR constructs depicted inFIG. 20 andFIG. 21 . In HER2(EQ)28ζ the scFv is tethered to the membrane by a modified IgG4 Fc linker (double mutant, L235E; N297Q), containing a CD28 transmembrane domain, an intracellular CD28 co-stimulatory domain and a cytolytic CD3ζ domain. The T2A skip sequence separates the CAR from a truncated CD19 (CD19t) protein employed for cell tracking. HER2(EQ)BBζ is similar except that the costimulatory domain is 4-1BB rather than CD28 and the transmembrane domain is a CD8 transmembrane domain rather than a CD28 transmembrane domain. Human central memory (TCM) cells were transfected with a lentiviral vector expressing either HER2(EQ)28ζ or HER2(EQ)BBζ.FIG. 22B depicts representative FACS data of human TCM surface phenotype.FIG. 22C depicts the results of assays for CD19 and Protein L expression in TCM transfected with a lentiviral vector expressing either HER2(EQ)28ζ or HER2(EQ)BBζ. As can be seen from these results, transfection efficiency as assessed by CD19 expression was similar for both CAR. However, Protein L expression was lower for HER2(EQ)BBζ than for HER2(EQ)28ζ suggesting that the HER2(EQ)BBζ CAR is less stable that the HER2(EQ)BBζ. Analysis of cell expansion (FIG. 22D ) shows that neither CAR interferes with T cell expansion. - A variety of breast cancer cell lines, including, HER2-negative lines (LCL lymphoma, MDA-MB-468, U87 glioma), low-HER2 expressing lines (MDA-MB-361, 231BR) and high-HER2 expressing lines (SKBR3, BT474, BBM1) were used to characterize HER2(EQ)28ζ and HER2(EQ)BBζ.
FIG. 23A depicts the HER2 expression level of each of these lines. Flow cytometry (gated on CAR+ T cells) was used to characterize CD107a degranulation and IFNγ production in Mock (untransduced), HER2(EQ)28ζ or HER2(EQ)BBζ CAR T cells following a 5 hr co-culture with either MDA-MB-361 tumor cells (low HER2 expressing) or BBM1 tumor cells (high HER2 expressing). The results of this analysis are presented inFIG. 23B . Similar studies were conducted with the other breast cancer cells lines, and the results are summarized inFIG. 23C . Production of IFNγ production by HER2-CAR T cells following a 24 hr culture with recombinant HER2 protein or tumor targets was measured by ELISA and the results of this analysis are shown inFIG. 23D . - Flow cytometry was used to assess tumor cell killing following a 72 h co-culture of Mock (untransduced), HER2(EQ)28ζ or HER2(EQ)BBζ CAR T cells with tumor targets. The results of this analysis are presented in
FIG. 24A . PD-1 and LAG-3 induction in total CAR T cells after a 72 h co-culture with HER2-negative MDA-MB-468 or HER2-positive BBM1 cells was measured, and the results of this analysis are presented inFIG. 24B . PD-1 induction in CD8+ CAR T cells following a 72 h co-culture with tumor targets that are HER2-negative (LCL lymphoma, MDA-MB-468, U87 glioma), low-HER2 expressing (MDA-MB-361, 231BR) or high-HER2 expressing (SKBR3, BT474, BBM1) was measured, and the results of this analysis are presented inFIG. 24C . These studies suggest that HER2(EQ)BBζ causes lower PD-1 induction that does HER2(EQ)28ζ. Tumor cell killing with Effector:Tumor (E:T) ratio ranging from 0.25:1 to 2:1 was measured for both HER2(EQ)28ζ or HER2(EQ)BBζ CAR T cells. The results of this analysis are presented inFIG. 24D , which shows that both HER2(EQ)28ζ and HER2(EQ)BBζ are effective in tumor cell killing in vitro. CFSE proliferation of HER2-CAR T cells following a 72 h co-culture with MDA-MB-468 or BBM1 cells was measured by flow cytometry. The results of this analysis are presented inFIG. 24E , which shows that HER2(EQ)BBζ CAR T cells proliferate more than HER2(EQ)28ζ CAR T cells. - The activity of intratumorally delivered HER2 CAR T cells was assessed in a patient-derived breast-to-brain metastasis model.
FIGS. 25A-25C are H&E staining of tumors. Mice were treating by injection directly into the tumor with Mock (untransduced) or HER2(EQ)BBζ CAR T cells.FIGS. 25D-25F depict the results of optical imaging of the tumors andFIGS. 25G-251 are Kaplan-Meier survival curves for mice treated locally with either atday - To assess anti-tumor efficacy in human xenograft models of breast-to-brain metastasis, BBM1 cells (0.2M) or BT474 (0.15M) were intracranially injected in NSG mice. At
day 8 post tumor injection, HER2(EQ)28ζ or HER2(EQ)BBζ, or Mock (untransduced) T cells (1M) were injected intratumorally. BBM1 (FIG. 26A ) and BT474 (FIG. 26B ) tumors were monitored by luciferase-based optical imaging. Kaplan Meier curves are presented inFIG. 26C andFIG. 26D . - A human patient-derived orthotopic xenograft model of breast-to-brain metastasis was also used to assess HER2(EQ)28ζ and HER2(EQ)BBζ CAR T cells.
FIG. 27A illustrates the region of tumor implantation by stereotactic injection of BBM1 cells (0.2M), and intraventricular T cell delivery. Staining of tumors is depicted inFIG. 27B . Atday 14 post tumor injection, HER2(EQ)28ζ, HER2(EQ)BBζ, or Mock (unstransduced) T cells (0.5M) were injected intratumorally. Tumor growth was monitored by luciferase-based optical imaging.FIG. 27C presents the flux averages for each treatment group, andFIG. 27D presents the Kaplan Meier survival curve for each treatment group. - Two different intracranial (ic) delivery routes, intratumoral (ict) and intraventricular (icy) were assessed in a murine model of glioblastoma for in vivo safety, trafficking and efficacy of CAR T cells generated from TCM-enriched cell lines that were transduced with the IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentiviral vector and expanded in vitro as proposed for the clinical treatment of glioblastoma (GBM). In vivo safety and functional potency of these cells administered either ict or icv was examined in immunodeficient NSG mice using the IL13Rα2+ primary low-passage GBM tumor sphere line PBT030-2, which has been engineered to express the firefly luciferase (ffLuc) reporter gene.
- TCM cell lines that had been enriched from PBMC by CliniMACS™/AutoMACS selection were lenti-transduced with IL13(EQ)BBZ-T2A-CD19t_epHIV7 lentivirus, expanded and then cryopreserved using methods similar to that described above. Freshly thawed CAR T cells administered either ict or icv were then evaluated for potential toxicity, their ability to traffic to multifocal GBM tumors and their potency in controlling the in vivo growth of ic engrafted IL13Rα2+ GBM line PBT030-2 cells. To assess general toxicity, mice were observed daily for overall health, including body weight and alertness. Tumor burden, as measured by Xenogen imaging, was examined; and immunohistochemistry (IHC) to detect T cell recruitment/infiltration of the tumors was also performed on a subset of mice.
- Male NSG mice (10-12 weeks old) were stereotactically injected ic with 1×105 ffLuc+ PBT030-2 cells in both the right and left contralateral hemispheres on
day 0 and allowed to engraft for 6 days. Mice were then grouped based on tumor size as determined by Xenogen imaging for equal tumor size distributions per group. Groups of mice were then left untreated (n=4), or treated either ict (right hemisphere, n=8) or icv (n=8) with 1×106 CAR+IL13(EQ)BBζ/CD19t+ TCM (FIG. 28 ). PBT030-2 tumor growth was monitored over time by Xenogen imaging and quantification of ffLuc flux (photons/sec). At different time points, mice from each group were euthanized, their brains harvested, embedded in paraffin and immunohistochemistry (IHC) was performed to evaluate the presence of human CD3-expressing cells (i.e., human T cells). Specifically, three mice were euthanized from each CAR T cell treated group one week after the T cell administration (Day 13 of the experiment), and thus these mice were not included in the Xenogen imaging analysis ofFIG. 29 ; and then two mice in each of the groups of mice were euthanized two weeks after the T cell administration (Day 21 of the experiment). - While this was not a survival study, and thus mice were all euthanized at specific time points to evaluate T cell trafficking in the brains (described below), the mice were monitored daily for any obvious signs of distress or general toxicity. Mice treated with either the ict or icv regimen did not exhibit any weight loss, and were bright, alert and reactive throughout the experiment. Thus, regardless of the route of T cell administration, there were no signs of any therapy-associated adverse effects.
- As shown in
FIGS. 29A-C , ict delivery of IL13(EQ)BBζ/CD19t+TCM exhibited robust anti-tumor activity against the PBT030-2 tumors as expected. However, icv delivery of IL13(EQ)BBζ/CD19t+ TCM appeared to provide greater therapeutic benefit against is engrafted PBT030-2 tumors than that observed with ict administration, especially against the tumor lesion in the contralateral (left) hemisphere. - To determine if route of administration affected the ability of T cells to migrate to the tumor site, IHC analysis for CD3+ T cells was performed on the brains of mice from each group at one and two weeks after the T cell administration. As shown in
FIG. 30 , human CD3+ T cells were found at both the left and right tumor sites in mice that had received either ict or icv administered T cells. These data are representative of 3 mice in each group at one week, and 2 mice in each group at two weeks post T cell administration. - This study demonstrates that both intratumoral and intraventricular administration of T cells were well-tolerated in this NSG mouse model. Furthermore, in vivo multi-focal anti-tumor efficacy and IHC detection of T cells at the tumor sites can be observed with both ict and icy delivery of TCM qualification run cells that had been transduced with the IL13(EQ)BBZ-T2A-CD19t_epHIV7 vector. This study further suggests that icv delivered T cells may have greater efficacy than ict delivered T cells.
- This example describes the initial findings of a clinical trial evaluating the safety, feasibility and bioactivity of weekly intracranial infusions of autologous IL13BBζ Tcm in patients with recurrent IL13Rα2+ GBM. As described in greater detail below, Enrolled patients undergo leukapheresis to collect autologous PBMC and, concurrent with IL13BBζ+ Tcm manufacturing, tumor biopsy or resection is performed, with placement of a reservoir/catheter device. Following baseline MR and PET imaging and recovery from surgery, patients are treated on a 4-week therapeutic regimen, consisting of 3-weekly intracranial infusions of IL13BBζ+ Tcm followed by one rest week for toxicity and disease assessment. The results to date for this first low dose cohort of three resection patients, suggest that local delivery of IL13BBζ Tcm post surgical resection is safe and well-tolerated with no
grade 3 or higher toxicities attributed to the therapy observed, and importantly, demonstrate early evidence for antitumor activity following CAR T cell administration. For all patients in which a sample was available, CAR T cells were detected in the tumor cyst fluid or cerebral spinal fluid (CSF) by flow cytometry for a minimum of 7 days post treatment. One patient of particular interest presented with a recurrent multifocal GBM, including one metastatic site in the spine and extensive leptomeningeal disease. This patient was initially treated per protocol with six local infusions of IL13BBζ Tcm into the resection cavity of the largest recurrent tumor focus in the posterior temporal-occipital region. Encouragingly, this CAR T cell injection site remained stable without evidence of disease recurrence for over 7-weeks, while other disease foci distant from the CAR T cell injection site continued to progress. This patient was then treated on a compassionate use protocol with five weekly intraventricular infusions of IL13BBζ Tcm without any other therapeutic interventions. One week following the final intraventricular CAR T cell infusion, all intracranial and spinal tumors had regressed with most decreasing more than 75% by volume, and this patient remained clinically stable four months following the start of CAR T cell treatment. - The CAR, IL13(EQ)BBζ, used in this study is described above. The sequence of the immature CAR, including the CD19t marker is depicted in
FIG. 9 . The entire immature sequence (SEQ ID NO:1) includes: a 22 amino acid GMCSF signal peptide (SEQ ID NO:2), a 112 amino acid IL-13 sequence (SEQ ID NO:3; amino acid substitution E13Y shown in bold); a 229 amino acid IgG4 sequence (SEQ ID NO:4; with amino acid substitutions L235E and N297Q shown in bold); a 22 amino acid CD4 transmembrane sequence (SEQ ID NO:5); a 42 amino acid 4-1BB sequence (SEQ ID NO:6); a 3 amino acid Gly linker; a 112 amino acid CD3ζ sequence (SEQ ID NO:7); a 24 amino acid T2A sequence (SEQ ID NO:8); and a 323 amino acid CD19t sequence (SEQ ID NO:9). - Autologous cells from each patient was used to prepare CD8+ CD4+ TCM cells which were then transfected with a lentiviral vector, described above, expressing IL13(EQ)BBζ. Briefly, TCM were enriched from peripheral blood mononuclear cells (PBMC) using the CliniMACS® device to immunomagnetically select for CD45RO+/CD62L+ TCM. These cells were activated with anti-CD3/CD28 Dynal beads, transduced with a SIN lentiviral vector that directs the expression of the IL13(EQ)BBζ CAR. The activated/genetically modified IL13(EQ)BBζ/CD19t+ TCM cells were expanded in vitro with IL-2/IL-15 and then cryopreserved.
- The treatment of two patients, both suffering from relapsed/refractory GBM is described below. Intracavity administration of CAR T cells was performed manually over about 5-10 minutes through a Rickham catheter followed by up to 1.0 mL preservative-free normal-saline (PFNS) flush delivered by convection enhanced delivery (CED) at 0.5 ml/hour. Intraventricular administration of CAR T cells was performed manually over approximately 5-10 minutes through a Rickham catheter placed into the lateral ventricle. This was followed by up to 0.5 mL preservative-free normal-saline (PFNS) flush delivered via a manual push technique over 5-10 minutes. The PFNS flush is meant to clear the administration line and push remaining CAR T cells through the catheter.
- The time course of CAR T cell preparation and treatment is depicted in
FIG. 31 . Concurrent with the manufacturing process, research participants underwent resection of their tumor(s) followed by placement of a Rickham catheter and baseline imaging. - Patient UPN097 underwent tumor resection and was treated in
Cycle 1 with 2×106 cells and inCycle 2 with 10×106 cells. In bothCycle 1 andCycle 2 the cells were administered to the cavity left by resection. After the second cycle Patient UPN097 was taken off the study due to rapid tumor progression. - Patient UPN109 was treated in
Cycle 1 with 2×106 cells and inCycles Cycles Cycle 7 the patient was treated with 2×106 cells. InCycles -
FIG. 32A presents analysis of CAR T cell persistence, as monitored by CD19. This analysis shows goodT cell persistence 8 days after theCycle 2.FIG. 32B shows decreased presence of GBM cells as monitored by IL13Rα2 expression on cells. -
FIG. 33A andFIG. 33B depict imaging results from Patient UPN097 in the region of the catheter used for intratumoral administration. InFIG. 33A one can see that few CD3+ or CD8+ T cells are present pretreatment.FIG. 33B , which is a sample atDay 16 post-treatment taken from the left frontal tumor cavity wall shows a large area of necrotic tumor and significant presence of CD3+ and CD8+ cells. - As shown in
FIGS. 34A-D , there was an increase in IFN-gamma (a Th1 cytokine) over the two Cycles of treatment while levels of IL-13 (a Th2 cytokine did not change significantly (FIG. 34A andFIG. 34B ). IL-6, a tumor related cytokine, decreased duringCycle 1 and remained at the lower level during Cycle 2 (FIG. 34C ). IL-8, another tumor related cytokine, decreased duringCycle 1, but increased towards its pre-Cycle 1 level during Cycle 2 (FIG. 34D ). - Patient UPN109 presented with a recurrent multifocal GBM, including one metastatic site in the spine and extensive leptomeningeal disease. As described above, this patient was treated with six local infusions of IL13BBζ Tcm into the resection cavity of the largest recurrent tumor focus. While the CAR T cell injection site remained stable without evidence of disease recurrence for over 7-weeks, other disease foci distant from the CAR T cell injection site continued to progress (data not shown). This patient then received five weekly intraventricular infusions of IL13BBζ Tcm, as described above.
FIGS. 35A-B presents MM and/or PET images of transverse brain section (FIG. 35A ) and saggital brain section (FIG. 35B ).FIG. 35C presents transverse (top) and frontal (bottom) sections of the spine before (left) and one week after (right) completion of intraventricular therapy, with tumor lesion sites indicated by red arrows in each image. - A 50 year old male was initially diagnosed with a low-grade brain tumor in the right temporal lobe after presenting with grand mal seizures. After four months of monitoring, this right temporal tumor displayed increased enhancement by MRI, and the patient underwent tumor resection which confirmed a diagnosis of WHO grade IV glioma (GBM). The patient then received standard-of-care adjuvant proton radiation to a total dose of 59.4 cobalt Gy equivalent with concurrent temozolomide (140 mg daily), followed by 4-cycles of temozolomide with concomitant use of the Novocure device (NovoTTF-100A) for three months. Six months after the primary tumor resection, PET and MRI images showed evidence of disease progression.
- The patient was then treated autologous IL13Rα2-targeted CAR T cells (
FIG. 36 ) following confirmation of IL13Rα2-expression in the primary right temporal lobe tumor by IHC, with an H score of 100 (FIG. 37 ). Peripheral blood mononuclear cells (PBMC) were then collected by leukapheresis followed by enrichment of CD4+ CD8+ TCM via a two-step depletion selection procedure as previously described. During IL13BBζ TCM manufacturing, the patient was treated on a separate clinical protocol evaluating a fibroblastic growth factor inhibitor (NCT01975701), and progressed through therapy with symptoms of headaches, confusion and disorientation increasing. Additionally, the patient was tapered off steroids prior to T cell injections. - Ten months post primary tumor resection, the patient underwent another surgical resection for three of five identified progressing GBM lesions (
FIG. 38 ), including the largest lesion in the right posterior temporal-occipital region (T1) where the reservoir/catheter device was placed, and two lesions in the right frontal lobe (T2, T3). Two additional tumors in the left temporal area were not surgically removed (T4, T5). Six days post-surgical resection, the patient received two 4-week treatment regimens, each consisting of three weekly intracavitary (ICT) infusions of IL13BBζ TCM followed by a week for toxicity evaluation and disease assessment. This patient was treated starting with a low dose of 2×106 CAR+ T cells followed by five infusions of 10×106 CAR+ T cells (FIG. 39 ). Following these six ICT infusions, under a compassionate use protocol, a second catheter was placed in the right lateral ventricle, allowing the patient to receive an additional five intracerebroventricular (ICV) treatment cycles of IL13BBζ TCM, again starting at a low dose of 2×106 CAR T cells followed by four infusions of 10×106 CAR T cells (FIG. 40 ). - Due to limited therapeutic product only five ICV infusion cycles were feasible. Overall, the patient received 11 cell infusions for a total dose of 94×106 CAR+ T cells. The treatment course encompassed 15-weeks, with evaluation weeks for toxicity and disease assessment (i.e., MM and PET imaging) taking place after every third cycle, and after the final two ICV infusions. The patient received no other therapeutic interventions during this CAR T cell treatment course, and findings up to the 190 day evaluation period, encompassing the 11 infusions cycles, is reported here. Subsequently, a second IL13BBζ TCM product was manufactured and beginning on day 192 this patient has continued to receive ICV infusions of this second manufactured product approximately every 3 weeks.
- These studies, including the compassionate use protocol, were approved by an institutional review board, and the patient provided written informed consent. Eligibility included prior histologically-confirmed diagnosis of an IL13Rα2+ grade IV glioma that is now recurrent, age>18 years with a Karnofsky performance status (KPS)>60, adequate cardiopulmonary function, and a survival expectation>4 weeks. The patient must have completed initial radiation therapy at least 12 weeks prior to enrollment, and must not have any other active malignancies, infections or intercurrent illness or be receiving other investigational agents or require more than 2 mg TID (3×/day) of Dexamethasone during T cell therapy.
- This patient was initially treated under our ongoing phase I study (NCT02208362) to evaluate the safety and feasibility of weekly intracranial infusions of autologous IL13Rα2-targeted CAR T cells (IL13BBζ TCM) in patients diagnosed with recurrent/refractory IL13Rα2+ high-grade glioma (WHO Grades III and IV). This is a two arm study with T cells administered either directly into the tumor (
stratum 1=intratumoral) or into the tumor resection cavity (stratum 2=intracavitary). After completing the six intracavitary (ICT) infusion cycles, this patient was then treated under a separate compassionate use protocol allowing for intracerebroventricular (ICV) delivery of IL13BBζ TCM. - The lentiviral vector encoding the 4-1BB costimulatory, IL13Rα2-targeted CAR, IL13BBζ, is detailed herein. Briefly, the codon optimized CAR sequence contains a membrane-tethered human IL-13 ligand mutated at a single site (E13Y) to reduce potential binding to IL13Rα1, a human IgG4 Fc spacer containing two mutations (L235E; N297Q) that prevent Fc receptor-mediated recognition, a human CD4 transmembrane domain, a human costimulatory 4-1BB cytoplasmic signaling domain, and a human CD3ζ cytoplasmic signaling domain. A T2A ribosome skip sequence then separates this IL13BBζ CAR sequence from a truncated human CD19 sequence (CD19t), an inert, nonimmunogenic cell surface marker.
- For IL13BBζ TCM manufacturing, on the day of leukapheresis, PBMC were isolated by density gradient centrifugation over Ficoll-Paque (GE Healthcare) followed by two washes in PBS/EDTA. PBMC were then washed once in PBS, resuspended in X Vivo15 media (Bio Whittaker) containing 10% fetal calf serum (FCS) (Hyclone), transferred to a 300 cc transfer bag, and stored on a 3-D rotator overnight at room temperature (RT). The following day, 5×109 PBMC were incubated in a 300 cc transfer bag with clinical grade anti-CD14 (1.25 mL), anti-CD25 (2.5 mL) and anti-CD45RA (2.5 mL) microbeads (Miltenyi Biotec) for 30 minutes at RT in X Vivo15 containing 10% FCS. CD14+, CD25+, and CD45RA+ cells were then immediately depleted using the CliniMACS™ depletion mode according to the manufacturer's instructions (Miltenyi Biotec). After centrifugation, the unlabeled negative fraction of cells was resuspended in CliniMACS™ PBS/EDTA buffer (Miltenyi Biotec) containing 0.5% human serum albumin (HSA) (CSL Behring) and then labeled with clinical grade biotinylated-DREG56 mAb (COHNMC CBG) at 0.6 mL for 30 minutes at RT. The cells were then washed and resuspended in a final volume of 100 mL CliniMACS™ PBS/EDTA containing 0.5% HSA and transferred into a new 300 cc transfer bag. After 30 minutes incubation with 1.25 mL anti-biotin microbeads (Miltenyi Biotec), the CD62L+ fraction (TCM) was purified with positive selection on CliniMACS™ according to the manufacturer's instructions, and resuspended in X Vivo15 containing 10% FCS.
- Within 2 hours of enrichment, 26.9×106 TCM were stimulated with GMP Dynabeads® Human T expander CD3/CD28 (Invitrogen) at a 1:3 ratio (T cell:bead), and transduced with clinical grade IL13BBζ-T2A-CD19t_epHIV7 at an MOI of 0.3 in 5.5 mL X Vivo15 containing 10% FCS with 5 μg/mL protamine sulfate (APP Pharmaceutical), 50 U/mL rhIL-2 and 0.5 ng/mL rhIL-15 in a 32 Vuelife tissue culture bag (AFC) that was placed at a horizontal position on a culture rack at 37° C., 5% CO2. Cultures were then maintained with addition of X-Vivo15 10% FCS as required to keep cell density between 4×105 and 2×106 viable cells/mL, with cytokine supplementation (final concentration of 50 U/mL rhIL-2 and 0.5 ng/mL rhIL-15) every Monday, Wednesday and Friday of culture. Based on culture volume, T cells were transferred to 730 Vuelife bags (AFC). Seven days after the lentiviral transduction, the CD3/CD28 Dynabeads were removed using the Dynal ClinEx Vivo Magnetic Particle Concentrator bag magnet, and bead-free T cells were drained into a new 730 Vuelife bag. Cultures were propagated until approximately 4.53×108 cells were generated as determined by Guava PCA, at which time cultures were harvested, washed in Isolyte (Braun) with 2% HSA, then resuspended in Cryostor CS5 (BioLife Solutions) at approximately 1.3×107 cells/mL for cryopreservation using a Mr. Frosty (Nalgene) and a portable controlled rate freezer system (Custom Biogenics). Quality control tests included viability, potency (CD19t expression), Identity (CD3 expression), transgene copy number (WPRE qPCR), replication competent virus testing (VSV-G qPCR and formal RCL testing at the University of Indiana), residual bead count, and sterility.
- As noted above, the T2A
ribosome skip sequence 12 then separates this IL13BBζ sequence from CD19t, an inert, nonimmunogenic cell surface marker marking cell transduction (FIG. 39A ). This T2A linkage results in the coordinate expression of both IL13BBζ and CD19t from a single transcript. - Manufacturing methods for the immunomagenetic enrichment of CD62L+CD45RA-CD4+CD8+ central memory T cells (TCM), lentiviral transduction and ex vivo expansion are also detailed herein. The end-of-process (EOP) cyropreserved IL13BBζ TCM product underwent quality control release testing as per the clinical protocol. For each infusion, T cells were thawed, washed and reformulated into a final volume of 0.5 mL in pharmaceutical preservative-free normal saline (PFNS) with 2% human serum albumin (HSA). Cells were manually injected into the Rickham reservoir using a 21 gauge butterfly needle to deliver a 0.5 mL volume over 5-10 minutes, followed by up to 1 mL PFNS flush delivered by convection enhanced delivery (CED) at 0.5 mL per hour.
- The post-gadolinium T1 weighted MRI sequences of the brain and spine were acquired on a
Siemens Viro 3 Tesla scanner. Lesions were measured on axial T1 MPR weighted images obtained after the administration of Multihance. Imaging with 18-F-fluorodeoxyglucose (18-F-FDG) was performed using a GE Discovery DST HP60 PET-CT scanner (70 cm axial field of view, slice thickness 3.75 mm). Maximal standardized uptake values (SUVs) were obtained utilizing Vital Images Vitrea version 6.7.2 software. Regions of contrast-enhancing tumor foci were outlined by a radiologist for measurements of largest tumor area (mm2) and tumor volumes (cm3) were computed. - Cryopreserved cell banks of quality control released autologous IL13BBζ TCM were thawed and reformulated for infusion by washing twice with phosphate buffered saline (PBS) with 2% HSA and resuspending in pharmaceutical preservative-free normal saline with 2% HSA. Delivery of the therapeutic CAR T cells into either the glioma resection cavity (ICT) or the lateral ventricle (ICV) was achieved using a Holter™ Rickham Ventriculostomy Reservoir (Codman), with a ventricular catheter (Integra Pudenz), and a stylet. For ICT delivery, the reservoir/catheter system was inserted at the time of tumor resection, and the tip of the catheter was partially embedded into the resection wall in order to allow for cell delivery both into the cavity and into the peritumoral brain tissue. Post-operative imaging (CT and MRI) were obtained to confirm catheter position and extent of tumor resection.
- Enriched TCM (36×106) were ex vivo stimulated, lentivirally transduced and expanded to yield 638×106 total cells in 17 days. The final T cell product (CD3+ and TCR+) consisted of CD4 (74%) and CD8 (16%) T cell subsets and expressed IL13BBζ and CD19t with gene modified co-staining for both cell surface proteins (
FIG. 39A ). The CAR T cell product exhibited a central memory T cell phenotype, expressing CD45RO (97%), CD62L (57%), CCR7 (28%), CD28 (97%) and CD27 (59%) (FIG. 39A ). The product also expressed of some markers of exhaustion, including TIM-3 (65%) and LAG-3 (49%), but not significant levels of PD-1 and KLRG1 (FIG. 39A ). - The patient was treated with weekly infusions of IL13BBζ TCM administered via a reservoir/catheter device through two different intracranial delivery routes, that being intracavitary (ICT) delivery following tumor resection (cycles 1-6) and intracerebroventricular (ICV) delivery into the cerebral spinal fluid (CSF) (cycles 7-11). The 11 intracranial infusions, at a maximum cell dose of 10×106 CAR+ T cells, were well-tolerated with no
grade 3 or higher toxicity (NCI Common Toxicity Criteria) with possible or higher attribution to the therapy observed. Mild events noted following CAR T cell infusions include. -
TABLE 6 SAFETY AND TOLERABILITY Maximum Cumulative Delivery T-cell T-cell T-cell Adverse Event Route Doses Dose Dose (Grade 1-2)* ICT 6 107 5.2 × 107 Chills Fatigue Fever Lymphopenia Myalgia Dizziness Headache Seizure ICV 5 107 4.2 × 107 Chills Fatigue Fever Myalgia Headache Short Olfactory Aura Seizure Anxiety Hypertension Sinus Tachycardia *Only events with possible or higher attribution to the T cell administration are reported; all occurred once and were Grade 1-2 according to the NCI Common Toxicity Criteria, with no events of Grade 3 or higher observed. - At the time of treatment, the patient's tumor displayed characteristics of a highly aggressive recurrent GBM with poor prognostic features. This included evidence of recurrence from primary diagnosis within six months following standard-of-care therapy, the presentation of multifocal tumor lesions, including spinal lesions and extensive leptomeningeal disease (
FIG. 38 ), histological features of a dedifferentiated GBM, and a high tumor proliferation rate with over 60% of the cells staining positive for Ki67 (FIG. 37B ). Tumor expression of IL13Rα2, as evaluated by IHC on FFPE of resected tumor tissue, was similar between the primary and recurrent tumors with an H score of 100 and 80, respectively (FIG. 37 ). Intratumoral IL13Rα2 expression for the recurrent tumor was heterogeneous, with 10% of the cells showing high staining intensity (2-3+), 60% showing low expression (1+), and 30% of the cells not staining above background (0+). Of potential interest, the highest levels of IL13Rα2 expression were often observed in tumor regions of pseudopalisading necrosis (FIG. 37A ), an expression pattern noted for other GBM tumors. - Following enrollment on the clinical protocol, this patient underwent surgical resection for three of the five recurrent lesions (
FIG. 38 ), and the reservoir/catheter device was place in the resected cavity of the largest recurrent foci (T1) in the right posterior temporal-occipital area. This patient was initially treated per protocol with six weekly intracavitary (ICT) infusions of CAR+ T cells (2×106cycle 1; 10×106 cycles 2-6) (FIG. 1B ), and during this time period the temporal-occipital tumor lesion (T1) remained stable for over 45-days post-surgery without evidence of progressive disease (FIG. 39C ). MM revealed, however, that other non-resected tumor foci in the left temporal lobes (T4 and T5), as well as a new recurrent lesion adjacent to tumor 3 (T6) and a lesion in the olfactory groove (T7) continued to progress over this same time period (FIG. 39C ). Additionally, metastatic lesions in the spine, including one large tumor (270 mm2) and more than one small tumor foci (<1 cm2) were also detected. These results, while mixed, were encouraging, in that they suggested the IL13BBζ TCM may have prevented disease recurrence at the resected posterior temporal-occipital area, however, they also suggested that local ICT delivery was not sufficient to effectively control tumor progression at distant locations away from the infusion site. - Based on these findings and supported by preclinical studies showing that ICV delivery of CAR T cells can traffic to multifocal GBM in NSG mouse models (data not shown), this patient was enrolled on a compassionate use protocol and treated with five weekly ICV infusions of IL13BBζ TCM without any other therapeutic interventions (2×106
cycle 7; 10×106 cycles 8-11) (FIG. 40A ). One week after three ICV infusions (cycle 9; day 133) all tumor lesions showed dramatic regression, and following the final ICV infusion (cycle 11; day 156), most intracranial and spinal tumors had regressed more than 70% by both maximum area and volume measurements (FIG. 40B-E , Table 7 below, andFIG. 41 ). Follow-up MR and PET imaging six weeks after the last ICV infusion (day 190), during which the patient received no other therapeutic intervention, showed continued disease regression, with all tumors decreasing ≧78% by both maximum area and volume measurements (FIG. 40B-E , Table 7 below, andFIG. 41 ). At this 190 day time point, it was not possible to differentiate between residual radiographic evidence of disease versus inflammation, scaring and/or dural enhancement. ICV delivery of IL13BBζ TCM elicited almost complete elimination of all metastatic tumors in the spine, with 97% reduction in the maximum area for the largest lesion and only one small tumor foci visible out of the more than ten present prior to ICV treatment. Over the time course of ICV treatment, and coinciding with tumor regression, the patient was able to reduce system dexamethosome from 2 mg bid to 0.5 mg qd. This patient remains clinically stable and has returned to normal life and work activities, thus supporting the durability of this CAR T cell-mediated antitumor response. These results demonstrate that treatment with IL13BBζ TCM mediated a near complete response based on the stringent RANO criteria. -
TABLE 7 MRI Evaluation of Non-Resected Lesions (Volume in cm3, Area in mm2) Anatom- Post Op Post Post Post Op Post Post Tu- ical Pre Op i.c.t. Cycles 1-3 Cycles 4-6 i.c.v. Cycles 7-9 Cycles 10-11 Max % mor Location D50 D51 D77 D86 D101 D108 D133 D156 D190 Decrease 4 Left 0.2 cm3 0.3 cm3 0.5 cm3 ND 0.8 cm3 1.4 cm 3 0.3 cm3 0.1 cm3 0.1 cm 3 Vol: 93% temporal, 65 mm2 98 mm2 112 mm2 168 mm2 224 mm 2 80 mm2 49 mm2 28 mm 2 Area: 88% pterion 5 Left 0 cm3 0 cm3 0.1 cm3 ND 0.3 cm3 0.7 cm 3 0.1 cm3 0 cm3 0 cm 3 Vol: 100% temporal, 20 mm2 20 mm2 36 mm2 54 mm2 126 mm 2 33 mm2 11 mm2 7 mm 2 Area: 94% apex 6* Right NA NA 0.5 cm3 ND 1 cm3 1.7 cm3 1.8 cm 3 1.4 cm3 0.4 cm 3 Vol: 78% frontal 0 mm2 0 mm2 42 mm2 176 mm2 187 mm2 300 mm 2 143 mm2 64 mm 2 Area: 79% lobe 7* Olfactory NA 0.1 cm3 0.4 cm3 ND 1.4 cm3 2.5 cm 3 1.9 cm3 1.3 cm3 0.3 cm 3 Vol: 88% groove 27 mm2 18 mm2 60 mm2 171 mm2 360 mm 2 312 mm2 98 mm2 40 mm 2 Area: 89% 8 Spinal ND ND ND 270 mm 2 ND ND 35 mm2 18 mm2 8 mm 2 Area: 97% *new lesion arising during Cycles 1-6 Bold, values compared for Maximum % Decrease NA, no lesion could be identified 0, lesion might be visually identified, but value was below that of analysis software parameters ND, imaging was not done - To elucidate immunological changes associated with antitumor responses observed following the ICV infusion of IL3BBζ TCM (Cycles 6-11), CSF was evaluated for cell infiltrates, CAR+ T cell persistence, and cytokine levels. Immediately following each ICV infusion (i.e., day 1-2 of cycles 6-11), cell numbers per mL of CSF increased 7.0±3.6 fold as compared to pre-infusion levels (
day 0 of each cycle), and increased 153±128 fold as compared to pre-ICV (C7D0) levels (FIG. 42 ). Total cell numbers in the CSF typically decreased over the 7-day treatment cycle. As evaluated for C9D2, the cell infiltrates included a large proportion of CD3+ T cells, both endogenous and CAR-expressing, as well as CD14+CD11b+ HLA-DR+ mature myeloid populations (FIG. 42A ). Only rare CD19+ B cells and CD11b+CD15+ granulocytes were detected (FIG. 42A ). Consistent with flow cytometry data, CSF cytopathology on C11D1 reported the presence of reactive lymphocytes, monocytes, and macrophages. - CAR-T persistence was also monitored over the ICV treatment course. Due to low cell recovery in the CSF for
cycles cycle 9 and time points immediately followingcycles FIG. 42B ), including C9D0 which corresponded to 7-days post cycle 8, thus demonstrating persistence of the therapeutic cells for at least 7 to 8 days post-infusion. However, CAR T numbers in the CSF post infusion decreased at the later cycles (C10D1 and C11D1) when tumor burden had also significantly decreased (FIG. 40B ). To note, significant expansion of the CAR T cells in the CSF overcycle 9 was not detected, with CAR+ cell numbers increasing 1.6-fold 2 days later (C9D2) from pre-infusion (C9D0) and then decreasing 2.3-fold by day 8 (C9D8). - The presence of immune cells, including CAR+ T cells, following each infusion corresponded to significant elevations of cytokine levels in the CSF. The measured levels and calculated fold-change over baseline for the 30-cytokines measured is presented in Tables 9 and 10 below. Notably, 11 cytokines increased more than 10-fold from pre-ICV baseline (C7D0) immediately following IL3BBζ TCM infusions, including cytokines IFNγ, TNF, IL-2, IL-10, IL-5, IL-6, and IL-8 and chemokines CXCL9/MIG, CXCL10/IP-10, and CCR2/MCP-1 and soluble cytokine receptor IL-1Rα (
FIG. 3C ). Seven other cytokines showed greater than a 5-fold increase from baseline (C7D0), including G-CSF, IL-12, IL2-R, IL-4, IL-7, and MIP-lb. The inflammatory cytokines that exhibited the highest fold increase immediately following IL3BBζ TCM infusion as compared to pre-ICV (C7D0) was IL-2 (>90-fold for C9D2) and the IFN-γ inducible chemokines CXCL9 and CXCL10 (>40-fold for C8D1, C9D2, C10D1 and C11D2). These cytokines returned to near baseline levels within 7-days between treatment cycles. Cytokines that did not show significant increase following CAR T cell infusions include IL-13, RANTES and VEGF (Tables 9 and 10). -
TABLE 9 UPN 109 CSF Cytokine Analysis (pg/mL), ICV Cycles 7 through 11.Cytokine C7D0 C7D2 C8D0 C8D1 C9D0 C9D2 C9D8 C10D0 C10D1 C11D0 C11D1 C11D44 EGF OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< 10.0 Eotaxin *2.1 *2.4 *2.4 6.2 3.0 3.8 *2.4 *2.4 6.3 *2.4 6.1 *2.6 FGF 7.1 8.0 8.8 14.1 *4.0 *3.1 *4.7 *6.3 12.2 7.3 13.6 11.5 G-CSF *25.1 68.6 *43.7 232.6 103.9 137.5 64.9 *23.3 245.6 *13.8 248.9 39.9 GM-CSF *2.0 *2.4 *2.5 *8.7 *2.5 *4.2 *1.4 *1.3 *3.2 *1.3 *2.7 OOR< HGF 74.4 113.1 127.7 253.9 162.3 250.8 145.8 110.9 213.6 125.2 241.8 81.0 IFN-α 45.5 56.8 42.0 109.7 59.5 66.1 35.6 17.9 90.0 24.8 74.5 OOR< IFN-γ *8.2 *7.0 *3.8 140.8 16.8 32.1 *5.0 *1.8 69.5 *4.0 42.8 *1.0 IL-10 *4.4 *6.0 *2.1 74.6 *20.7 70.4 *16.0 *3.5 147.1 *6.9 167.5 OOR< IL-12 16.7 23.5 24.7 92.4 41.5 82.7 62.4 35.5 57.0 42.6 85.7 12.7 IL-13 *15.8 *15.3 *13.1 29.9 *15.9 18.1 *4.8 OOR< 22.7 OOR< 18.8 OOR< IL-15 OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< *7.1 IL-17 *2.4 *2.8 *0.9 *9.2 *5.4 *5.1 *2.3 *1.2 *8.5 *1.0 *8.1 OOR< IL-1Rα *50.1 *35.7 *56.9 405.9 238.6 699.3 358.0 605.2 1113.0 *53.4 1141.9 259.9 IL-1β *5.0 10.1 *6.2 22.1 *3.0 12.9 *6.7 *6.7 15.6 *8.0 17.0 *4.69 IL-2 OOR< *4.2 *0.8 55.4 *1.0 *2.7 OOR< *0.6 10.8 *0.6 *5.5 OOR< IL-2R 43.8 81.0 51.2 223.7 89.6 243.1 67.7 *13.1 219.3 *18.3 241.5 54.2 IL-4 *2.5 *3.8 *2.9 *17.0 *5.5 *8.3 *3.9 *2.3 *13.8 *1.3 *10.5 OOR< IL-5 OOR< *1.3 *0.5 14.7 *2.6 9.1 *1.0 OOR< 7.9 OOR< 7.7 OOR< IL-6 56.5 78.4 40.9 1062.5 106.5 318.4 47.0 33.2 688.5 31.4 857.3 23.2 IL-7 OOR< 6.3 OOR< 42.7 20.0 19.9 OOR< 6.3 23.4 OOR< 22.0 28.0 IL-8 226.2 231.0 253.4 4904.6 827.4 1591.0 677.8 283.2 1023.9 84.4 794.9 66.0 IP-10 161.4 766.7 307.3 6213.7 916.7 59779.1 510.1 156.9 393430.8 345.3 305579.5 79.2 MCP-1 1660.6 1752.3 1280.8 18439.9 4437.4 1939.1 791.9 1598.9 10868.4 420.0 3157.4 888.7 MIG 82.9 302.1 179.1 4500.5 1360.6 3621.2 1342.1 380.7 3423.0 288.2 3823.6 29.3 MIP-1α 22.0 28.0 20.7 68.1 31.9 50.8 19.7 *14.8 68.6 *14.6 64.4 *8.8 MIP-1β 26.3 33.8 26.1 213.8 49.7 106.1 24.2 16.8 126.8 22.3 52.6 13.6 RANTES *15.5 OOR< OOR< 41.7 25.7 OOR< OOR< OOR< 68.5 *1.0 *12.5 OOR< TNF-α OOR< OOR< OOR< 19.9 *1.6 *6.3 OOR< OOR< 11.0 OOR< *5.1 OOR< VEGF 17.0 21.8 16.7 90.2 25.5 38.6 10.9 7.8 65.5 OOR< 70.0 14.1 OCR<, Out of Range (below) *Value extrapolated beyond standard range -
TABLE 10 UPN 109 CSF Cytokine Fold Change Analysis, ICV Cycles 7 through 11. Cytokine C7D0 C7D2 C8D0 C8D1 C9D0 C9D2 C9D8 C10D0 C10D1 C11D0 C11D1 C11D44 EGF 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Eotaxin 1.0 1.1 1.1 3.0 1.4 1.8 1.1 1.1 3.0 1.1 2.9 1.2 FGF 1.0 1.1 1.2 2.0 0.6 0.4 0.7 0.9 1.7 1.0 1.9 1.6 G-CSF 1.0 2.7 1.7 9.3 4.1 5.5 2.6 0.9 9.8 0.5 9.9 1.6 GM-CSF 1.0 1.2 1.3 4.4 1.3 2.1 0.7 0.7 1.6 0.7 1.4 0.7 HGF 1.0 1.5 1.7 3.4 2.2 3.4 2.0 1.5 2.9 1.7 3.3 1.1 IFN-α 1.0 1.2 0.9 2.4 1.3 1.5 0.8 0.4 2.0 0.5 1.6 0.5 IFN-γ* 1.0 0.9 0.5 17.2 2.0 3.9 0.6 0.2 8.5 0.5 5.2 0.1 IL-10* 1.0 1.4 0.5 17.0 4.7 16.0 3.6 0.8 33.4 1.6 38.1 0.5 IL-12 1.0 1.4 1.5 5.5 2.5 5.0 3.7 2.1 3.4 2.6 5.1 0.8 IL-13 1.0 1.0 0.8 1.9 1.0 1.1 0.3 0.3 1.4 0.3 1.2 0.3 IL-15 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 IL-17 1.0 1.2 0.4 3.8 2.3 2.1 1.0 0.5 3.5 0.4 3.4 0.4 IL-1Rα* 1.0 0.7 1.1 8.1 4.8 14.0 7.1 12.1 22.2 1.1 22.8 5.2 IL-1β 1.0 2.0 1.2 4.4 0.6 2.6 1.3 1.3 3.1 1.6 3.4 0.9 IL-2* 1.0 7.0 1.3 92.3 1.7 4.5 1.0 1.0 18.0 1.0 9.2 1.0 IL-2R 1.0 1.8 1.2 5.1 2.0 5.6 1.5 0.3 5.0 0.4 5.5 1.2 IL-4 1.0 1.5 1.2 6.8 2.2 3.3 1.6 0.9 5.5 0.5 4.2 0.5 IL-5* 1.0 2.6 1.0 29.4 5.2 18.2 2.0 1.0 15.8 1.0 15.4 1.0 IL-6* 1.0 1.4 0.7 18.8 1.9 5.6 0.8 0.6 12.2 0.6 15.2 0.4 IL-7 1.0 1.0 1.0 6.8 3.2 3.2 1.0 1.0 3.7 1.0 3.5 4.4 IL-8* 1.0 1.0 1.1 21.7 3.7 7.0 3.0 1.3 4.5 0.4 3.5 0.3 IP-10* 1.0 4.8 1.9 38.5 5.7 370.4 3.2 1.0 2437.6 2.1 1893.3 0.5 MCP-1* 1.0 1.1 0.8 11.1 2.7 1.2 0.5 1.0 6.5 0.3 1.9 0.5 MIG* 1.0 3.6 2.2 54.3 16.4 43.7 16.2 4.6 41.3 3.5 46.1 0.4 MIP-1α 1.0 1.3 0.9 3.1 1.5 2.3 0.9 0.7 3.1 0.7 2.9 0.4 MIP-1β 1.0 1.3 1.0 8.1 1.9 4.0 0.9 0.6 4.8 0.8 2.0 0.5 RANTES 1.0 0.1 0.1 2.7 1.7 0.1 0.1 0.1 4.4 0.1 0.8 0.1 TNF-α* 1.0 1.0 1.0 12.4 1.0 3.9 1.0 1.0 6.9 1.0 3.2 1.0 VEGF 1.0 1.3 1.0 5.3 1.5 2.3 0.6 0.5 3.9 0.5 4.1 0.8 Bold values, ‘OOR<’ value from Table 10 was replaced with the lowest measurable value for that cytokine to allow for fold change calculation. *Cytokines in which a >10 fold increase was observed at least once - These immunological changes in the CSF were local, as no significant changes in cytokine levels (Table 11), and no detectable CAR+ T cells by qPCR and flow cytometry (data not shown) in the peripheral blood were observed. The changes in the CSF could not be compared to changes in the resected cavity of tumor lesion 1 (T1) due to the inability to obtain cyst fluid from the cavity during the ICT treatment course.
-
TABLE 11 UPN 109 Serum Cytokine Analysis (pg/mL), ICV Cycles 7 through 11. Cytokine C7D0 C7D2 C7D4 C8D0 C8D1 C8D4 C9D0 C9D2 C10D0 C10D1 C10D3 C11D0 C11D1 C11D2 EGF 148.1 166.7 171.9 168.8 132.2 118.3 105.9 73.8 154.8 158.9 121.9 114.8 152.2 151.8 Eotaxin 110.1 116.8 112.6 101.2 83.7 133.8 152.1 156.4 172.1 167.9 143.2 147.3 197.7 168.3 FGF *5.3 8.3 6.8 OOR< OOR< OOR< OOR< 14.7 17.4 22.7 20.2 14.8 15.3 15.9 G-CSF 211.6 236.7 284.5 229.3 208.2 208.2 210.8 230.1 216.7 334.3 221.8 282.9 207.4 241.6 GM-CSF *2.0 *2.1 *2.4 *1.9 *1.6 *2.0 *1.9 *1.7 *2.0 *3.1 *2.3 *1.9 *1.8 *1.7 HGF 471.5 596.1 611.6 420.1 403.0 508.1 362.4 400.0 385.9 502.5 456.6 395.3 476.1 451.6 IFN-α 43.9 47.4 49.9 43.8 42.2 47.1 43.9 40.0 41.1 64.5 43.1 50.4 43.3 43.4 IFN-γ 53.0 52.5 56.4 52.2 52.1 55.5 52.2 44.8 45.6 58.5 47.0 54.8 49.7 50.7 IL-10 *2.9 *3.9 *3.4 *0.8 OOR< *2.4 *1.0 *3.3 *2.6 *9.4 *3.5 *1.8 *1.9 *0.6 IL-12 211.7 192.3 195.0 187.2 182.3 190.9 192.8 223.3 227.9 241.6 254.4 220.2 240.5 219.1 IL-13 21.1 27.4 30.7 23.1 36.8 31.0 28.0 24.2 22.3 38.3 31.4 32.2 25.8 34.8 IL-15 OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< IL-17 *3.5 *4.1 *5.2 OOR< *1.8 *0.7 *0.8 *3.3 *4.6 *11.5 *5.2 *7.3 *4.4 *4.4 IL-1Rα 112.7 145.3 *68.2 *94.3 *73.8 *64.5 *58.2 *64.9 101.1 133.8 96.3 *68.7 107.9 105.8 IL-1β *2.1 *4.6 *4.9 *1.0 OOR< OOR< OOR< 11.3 15.9 30.6 18.2 12.7 14.3 14.7 IL-2 *0.1 *0.9 *1.3 *0.3 OOR< *0.2 *0.3 *0.4 *0.9 *5.2 *1.2 *1.8 *0.9 *1.0 IL-2R 372.0 391.2 438.5 352.6 273.9 272.7 241.9 304.9 312.2 363.8 314.8 338.0 296.4 314.5 IL-4 *8.9 *11.5 *13.5 *9.0 *10.4 *10.5 *10.1 *10.2 *8.7 *20.9 *11.1 *13.8 *9.7 *10.8 IL-5 *1.6 *2.0 *3.2 *0.2 *1.5 *1.1 *0.8 OOR< OOR< 5.1 *0.2 *2.2 OOR< OOR< IL-6 OOR< *1.6 *0.4 OOR< *0.7 OOR< OOR< *2.5 *2.6 7.1 *4.2 *2.9 *3.9 *3.0 IL-7 OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< IL-8 49.4 130.2 88.4 96.4 56.3 17.1 43.6 *9.4 32.8 93.1 112.1 18.3 30.1 59.0 IP-10 33.9 23.5 17.2 11.7 9.0 11.5 15.0 12.7 17.4 33.6 16.3 15.3 23.2 18.9 MCP-1 459.6 610.9 475.9 426.2 414.8 561.0 944.8 538.5 848.2 1074.3 703.0 954.9 950.0 826.3 MIG 141.3 108.1 50.6 8.0 OOR< 10.0 28.5 34.0 41.2 79.1 42.6 47.3 42.2 44.2 MIP-1α 58.4 58.4 62.2 51.1 49.2 53.4 53.1 47.1 55.8 81.2 57.7 64.6 52.7 54.1 MIP-1β 103.3 93.4 92.0 78.1 64.4 76.8 83.1 57.3 84.5 157.1 86.3 90.0 87.6 90.0 RANTES 11127.1 11965.0 14328.5 10584.5 12610.1 12415.5 12937.9 9221.7 8567.4 10428.1 8886.3 11117.8 9782.5 9771.1 TNF-α *1.2 *2.1 *4.5 *2.3 *2.6 *2.1 *2.3 OOR< OOR< 7.2 OOR< *2.1 OOR< OOR< VEGF OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<, Out of Range (below) *Value extrapolated beyond standard range - Tumor resection material was collected through the COH department of Pathology according to the clinical protocol.
- IL13Rα2 immunohistochemistry (IHC) was performed on 5 μm-sections of formalin-fixed paraffin-embedded specimens as previously described, and Ki67 IHC was similarly performed with the exception of antigen retrieval by heating @ pH 8.0, and incubation with a 1:75 dilution of anti-K167 (Dako Corp). IL-13Rα2 immunoreactivity was scored by a clinical neuropathologist and quantified based on the percentage of tumor cells exhibiting weak (1+), moderate (2+), or strong (3+) intensity of cytoplasmic and golgi-like staining. The H score is obtained by the formula: (3×percentage of strongly staining cells)+(2×percentage of moderately staining cells)+percentage of weakly staining cells, giving a range of 0 to 300. The H score can be translated into the intensity scoring system described in the enrollment criteria as follows: 0 representing negative (H score 0), 1+ low (H score 1-100), 2+ moderate (H score 101-200) and 3+ high (H score 201-300). The criteria for inclusion was at least 20% of the cells scoring 1+ staining intensity (>20%, 1+), representing an H score of 20. Appropriate positive (testicular) and negative (prostate) controls were employed for IL-13Rα2 IHC staining. A “+” sign reflects the presence of membranous staining. This test has been performed at the Department of Pathology, City of Hope National Medical Center and is regarded as investigational for research. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
- Peripheral blood samples were collected in vacutainer tubes±EDTA. Samples with EDTA were ficolled immediately upon receipt and peripheral blood mononuclear cells (PBMC) were frozen in Crystor CS5 at −80° C. and then transferred to liquid nitrogen for long term storage. Samples without EDTA were allowed to coagulate for 2-3 hours at room temperature; serum was collected by centrifugation, aliquoted in single use 100-200 μl aliquots and stored at −80° C. Cerebral spinal fluid (CSF) was collected from the ICV reservoir in a 3 cc syringe, spun down, and supernatants were aliquoted and stored at −80° C. The CSF cells were resuspended in HBSS−/− (Corning CellGro) with 2% FCS and sodium azide for immediate flow cytometric analysis, with the remaining cells resuspended and frozen in Cryostor CS4 at −80° C. and then transferred to liquid nitrogen for long term storage
- Cell surface phenotyping of immune cells was performed by flow cytometry using fluorochrome conjugated antibodies specific for CD3, CD4, CD11b, CD14, CD19, CD27, CD28, CD62L, CD45RA, CD45RO, IL-13, TCR-α/β (BD Biosciences), KLRG1, CD15 (BioLegend), HLA-DR, PD1 (eBiosciences), CD8 (Fisher Scientific), LAG-3 (Lifespan Biosciences), CCR7, or TIM-3 (R&D Systems), and their respective isotype controls.
- Research participant serum and CSF samples were analyzed by cytokine bead array. Assays were performed using the Human Cytokine 30-Plex Panel kit (Invitrogen) and a FLEXMAP 3D® (Luminex).
Claims (26)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/425,773 US20170224733A1 (en) | 2016-02-05 | 2017-02-06 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
US17/025,723 US20210244761A1 (en) | 2016-02-05 | 2020-09-18 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292152P | 2016-02-05 | 2016-02-05 | |
US201662309348P | 2016-03-16 | 2016-03-16 | |
US15/425,773 US20170224733A1 (en) | 2016-02-05 | 2017-02-06 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/025,723 Continuation US20210244761A1 (en) | 2016-02-05 | 2020-09-18 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170224733A1 true US20170224733A1 (en) | 2017-08-10 |
Family
ID=59496551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/425,773 Abandoned US20170224733A1 (en) | 2016-02-05 | 2017-02-06 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
US17/025,723 Pending US20210244761A1 (en) | 2016-02-05 | 2020-09-18 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/025,723 Pending US20210244761A1 (en) | 2016-02-05 | 2020-09-18 | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170224733A1 (en) |
EP (2) | EP3912993A1 (en) |
JP (2) | JP7189019B2 (en) |
KR (1) | KR20180105709A (en) |
CN (1) | CN108779160A (en) |
AU (2) | AU2017213661B2 (en) |
BR (1) | BR112018015836A2 (en) |
CA (1) | CA3013773A1 (en) |
DK (1) | DK3411393T3 (en) |
ES (1) | ES2879700T3 (en) |
HK (1) | HK1257741A1 (en) |
IL (2) | IL287889B2 (en) |
MX (1) | MX2023006304A (en) |
RU (1) | RU2757308C2 (en) |
WO (1) | WO2017136829A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019178085A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
WO2019232523A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
WO2021154543A3 (en) * | 2020-01-31 | 2021-09-02 | City Of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES |
US11111493B2 (en) | 2018-03-15 | 2021-09-07 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11123369B2 (en) | 2015-08-07 | 2021-09-21 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
WO2021202793A3 (en) * | 2020-03-31 | 2021-11-11 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
WO2022212525A3 (en) * | 2021-03-30 | 2022-11-10 | City Of Hope | Chimeric antigen receptors comprising ifn gamma |
US11759480B2 (en) | 2017-02-28 | 2023-09-19 | Endocyte, Inc. | Compositions and methods for CAR T cell therapy |
US11779602B2 (en) | 2018-01-22 | 2023-10-10 | Endocyte, Inc. | Methods of use for CAR T cells |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109971725B (en) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | Antibody-modified chimeric antigen receptor-modified T cells and uses thereof |
CN113646433B (en) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | Compositions and methods for targeting anti-TNF-alpha antibodies |
WO2022012610A1 (en) * | 2020-07-16 | 2022-01-20 | Porton Biologics Ltd | Compositions and methods to target anti-tnf-alpha antibody |
US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120148552A1 (en) * | 2008-08-26 | 2012-06-14 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
US20130280224A1 (en) * | 2010-11-17 | 2013-10-24 | Alon Monsonego | T-cell therapy to neurodegenerative diseases |
US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
SI2856876T1 (en) * | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
AU2013302406B2 (en) * | 2012-08-17 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Gene expression profile associated with prostate cancer |
AU2013337926B2 (en) * | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CN107074957B (en) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | Chimeric Antigen Receptors (CARs) having mutations in the Fc spacer region and methods of use thereof |
EP3134437A1 (en) * | 2014-04-23 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
CN108174604B (en) * | 2015-08-07 | 2023-06-23 | 西雅图儿童医院(Dba西雅图儿童研究所) | Bispecific CAR T cells for solid tumor targeting |
CN105131126B (en) * | 2015-10-10 | 2019-02-01 | 北京康爱瑞浩细胞技术有限公司 | Chimeric antigen receptor and the preparation method and application thereof for treating malignant tumour |
ES2909973T3 (en) * | 2015-11-04 | 2022-05-10 | Hope City | Chimeric receptors for the antigen that target HER2 |
-
2017
- 2017-02-06 CN CN201780017442.9A patent/CN108779160A/en active Pending
- 2017-02-06 JP JP2018540862A patent/JP7189019B2/en active Active
- 2017-02-06 EP EP21166981.7A patent/EP3912993A1/en active Pending
- 2017-02-06 AU AU2017213661A patent/AU2017213661B2/en active Active
- 2017-02-06 CA CA3013773A patent/CA3013773A1/en active Pending
- 2017-02-06 BR BR112018015836A patent/BR112018015836A2/en unknown
- 2017-02-06 ES ES17748349T patent/ES2879700T3/en active Active
- 2017-02-06 WO PCT/US2017/016711 patent/WO2017136829A1/en active Application Filing
- 2017-02-06 RU RU2018130752A patent/RU2757308C2/en active
- 2017-02-06 KR KR1020187025196A patent/KR20180105709A/en not_active Application Discontinuation
- 2017-02-06 US US15/425,773 patent/US20170224733A1/en not_active Abandoned
- 2017-02-06 IL IL287889A patent/IL287889B2/en unknown
- 2017-02-06 DK DK17748349.2T patent/DK3411393T3/en active
- 2017-02-06 EP EP17748349.2A patent/EP3411393B1/en active Active
-
2018
- 2018-08-01 IL IL260930A patent/IL260930B/en unknown
- 2018-08-03 MX MX2023006304A patent/MX2023006304A/en unknown
-
2019
- 2019-01-04 HK HK19100115.9A patent/HK1257741A1/en unknown
-
2020
- 2020-09-18 US US17/025,723 patent/US20210244761A1/en active Pending
-
2022
- 2022-09-02 AU AU2022224866A patent/AU2022224866A1/en active Pending
- 2022-12-01 JP JP2022192529A patent/JP2023026758A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120148552A1 (en) * | 2008-08-26 | 2012-06-14 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US20130280224A1 (en) * | 2010-11-17 | 2013-10-24 | Alon Monsonego | T-cell therapy to neurodegenerative diseases |
Non-Patent Citations (2)
Title |
---|
Tsurushima et al., Reduction of End-stage Malignant Glioma by Injection with Autologous Cytotoxic T Lymphocytes. Jpn. J. Cancer Res. 90, 536–545, May 1999 (Year: 1999) * |
Tsurushima Jp J Cancer Res, 1999, 90 536-545 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11414486B2 (en) | 2014-04-10 | 2022-08-16 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
US11155616B2 (en) | 2014-04-10 | 2021-10-26 | Seattle Children's Hospital | Drug regulated transgene expression |
US10865242B2 (en) | 2014-04-10 | 2020-12-15 | Seattle Children's Hospital | Method and compositions for cellular immunotherapy |
US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
US11123369B2 (en) | 2015-08-07 | 2021-09-21 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
US11759480B2 (en) | 2017-02-28 | 2023-09-19 | Endocyte, Inc. | Compositions and methods for CAR T cell therapy |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
US11779602B2 (en) | 2018-01-22 | 2023-10-10 | Endocyte, Inc. | Methods of use for CAR T cells |
WO2019178085A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
EP3765487A4 (en) * | 2018-03-14 | 2022-01-05 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
US11421228B2 (en) | 2018-03-15 | 2022-08-23 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11111493B2 (en) | 2018-03-15 | 2021-09-07 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11608500B2 (en) | 2018-03-15 | 2023-03-21 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
WO2019232523A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
CN112533943A (en) * | 2018-06-01 | 2021-03-19 | 利兰斯坦福初级大学董事会 | IL-13/IL-4 super factor: immune cell targeting constructs and methods of use thereof |
WO2021154543A3 (en) * | 2020-01-31 | 2021-09-02 | City Of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES |
WO2021202793A3 (en) * | 2020-03-31 | 2021-11-11 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
WO2022212525A3 (en) * | 2021-03-30 | 2022-11-10 | City Of Hope | Chimeric antigen receptors comprising ifn gamma |
Also Published As
Publication number | Publication date |
---|---|
DK3411393T3 (en) | 2021-06-28 |
KR20180105709A (en) | 2018-09-28 |
AU2022224866A1 (en) | 2022-09-29 |
AU2017213661B2 (en) | 2022-06-02 |
RU2757308C2 (en) | 2021-10-13 |
JP7189019B2 (en) | 2022-12-13 |
HK1257741A1 (en) | 2019-10-25 |
JP2019504105A (en) | 2019-02-14 |
IL287889A (en) | 2022-01-01 |
US20210244761A1 (en) | 2021-08-12 |
EP3411393A4 (en) | 2019-09-25 |
EP3912993A1 (en) | 2021-11-24 |
IL260930B (en) | 2021-12-01 |
EP3411393B1 (en) | 2021-04-07 |
RU2018130752A3 (en) | 2020-10-07 |
IL287889B1 (en) | 2023-11-01 |
CA3013773A1 (en) | 2017-08-10 |
WO2017136829A1 (en) | 2017-08-10 |
CN108779160A (en) | 2018-11-09 |
JP2023026758A (en) | 2023-02-28 |
ES2879700T3 (en) | 2021-11-22 |
BR112018015836A2 (en) | 2018-12-26 |
EP3411393A1 (en) | 2018-12-12 |
IL287889B2 (en) | 2024-03-01 |
RU2018130752A (en) | 2020-03-06 |
AU2017213661A1 (en) | 2018-08-16 |
MX2023006304A (en) | 2023-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210244761A1 (en) | Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System | |
JP7216045B2 (en) | Central memory T cells for adoptive T cell therapy | |
CN105408473B9 (en) | Human applications of engineered Chimeric Antigen Receptor (CAR) T cells | |
CN115243713A (en) | Methods and compositions for delivering modified lymphocyte aggregates | |
US11389481B2 (en) | Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 | |
AU2019347873A1 (en) | Immunoresponsive cells expressing dominant negative Fas and uses thereof | |
US20220118019A1 (en) | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 | |
WO2024055339A1 (en) | Method for preparing and amplifying universal humanized anti-cd19 car-nk cell and use thereof | |
US20230071910A1 (en) | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy | |
JPWO2018110374A1 (en) | Chimeric antigen receptor gene-modified lymphocytes with cytocidal effect | |
EP3707246B1 (en) | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CITY OF HOPE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADIE, BEHNAM;BROWN, CHRISTINE E.;FORMAN, STEPHEN J.;AND OTHERS;SIGNING DATES FROM 20170207 TO 20170213;REEL/FRAME:042220/0118 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |